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Abstract 
 
The integrin αVβ5 is a receptor for sCD23 molecule and the αVβ5-CD23 
interaction sustains proliferation of the pre-B cell line SMS-SB. This thesis 
describes further investigation into the role of αVβ5 integrin during human B cell 
development. B cell development in the bone marrow involves stepwise 
maturation of progenitor cells through different defined stages. A tight 
regulation of proliferation and differentiation mediates the progression of 
progenitor cells through this developmental pathway. A variety of signals from 
soluble molecules and adhesive interactions regulate this balance of 
proliferation and differentiation. The main aim of this work was to assess the 
importance of the integrin αVβ5 during B cell development by defining its 
expression and function during specific stages of B cell development in the bone 
marrow.  
The αVβ5 integrin was expressed by B cell precursors in the bone marrow, by 
different pre-B cell lines and the αVβ5-CD23 interaction sustained proliferation 
of some pre-B cell lines. The pre-B cell lines SMS-SB, RS4;11 and 697 showed a 
significant proliferative response to αVβ5 stimulation by sCD23, a sCD23-derived 
long peptide and anti-αVβ5 MAb 15F11. Transitional and more mature B cell lines 
down-regulated αVβ5 expression and did not show a proliferative response. Both 
αVβ5 and αVβ3 integrin could be detected on normal bone marrow B cell 
precursor populations, though αVβ5 was the more highly expressed integrin. In 
preliminary functional experiments, stimulation of CD19+/κ- cells with sCD23 
induced cell proliferation whereas equivalent treatment of CD19+/κ+ cells did 
not. The data are consistent with the interpretation that αVβ5 integrin is 
expressed in B cell precursors but that its ability to sustain growth of these cells 
wanes as the cells mature towards a membrane immunoglobulin-positive state. 
The αVβ5-mediated proliferation was enhanced by the chemokine SDF-1 and 
PDGF but not by the cytokines IL-3, IL-4, IL-7 or IL-11. This effect was 
apparently restricted to earlier B cell precursors and was independent of levels 
of expression of both αVβ5 and CXCR4. Stimulation of SMS-SB cells with CD23, 
15F11 or CD23-derived long peptide provoked ERK phosphorylation and co-
stimulation with SDF-1 promoted a more rapid and sustained ERK activation. 
PDGF induced a similar effect on αVβ5-mediated activation of 
3 
ERKphosphorylation. These data suggest that ligation of αVβ5 by soluble, 
adhesion-independent stimuli activates ERK phosphorylation and this pathway 
can be modulated by inputs from G-protein-coupled and tyrosine kinase 
receptors.   
The murine pro-B cell line BAF03 also displayed αVβ5-mediated proliferation in 
response to human CD23. Murine CD23 is generally regarded as lacking the 
cytokine-like activities found in human CD23. The αVβ5 integrin binds an arg-lys-
cys motif beginning at arginine-172 (arg-172) in human CD23 and the equivalent 
murine sequence is gln-lys-cys. Studies using CD23-derived peptides indicated 
that arg-172 is not required for binding to murine αVβ5+ BAF03 cells, but that it 
is required for full biological activity. Preliminary experiments showed that 
human CD23 sustained growth of murine bone marrow B cell precursors. 
Therefore, these data suggest that murine B cells can also use αVβ5 integrin to 
sustain their growth and the studies described here in human cell lines could be 
translated into in vivo murine models. 
Further work is needed to confirm the proliferative response due to the αVβ5-
CD23 interaction in normal B cell precursors in the bone marrow and to define 
the exact stage of development where this interaction is critical. In addition to 
its expression in the bone marrow B cell precursors, previous work has also 
demonstrated the expression of αVβ5 integrin in B cells from patients with ALL. 
Therefore, the αVβ5-CD23 interaction could have important implications not 
only in proliferation of normal B cell precursors but also in proliferation of 
neoplastic B cells. These data identify the αVβ5-CD23 interaction as a 
potentially important interaction during early B cell development, as αVβ5 
expression and function is stage-specific, regulated by other molecules and can 
be demonstrated in both human and murine cell lines. 
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1 Introduction 
The mammalian immune system is a highly complex network of specialized cells 
and soluble factors which cooperate to protect the body against invasion by 
pathogens. Lymphocytes (T or B lymphocytes) are types of cells of the immune 
system that are able to mount a specific immune response against virtually any 
foreign antigen. This is possible because each individual T or B lymphocyte 
matures bearing a unique variant of a prototype antigen receptor resulting in a 
population of T and B lymphocytes that collectively bears a huge repertoire of 
receptors that are highly diverse in their antigen binding specificities. 
The B lymphocytes express membrane immunoglobulin (Ig) on their surface as 
the B cell receptor (BCR) and are activated when this receptor binds its specific 
antigen. To develop into plasma cells which secrete antibodies, B cells usually 
require T cell help, in the form of secreted interleukins and cell-cell surface 
interactions. Antibodies mediate humoral immune responses by binding to 
specific antigens and aiding their elimination. Antibodies possess numerous 
protective biological effects including: neutralisation of soluble antigens (viruses 
and bacteria); activation of the classical complement pathway; opsonization of 
particulate matter to allow enhanced phagocytosis; and antibody-dependent 
cell-mediated cytotoxicity (ADCC). In addition, antigen-specific B cells are highly 
efficient at presenting their cognate antigens and therefore act as antigen-
presenting cells to activate T-helper cells. Thus, B lymphocytes play a central 
role in the immune system and inappropriate cell activation or proliferation of B 
cells can lead to development of immunodeficiencies, allergy, autoimmunity or 
malignancies such as lymphomas and leukaemias. 
1.1 B cell development 
Haematopoietic stem cells (HSCs) with extensive self-renewal potential generate 
all blood cell types and as they differentiate into progenitor cells they become 
more restricted in their differentiation potential. B lymphocytes develop from 
pluripotent HSCs in specialised microenvironments such as foetal liver and adult  
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bone marrow. During this process the progenitor cells undergo stepwise 
maturation through defined stages of development. This dynamic process of 
growth, survival and differentiation is strictly regulated by multiple mechanisms 
including sequential changes in gene expression, signals from cytokines and 
other soluble molecules and interactions between the progenitor cells and bone 
marrow adherent cells 1. 
Several classification schemes for human and murine B cell development have 
been described, based on the expression of cell surface markers on the 
progenitor cells. CD19 is a signal transduction molecule which is the earliest 
marker known to be expressed on B-lineage cells and is expressed throughout B 
cell development except on plasma cells 2. Other markers that define early 
developmental stages include CD34, CD22 and CD10 in humans and B220 
(CD45R), the tyrosine kinase c-kit, CD43 and CD24 in mouse. A model of human 
B-cell development and its corresponding counterparts described in mouse is 
represented in Figure 1.1. Although differences exist between murine and 
human B cell progenitors the key events occurring during B lymphopoiesis are 
known to be similar. The common lymphoid progenitor (CLP) arising from the 
HSC is defined as the progenitor with the capacity to develop into T, B-
lymphocytes or NK (natural killer) cells. These cells do not express the T, B or 
NK lineage markers (CD2, CD4, CD8, CD16, CD19, CD20, CD58) but are CD34+, 
CD10+ (in humans) 3.  
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Figure  1.1 Schematic representation of a model of B cell development in human bone 
marrow. 
 
The B cell developmental stages are shown beginning from the CLPs to immature B cells with the 
key surface molecules expressed in each stage. Expression of the intracellular enzymes such as 
TdT and RAG and stages in immunoglobulin gene rearrangement are also indicated. The pre-BCR 
is indicated as the µ-ψLC and BCR as µ-k/λ. The approximate counterpart stages in murine B-cell 
development are represented in parenthesis as A-E using the nomenclature of Hardy and 
colleagues 4,5. The arrows indicate the potential regulatory factors produced by stromal cells and 
the numbers represent surface expression of CD markers. Picture reproduced from LeBien 2000 1. 
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1.1.1 Pro-B cells  
CLPs in the bone marrow enter the B lineage as pre-pro-B cells which further 
differentiate into pro-B cells 1. However there is no known surface marker that 
differentiates CLPs from early pro-B cells. Murine CLPs are known to be 
particularly sensitive to IL-7 signalling and signalling through the interleukin 7 
receptor (IL-7R) is required in the mouse to generate CD19+, CD43+ B220+ pro-B 
cells 6,7. IL-7 signalling is not as crucial in humans, as patients with mutations in 
the IL-7Rα chain have normal numbers of peripheral blood B cells 8,9. However 
IL-7 is known to induce pro-B cells to expand and has been shown to up- regulate 
the expression of CD19 and the transcription factor Pax5 6. Pro-B cells represent 
the irrevocably committed B cell precursors and in humans are characterised by 
the surface expression of the B cell marker CD19 along with CD10 and CD34 2.  
Some studies have shown that pro-B cells express neither cytoplasmic nor cell-
surface µ heavy chain (µHC) 10,11 while others studies have shown that  
cytoplasmic µHC can be detected on 5-10% of pro-B cells 12. Pro-B cells have also 
been shown to express a precursor form of the BCR composed of immunoglobulin 
α (Igα), Igβ and calnexin termed pro-BCR 13-15. Cross-linking the pro-BCR with 
anti-Igβ was shown to induce pro-B cells to acquire some of the cell surface 
markers of pre-B cells, therefore indicating that the pro-BCR is potentially a 
functional receptor in pro-B cells 15. 
One of the factors guiding B lymphopoiesis is immunoglobulin (Ig) gene 
rearrangement leading to the generation of a functional antigen receptor. The 
antigen receptor (or B cell receptor) is a complex of an antigen recognition 
structure composed of two identical heavy and light chains associated non-
covalently with a signal transduction heterodimer of Igα and Igβ.  Each of the 
light and heavy chains can further be divided into the variable region (variable 
heavy VH and variable light VL regions) and constant regions. Variable regions for 
both the heavy and light chains are encoded by separate gene segments. These 
segments are brought together by somatic recombination to make a complete V 
region gene and are joined with the constant region genes by RNA splicing after 
transcription. This recombination of Ig genes is of fundamental importance for 
generation of diverse antigen receptor repertoires. The variable (antigen 
recognition) domain of Ig heavy chain (IgH) is encoded by many scattered 
germline gene segments of three types-variable (V), diversity (D) and joining (J)  
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and the variable region of Ig light chain is encoded by V and J gene segments. 
These gene segments are appropriately rearranged before expression 16. 
Immunoglobulin gene recombination begins with D to JH segment rearrangements 
in pro-B cells 17-19. The vast majority of pro-B cells express the enzyme terminal 
deoxynucleotidyl transferase (TdT) essential during immunoglobuline gene 
recombination 20-22. Although VDJH gene rearrangement is easily detected on 
many pro-B cells, a minority of pro-B cells have both heavy chain (HC) alleles in 
the germline configuration 10. The DH-JH rearrangement of immunoglobulin heavy 
chain gene segments is already initiated at the pre–pro-B cell stage and pro-B 
cells express B lineage specific proteins such as the Igα-Igβ heterodimer and 
VpreB 23. A variety of transcription factors play important roles in B lineage 
commitment and progression by activating or repressing certain genes.  
Transcription factors such as E2A, EBF and Pax5 are required for up-regulation of 
pro-B cell stage- specific proteins as well as for expression of lymphoid-specific 
recombinase activating genes, RAG1 and RAG2 24,25. These enzymes are essential 
for rearrangement of the immunoglobulin genes.  Human pro-B cells may 
correspond to Hardy fraction B ± fraction C (murine counterpart) based on 
analysis of VDJH rearrangement 
10. 
1.1.2 Pre-B cells  
A functional VDJH rearrangement of the gene segments coding for the variable 
region of immunoglobulin heavy chains is essential for the progression of pro-B 
cells into the pre-B cell stage1. This rearrangement results in the surface 
expression of µHC (heavy chain). Expression of surface µ results in the assembly 
of the pre-BCR and marks the transition to the pre-B cell stage leading to the 
process of allelic exclusion which results in the productive rearrangement of 
only one of the two parental Ig HC alleles. Expression of membrane Igµ in pre-B 
cells has been shown to inhibit further V(D)JH recombination 
26. µHC in 
association with the surrogate light chain (LC) components VpreB, λ5 and the 
signalling heterodimer Igα and Igβ comprise the pre-BCR.   
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In both humans and mouse the pre-B cells can be divided into large proliferating 
pre-BI and small post mitotic pre-BII cells. The pre-BI cells express cytoplasmic 
µHC while the pre-BII cells express the pre-BCR 1. Human pre-BI cells partially 
overlap with Hardy fraction C 4.  
The genes encoding the two proteins VpreB and λ5 were originally identified in 
mouse and their organisation differs in mouse and humans 1. Mice with a 
targeted disruption in the λ5 locus exhibit a block at the pro-B to pre-B 
transition 27 but the number of B cells in secondary lymphoid tissue gradually 
increases over time so this block is not absolute. Moreover, the discovery of an 
agammaglobulinemia patient with mutations in both λ5 and a severe disruption 
in B cell development underscores the importance of the surrogate light chain 
components in human B cell development 28. Expression of these proteins in 
human cell lines has been defined using MAbs (monoclonal antibodies) that 
recognise the specific components of the surrogate light chains. Expression of a 
signalling-competent pre-BCR is an important checkpoint for developmental 
progression and survival. In mice, targeted mutations in the different pre-BCR 
components including the trans-membrane domains of Igα or Igβ result in 
developmental arrest at the pro to pre-B cell checkpoint 28-30.  Pre-B cells lose 
TdT and CD34 expression. Pre-BCR signalling is shown to be required for allelic 
exclusion at the heavy chain locus and phenotypic changes in proliferating B 
cells in response to IL-7 signalling 31.  
Igα and Igβ are immunoglobulin superfamily members that activate cellular 
signalling pathways through cytoplasmic immunoreceptor tyrosine-activating 
motifs (ITAMS) by recruiting Src, Syk family kinases and  the Tec family kinase 
Btk (Burton’s tyrosine kinase) 32-35.  Several Src kinases, including Lyn, Fyn and 
Blk and variety of other signalling molecules appear to contribute to BCR or pre-
BCR signalling in a redundant fashion as deletion of genes encoding individual Src 
kinases has little effect on B cell development 36-38. However other components 
of the BCR signalling pathway such as Syk, Blnk , PI3K, Btk  have been shown to 
be non-redundant as deletion of these components impairs B cell development 
39-44.  Signalling through the pre-BCR regulate HC allelic exclusion and induce 
pre-B cell development. Neither allelic exclusion nor pre-B cell development  
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occurs in the absence of tyrosine phosphorylation of ITAM motifs in the 
cytoplasmic domain of Igα and Igβ 45.  B cells that fail to assemble pre-BCR fail 
to progress in development and are deleted. It is still debated whether pre-BCR 
cross-linking by an unknown ligand or simple surface expression is sufficient to 
trigger allelic exclusion and pre-B cell development. 
Cells displaying the pre-BCR expand through a proliferative burst and initiate 
light chain gene (k or λ) rearrangements. After clonal expansion the pre-B cells 
arrest in G1 phase of cell cycle and RAG and Igκ germline gene transcripts are 
expressed for light chain gene recombination. Successful rearrangement of the 
light chain genes results in the expression of the BCR on the cell surface. These 
cells, termed immature B cells, express cell specific surface IgM and emigrate to 
secondary lymphoid organs. Here, they mature further into immunocompetent B 
cells (IgM+ and IgD+), which in response to primary antigen challenge and T cell 
support can differentiate into Ig secreting plasma cells.  
Immature B cells are particularly susceptible to BCR-induced apoptosis 46  and it 
is in this compartment that self-reactive B cells failing to edit their receptors 
are deleted or anergized 46 . The BCR is an essential regulator of immature B cell 
development since in the absence of cytoplasmic domain of Igα, BCR with a 
single functional Igβ produce few pre-B cells and immature B cells and most of 
these fail to progress to mature B cell stage 47. Immature B cells that emigrate 
from the bone marrow to the periphery are termed transitional B cells and can 
be distinguished from mature B cells by a series of cell surface markers such as 
CD10, CD38,  IgD and IgM  48. 
Transitional B cells are short-lived and only 10-30% of these cells enter the long-
lived mature peripheral B cell compartment 49,50. The mechanisms that govern 
selection of newly-generated transitional B cells to the long-lived B cell 
compartment are poorly understood but once again BCR signalling appears to be 
an important determinant as loss of BCR expression by conditional IgM ablation 
inhibits this transition to mature B cell stage 51.  In addition, in the absence of 
functional Igα, Syk, Btk, Vav, Lyn, CD45 or CD19 molecules BCR signalling is 
insufficient to induce differentiation of transitional B cells into mature B cells 
47,52,53. 
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1.1.3 B-1 B cells 
The predominant population of B lymphocytes, known as B-2 B lymphocytes, is 
present in the spleen and lymph nodes. These B-2 B cells are produced in the 
bone marrow during postnatal life and migrate to the spleen and lymph nodes 
where, after progressing through several transitional stages, they mature into a 
major follicular (FO) and  minor marginal zone (MZ) B lymphocyte populations. 
While the MZ B lymphocytes do not circulate and respond to blood borne 
antigens, the FO B lymphocytes respond to protein antigens and in response to 
T-cell help undergo class switching and affinity maturation into B-2 lymphocytes. 
A minor population of B-1 B lymphocytes (about 5%) is localised to serous 
cavities. Although the bone marrow retains the potential to produce B-1 B 
lymphocytes they are most effectively generated from progenitors that arise 
during foetal hematopoiesis. Similar to all B cells, B-1 cells express the B lineage 
antigens CD19 and CD45, although CD45R is present at lower levels on B-1 cells 
than on B-2 cells 54. Murine B-1 cells can be distinguished by the phenotype 
B220low CD23- CD43+ IgMhi and IgDlow. B-1 cells in the peritoneal and pleural 
cavities also express CD11b. Therefore they are of the phenotype CD11b+ IgMhi 
IgDlow. These cells can further be sub-divided on the basis of differential 
expression of cell surface antigen CD5 as CD5+ B-1a cells or CD5- B-1b cells 55. B-
1 cells can also be distinguished from conventional B cells by patterns of 
anatomical localisation. In mice, B-1 cells are almost completely absent from 
lymph nodes and  make up about 5% of splenic B cells. However they constitute 
a substantial fraction of B cells in the peritoneal and pleural cavities 56,57. In 
addition to surface phenotype, B-1 cells have a number of distinguishing 
properties. In vitro they are long lived 58, refractory to activation through BCR 
ligation 59-61 and in contrast to B-2 cells they can be induced to proliferate by 
treatment with phorbol esters 62. 
B-1 cells are effectors of innate immunity and mainly respond to T-cell-
independent immunogens (thymus-independent type 2 antigens) that include 
carbohydrate antigens, by producing mainly IgM and some IgG3 antibodies. These  
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cells provide a first line of defence against pathogens by spontaneously secreting 
IgM antibodies. B-1 cells share many phenotypic characteristics of MZ B cells and 
like these latter cells appear to develop in response to T-cell-independent type 
2 antigens. The immunoglobulin repertoire of B-1 cells is less diverse compared 
to B-2 cells and this is reflected in their capacity to respond to antigens 63,64. 
Studies have shown that CD5+ cells produce natural polyreactive antibodies, that 
are often auto-reactive, of the IgM isotype 65.  
Although B-1 cell function in innate immunity is generally well-established the 
origin of B-1 cells has been a controversial topic. The debate has centred around 
two models of B-1 cell development. The selection model proposes that B-1 and 
B-2 cells are derived from a common progenitor and antigen selection at the 
IgM+ stage determines whether a B cell will follow the B-2 or B-1 differentiation 
pathway 66,67. This model is based on experiments demonstrating that cross 
linking of the BCR in the absence of antigen or T-cell help resulted in expression 
of CD5 by splenic B-2 cells and conferred upon them the ability to proliferate in 
response to phorbol esters  68,69. Further evidence for this model was provided by 
results from transgenic mice generated with the VH gene from the VH12 family, 
which is preferentially expressed by B-1-lineage cells and was inserted into the 
immunoglobulin heavy chain locus. The VH12 expressing mice mainly generated 
B-1 cells, whereas those expressing B-2-cell-associated VH specificities mainly 
generated B-2 cells 67. 
By contrast, the lineage model proposes that B-1 and B-2 cells are separate 
lineages that derive from distinct haematopoietic progenitors. This is based on 
the observation that foetal tissues most efficiently repopulate B-1 cells in 
irradiated immunodeficient recipients while  adult bone marrow preferentially 
repopulates B-2 cells 55,70,71. Moreover, recent studies identifying B-1-cell 
progenitors 72 and showing distinct cytokine requirements for B-1-cell and B-2-
cell development  provide further support for this model 73,74 . The fact that the 
foetal B cell development is skewed to B-1 cells indicates interesting differences 
between foetal and adult hematopoiesis.  Although the adult HSCs preferentially 
generate B-2 cells, they retain the potential to generate B-1 cell progenitors.  
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A variety of influences from transcription factors, differences in the 
microenvironment and cytokine expression during adult and foetal 
haematopoiesis will have important regulatory roles in guiding B-1 or B-2 cell 
development pathways. 
Another important factor in B-1 cell differentiation is the BCR. It is known that 
B-1 cell development is promoted by strong signalling through the BCR 75.  
Blockade of most of the positive regulators of BCR signalling such as BLNK, 
PLCγ2, VaV, Rac, PI3K, BCAP and CD19 leads to absence of peritoneal B-1 cells 
40,42,76-78, while disruption of some negative regulators of BCR signalling such as 
CD22 and PIRB which leads to greater strength of BCR signalling, leads to a 
greater number of peritoneal B-1 cells only  79,80.  This indicates that the 
strength of BCR signalling regulates which mature subsets can develop.  
The murine B-1a cells have been considered the murine equivalent of human 
CD5+ B cells. In humans, the CD5 marker was first identified on malignant B-CLL 
(chronic lymphocytic leukaemia) cells and only subsequently demonstrated as a 
marker for normal B cells 81. Because B-1 cells often produce auto-reactive 
antibodies, although non-pathogenic and of a low affinity, this has led to 
interest in these cells as possible sources of high affinity pathogenic 
autoantibodies seen in polysystem autoimmune diseases. Indeed, there are 
examples, in both humans and mice, of an association between autoimmune 
disease and B-1 cells. CD5+ B cells emerge at a crossroad between malignant and 
auto-reactive B cells. A monoclonal expansion of CD5+ B cells is a feature of  
malignant diseases such as B-CLL and MZ lymphoma 82,  while a polyclonal 
expansion is observed in systemic autoimmune diseases like RA, SS (systemic 
sclerosis) and occasionally SLE  (systemic lupus erythematosus) 83,84 85. Therefore 
a study of B cell differentiation into B-1 or B-2 subsets could provide important 
information in understanding malignant transformations as well as 
autoimmunity.  
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1.2 Haematopoietic microenvironment 
Hematopoiesis is known to take place in the intersinusoidal spaces of medullary 
cavities in the bone. HSCs are located at the stem cell niche in the  endosteal 
surface in association with osteoblasts 86 and the HSCs destined to generate the 
different blood cell types ultimately exit from this niche and associate with 
stromal cell populations that form a three-dimensional network between venous 
sinusoids 87,88. The bone marrow microenvironment is composed of a 
heterogeneous population of stromal cells and their products, such as extra 
cellular matrix components and various cytokines and chemokines. These 
cytokines, chemokines and adhesive molecules play a critical role in regulating 
the survival, proliferation and differentiation of the precursor cells.   Studies on 
mice and patients with human immunodeficiencies have led to the identification 
of some important regulatory molecules including IL-7, Flt3 ligand, the 
chemokine SDF-1 (stromal cell derived factor-1) and many still remain to be 
identified. The binding of Flt3 ligand (FL) to Flt3 receptor is important in normal 
B lymphopoiesis as the number of pre-pro-B and pro-B lymphocytes is reduced in 
FL-/- and Flt3-/- mice 89,90. Murine but not human B cell development is absolutely 
dependent on the presence of stromal cell-derived IL-7 and the expression of its 
receptor on developing B cells 91,92. Stromal cell derived factor is a chemokine 
that has been shown to have established roles in B cell development.  
1.2.1 SDF-1 
Stromal cell interactions and mobilisation and trafficking of haematopoietic 
precursors are thought to be controlled by cytokines, particularly chemokines 93. 
In addition, some chemokines have been reported to modulate cell growth and 
survival 94-99. Chemokines are a family of low molecular weight chemoattractant 
cytokines that bind specific G protein-coupled transmembrane receptors on 
target cells.  
Stromal cell derived factor-1 (SDF-1) or CXCL12 is a member of the CXC 
chemokine family 100 and binds to  its receptors CXCR4 and CXCR7 101,102. Two 
alternate splice variants of the SDF-1 gene give rise to SDF-1α and SDF-1β which  
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are identical except for an additional four amino acid residues in the carboxy 
terminus of SDF-1β. Gene inactivation of SDF-1 and CXCR4 in vivo leads to 
embryonic lethality due to abnormal cerebellar and gastrointestinal vasculatures 
and haematopoietic development 103-105. Studies by Ma, et.al., in knockout mice 
and in chimeric mice that transmitted the CXCR4 mutations in the genome, show 
that mice deficient for CXCR4 die perinatally and display profound defects in the 
haematopoietic and nervous systems. CXCR4-deficient mice have severely 
impaired B lymphopoiesis and reduced myelopoiesis in the foetal liver and a 
virtual absence of myelopoiesis in the bone marrow 106.   
SDF-1 and CXCR4 are expressed constitutively in a wide range of tissue types 
including brain, heart, kidney, liver and spleen. CXCR4 is expressed not only on 
lymphocytes and monocytes in peripheral blood, but also on a variety of other 
cell types including microglia, astrocytes and neurons. SDF-1 is constitutively 
produced by many cell types including immature osteoblasts and endothelial 
cells within the bone marrow as well as by epithelial cells in many organs such as 
in the central nervous system 107,108.  
The role of SDF-1 in migration and homing of haematopoietic progenitors is well 
established. It is known to be the most powerful chemoattractant for 
undifferentiated human CD34+ haematopoietic progenitors 109,110. A number of 
studies have shown that SDF-1 is essential for activation of the integrins LFA-1, 
VLA-4 and VLA-5 111,112 leading to enhanced integrin-mediated adhesion to 
ligands such as ICAM-1, VCAM-1 and in facilitating transendothelial migration as 
well as homing and  engraftment of  precursor B cells in the bone marrow of 
NOD/SCID mice 113,114. In addition to its established role in regulating cell 
motility, a number of studies have shown that SDF-1 can also play a role in cell 
survival 93,115 and proliferation 116 often in synergy with other cytokines. SDF-1 
has been directly implicated in survival of pre-B cells in vitro 115. Lataillade, et. 
al., showed that SDF-1 enhances circulating CD34+ cell proliferation with other 
cytokines and that SDF-1 acts as a survival factor in counteracting peripheral 
blood CD34 + cell apoptosis 117.  
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CXCR4 ligation by SDF-1 has been shown to induce receptor internalisation, 
elevation of cytoplasmic Ca2+ levels, activation of phosphatidylinositol 3-kinase 
(PI3K), phosphorylation of MEK/ERK and phosphorylation of components of focal 
adhesion complexes including paxillin, p130cas, and focal adhesion kinase in 
many cell types 118-121. Work by Arai, et.al., showed that SDF-1 and IL-3 
synergistically increase the number of viable cells and induce a chemotactic 
response of haematopoietic cells, in an ERK-dependent manner 122. SDF-1-driven 
proliferative signals are thought to be mediated via the MEK/ERK and PI3K/AKT 
signalling pathways 123,124 and survival signals through PI3K/AKT 125. Recent work 
by Bendall, et. al., also shows that defective p38 MAPK signalling impairs 
chemotactic but not proliferative responses to SDF-1 in acute lymphoblastic 
leukaemia (ALL) cells indicating a distinct role for SDF-1 in leukemic B cell 
survival 126.  
1.2.2 Signalling pathways mediating B cell survival 
B cell survival, differentiation and maturation involves a delicate balance 
between apoptosis and proliferation. The complex mixture of growth factors, 
extracellular matrix and stromal cells provides extrinsic signals that can activate 
a variety of signalling pathways leading to growth, differentiation and survival of 
B cell precursors. Survival stimuli activate intracellular signalling through the 
ligation of transmembrane receptors which either possess intrinsic tyrosine 
kinase activity, are indirectly linked to tyrosine kinases (such as integrins) or are 
coupled to seven transmembrane G –protein-coupled receptors. Activation of 
these receptors results in the recruitment of signalling molecules that activate 
signalling pathways such as the ERK/mitogen activated protein kinase (MAPK) 
pathway and the phosphatidylinositol 3-kinase (PI3K) pathway. 
1.2.2.1 ERK- mitogen activated protein kinase ( MAPK) pathway 
It is well established that many of the cytokines and growth factors regulating 
hematopoiesis activate MAP kinase sigalling pathways to generate their effects 
including phosphorylation of transcription factors, regulation of transcription, 
nuclear chromatin remodelling, immediate gene induction as well as regulation 
of apoptosis and cell cycle progression 127. 
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Three major groups of MAP kinases (MAPKs) exist: the p38 MAP kinase family, the 
extracellular signal-regulated kinase (ERK) family, and c-Jun NH2-terminal kinase 
(JNK) kinase family. Biological activities vary with specific family of MAPKs 
activated and stimulus initiating the activation. In general, the Ras/ERK pathway 
mediates primarily cell growth and survival signals and in certain circumstances 
is known to promote cell differentiation 127-132. The p38 and JNK pathways are 
known to mediate pro-apoptotic and growth inhibitory signals as well as 
proinflammatory signals128-132. However, the p38 MAPK pathway may also be 
involved in inducing anti-apoptotic, proliferative and survival signals under 
certain conditions, depending upon the tissue-specific isoforms involved.  
One of the most extensively studied MAPK pathways is the Raf/MEK/ERK cascade 
and it has been implicated in many chronic and acute leukaemias. The upstream 
activators of ERK are the MEK (or Map kinase kinase) family of kinases which are 
dual-specificity kinases that can phosphorylate both serine/threonine and 
tyrosine residues on the MAPKs. A kinase responsible for activation of MEK is Raf 
and upstream of Raf is the GTPase Ras. Ras is an oncoprotein and has been 
shown to be mutated in approximately 20% of all human malignancies 133. ERK1 
and ERK2 are 43/44 and 41/42 kDa kinases, respectively, that are directly 
downstream of the MEKs. Phosphorylated ERKs in turn phosphorylate and 
activate a number of transcription factors such as ELK-1,  CREB (cAMP) response 
element binding protein, c-Myc, Nuclear factor-κB, Activator protein family 
transcription factors-1(AP-1),  and Ets family members. They also activate other 
protein kinases such as p90RSK and enzymes such as cytoplasmic phospholipase 
A2
127. In addition, ERK1/2 are also known to regulate apoptosis by 
phosphorylation of  the pro-apototic protein BIM (Bcl-2-interacting mediator of 
cell death) 134. The duration and degree of MAPK activation is dependent on a 
delicate balance between the activating signals and inactivation mechanisms. 
Removal of a phosphate from the phosphorylated residues (tyrosine and 
threonine),  through the action of phosphatases  results in decreased activity.  
Constitutive ERK1/2 activation has been reported frequently in solid tumors 
135,136as well as in hematological and neoplastic disease, particularly AML (acute 
myelogenous leukaemia) 137. In relation to ALL, constitutive ERK1/2 activation  
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was reported in ALL cell lines and in a limited number  of clinical ALL specimens 
138 Gregorj, et. al., demonstrated constitutive ERK activation in leukemic 
samples and showed that ERK1/2 phosphorylation is an independent predictor of 
complete remission in newly-diagonsed adult ALL 139. Furthermore R115777, an 
enzyme-specific inhibitor of farnesyl protein transfterase (FT), developed as a 
potential inhibitor of Ras signalling in ALL, was shown to have important anti-
leukemic activity in phase 1 clinical trials 140.  
1.2.2.2 Phosphatidylinositol 3-kinase (PI3K)/ AKT pathway  
The PI3K/AKT pathway often transduces signals that are similar in nature to that 
of the Raf/MEK/ERK pathway. Phosphatidylinositol-3-kinase (PI3K) is found as a 
dimer of two subunits (p85 regulatory subunit and p110 catalytic subunit) in 
resting cells. Upon activation of receptor tyrosine kinases, and subsequent 
autophosphorylation, the SH2 domains of the p85 subunit bind to the receptor’s 
phosphorylated residue and PI3K then phosphorylates PIP2 (phosphatidylinositol 
4,5 bisphosphate) generating PIP3 (phosphatidylinositol 3,4,5 triphosphate) at 
the cytoplasmic membrane 141. PIP3 in turn activates and  phosphatidyl inositol 
dependent kinases (PDKs) and their downstream substrate AKT/PKB 142. AKT, 
activated by phosphorylation by the PDKs, in turn phosphorylates a variety of 
downstream substrates including the pro-apoptotic BCL-2 family member BAD 
143. BCL-2 is the prototype for a large family of related proteins that regulate 
cell death in mammalian cells 144. Some of these proteins such as BCL-2 and BCL-
XL promote cell survival whereas other proteins in the family such as BAX and 
BAD promote cell death. AKT phosphorylation of BAD on serine-136 results in its 
inactivation and cell survival. When BAD is dephosphorylated in the absence of 
survival signals it interacts with the pro-survival BCL-2 family members and 
inactivates them causing cell death. Two pharmacological inhibitors of PI3K have 
been used extensively: Wortmannin and LY294002 [2-(4-morpholinyl)-8-phenyl-
4H-1-benzopryran-4-one] 145,146. Although both of these inhibitors are useful in 
blocking PI3K signalling neither of them has the capacity to directly inhibit AKT.  
Abrogation of oncogenic signals from PI3K occurs mainly via the tumour 
supressor gene product PTEN which is a phosphatase 147. 
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Cross-talk between PI3K and Raf/MEK/ERK pathways has been reported on 
multiple levels  148-150. In addition to controlling Raf kinases, Ras has also been 
shown to interact and stimulate PI3K activity leading to AKT activation. Some 
studies suggest that the PI3K pathway enhances and/or synergises with 
Raf/MEK/ERK pathway to provide robust signalling through ERK 151-153, while 
there is also conflicting evidence that AKT phosphorylates Raf abrogating 
downstream signalling pathway activation 153-155. However, this effect may be 
dependent on the differentiation state of the cell 156. Regardless of the cell 
type, differentiation state or assay conditions used it is apparent that there is a 
varying degree of cross-talk between these two pathways important in cell 
proliferation and survival. Study of the activation and inhibition of these 
pathways in B cell proliferation and survival is instrumental in the development 
of new agents designed to treat leukaemias. 
1.3 Precursor cells and stromal cell interactions 
A second general means by which stromal microenvironment regulates B cell 
development is via direct cell contact. Direct contact of the progenitor cells 
with bone marrow stromal cells is particularly important during the early B cell 
developmental stages 157. Developing B cells have been observed to grow in close 
association with stromal cells and the contact between the progenitor cells and 
bone marrow adherent layers is maintained by a combination of adhesion 
molecules including VCAM-1, ICAM-1 on bone marrow stromal cells and the β1 
integrins VLA-4, VLA-5 and β2 integrin LFA-1 on the B cell surface 158,159.  
Stromal cell and B cell interactions possibly involve a variety of mechanisms 
important for regulating growth survival and differentiation of B cell precursors. 
CD23 is a glycoprotein known to be expressed on human bone marrow stromal 
cells 160 and the  membrane bound or soluble CD23 could potentially  play an 
important regulatory role in growth and survival of B cell precursors.  
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1.3.1 CD23 
CD23 was initially identified as a B cell differentiation antigen and subsequently 
established as the low-affinity receptor (FcεRII) for immunoglobulin E (IgE). It is 
a surface antigen expressed by haematopoietic cells and some epithelial cell 
subsets. CD23 is expressed weakly on a minority of freshly-isolated resting B 
cells from peripheral blood or tonsils and is both dramatically and rapidly up-
regulated on the B cell surface following activation by stimuli such as EBV 
(Epstein Barr Virus), phorbol esters and interleukin 4 (IL-4), IL-3 and CD40 161-165. 
Furthermore, CD23 expression is a requisite marker for susceptibility to growth 
transformation by EBV and indeed all EBV-immortalized B cell lines are CD23 
positive 166,167. CD23 expression was said to be a feature restricted to primary B 
cells expressing IgM/IgD 168, however CD23 was also shown to be expressed by 
pro-B cells after triggering of CD40 in the presence of IL-3 169. 
CD23 functions both as a receptor and a ligand. As the low-affinity receptor for 
IgE, it is a focus for IgE immune complexes leading to modulation of allergic 
responses. As an adhesive molecule, CD23 interacts with CD21 to regulate IgE 
production, germinal centre B cell survival and presentation of soluble protein 
antigen by B cells to T cells. Membrane-bound CD23 can be cleaved into soluble 
fragments that act as cytokines in vitro. Potentially different forms of the 
membrane-bound and soluble forms of CD23 have been described, making it an 
important player in allergic, autoimmune and lymphoproliferative disorders. 
1.3.1.1 CD23 Structure  
CD23 is the only FcR which does not belong to the immunoglobulin super-family 
170. The CD23 gene on chromosome 19 171 codes for two isoforms (a and b) 
differing in their 5’ untranslated sequence and in their intracytoplasmic region. 
The CD23a isoform expression is restricted primarily to B cells but CD23b isoform 
is inducible by IL-4 on a variety of haematopoietic cells 172. Human CD23 is a 45 
kDa glycoprotein member of the C-type lectin family, with a long C-terminal 
extracellular domain (277 residues), a short cytoplasmic N-terminus (23 
residues) and is anchored by a single transmembrane domain (20 residues). As a 
type II integral transmembrane protein it has the COOH terminus oriented 
extracellulary and the short NH2 terminus oriented intracellularly 
173-176. 
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Figure  1.2 Schematic representation of membrane bound CD23. 
 
The important structural features shown are the lectin head domain, leucine zipper motif that 
mediates formation of trimers and the arrows indicate the cleavage sites for soluble CD23 
fragments. Sequences differing in the two isoforms at the N-terminal region are also shown. Figure 
reproduced from Schwarzmeier J. D, et.al., (2005) 177. 
 
 
 
 
 
 
Mridu Acharya,2008   Chapter 1, 32 
 
A model of membrane bound CD23 is represented in Figure 1.2. The extracellular 
region of CD23 comprises three important features:  
(a) The leucine zipper motif near the transmembrane domain consists of seven 
amino-acid motifs that are repeated five times in case of the human CD23 and 
forms an α-helical coil stalk region. This region mediates the formation of 
trimers. 
(b) The lectin head domain that comprises IgE binding site 178 consists of four 
highly conserved and two partially conserved cysteine residues that interact by 
disulphide bonds and contain the Ca2+ and sugar binding amino acids. The region 
delimited by Cys163 and Cys282 encodes all the structural information required 
to form the IgE binding site 179. The cytokine effects of CD23 are mediated by an 
epitope distinct from the IgE binding site 180.  
(c) A DGR sequence, which in inverse is a common recognition site for integrins 
is located near the C-terminus of the molecule.  
Similar to most FcR, CD23 exists in soluble and membrane-bound forms. 
Membrane-bound CD23 is cleaved into soluble fragments 181 by mechanisms 
involving matrix metalloproteases. Soluble CD23 is first released as an unstable 
37-33 kDa molecule which is subsequently transformed into more stable 25 kDa 
fragments 182. 
IgE plays a central role in allergic diseases and the first receptor identified for 
this molecule, termed FcεRI, binds IgE with such a high affinity (Ka~ 1010M-1)  on 
cells bearing FcεRI  are permanently coated with IgE and thus sensitized for 
rapid release of molecules promoting immediate inflammatory response  when 
cross-linked with allergen. CD23 binds to IgE with lower affinity (Ka~ 107M-1) and 
this interaction is involved in both IgE regulation and antigen presentation by B 
cells.  
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Binding of IgE to CD23 is calcium-dependent and appears to involve protein-
protein interactions since deglycolysated native IgE peptides are able to bind 
CD23 183. However, Delespesse, et. al., 1992 showed an ability of fucose-1-
phosphate to inhibit binding of native IgE to soluble CD23, therefore CD23-IgE 
binding probably involves protein-protein and protein-carbohydrate interactions 
184. IgE-CD23 interactions have been implicated in many IgE dependent roles, 
including combating parasitic infestations 185, induction of IgE synthesis 186 and 
maintenance/modulation of IgE responses 187. 
CD23 is known to play a regulatory role in IgE production with positive and 
negative effects. CD23 acts as a buffer in negative feedback regulation of IgE, as  
membrane-bound CD23 delivers a down-regulatory signal for IgE synthesis by B 
cells when engaged by IgE-allergen complexes 188, while sCD23  is known to act 
as a B cell growth factor up-regulating the production of IgE when in trimeric 
forms. It has been proposed that trimeric sCD23 promotes IgE synthesis by cross-
linking membrane IgE and CD21 on B cells committed to IgE synthesis 189. CD21, 
the EBV and complement receptor-2 (CR2) were identified as second ligands for 
CD23 190 . Engagement of B cell CD21 by either anti-CD21 antibodies or by 
recombinant CD23 leads to IgE secretion by B lymphocytes in the presence of IL-
4 190,191. The CD23-CD21 interaction is known to be critical for enhancing contacts 
between T and B cells and other molecules such as CD40 provide co-signals for 
this interaction 192,193.  
CD23 has been shown to be physically associated with the MHC class II molecule, 
HLA-DR on B cells which indicated that it could act as an accessory molecule in T 
cell interactions with antigen presenting cells 194,195. CD23 occupancy by anti-
CD23 antiboides (MHM6 and EBVCS4) and IgE  was shown to prevent B cells from 
stimulating allogeneic T cells 194 and further investigation showed that the 
CD23/CD21 interaction is required for presentation of conventional, soluble 
protein antigens by B cell lines to CD4+ T cell clones 196. This antigen 
presentation function requires the binding of antigen-IgE immune complexes to 
CD23, internalization of the complexes and transport to compartments of the 
endosomal network containing proteolytic enzymes and MHC class II antigens.  
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CD23 on macrophages, eosinophils and platelets mediates IgE-dependent 
cytotoxicity and promotes phagocytosis of IgE-coated particles 185. Various 
studies have shown that engagement of membrane CD23, on 
monocytes/macrophages leads to production of important inflammatory 
modulators; for example, production of cyclic AMP (cAMP), TNF-α and lipid 
mediators after ligation of CD23 in IL-4 activated monocytes 197,198,  nitric oxide 
production (NO) in human monocytes, macrophages and eosinophils 198-200. 
Furthermore, CD23 engagement in pro-monocytes was shown to induce 
differentiation as well as activation of the transcription factor NF-κB, induction 
of the proto-oncogenes c-fos, c-jun and junB and production of TNF-α 201. 
The fact that not all of the activities of CD23 can be attributed to its interaction 
with IgE or CD21 has led to research on novel ligands for CD23. β2 integrins 
CD11b/CD18 and CD11c/CD18 and the vitronectin receptor αvβ3 integrins were 
identified as receptors for CD23 202,203. Triggering CD11b and CD11c on 
monocytes with recombinant CD23 was shown to cause an increase in production 
of proinflammatory cytokines IL-1α, IL-1β, Interferon-γ (INF-γ), IL-6 and tumour 
necrosis factor α (TNFα) as well as marked increase in nitrite (NO2
-) and H2O2 
production 202,204. Another study showed triggering of the β2 integrins on primary 
human monocytes provides activation signals leading to nuclear translocation of 
NF-kB and subsequent secretion of MIP1α (macrophage inflammatory protein) 
and MIP-1β 205. This may have important roles in recruitment of other 
inflammatory cells during initiation of an inflammatory response. The vitronectin 
receptor αvβ3 in association with CD47 was shown to induce sCD23-mediated 
pro-inflammatory function by production of TNF-α, IL-12 and IFN-γ 203. 
1.3.1.2 sCD23 and B cell growth 
CD23 can be described as a multifunctional cytokine. Soluble fragments of CD23 
retain the capacity to bind IgE but have also been ascribed numerous cytokine-
like activities. CD23 induces various growth promoting and differentiation 
effects on haematopoietic cells in synergy with the cytokine IL-1α.  In vitro 
experiments show that sCD23 in synergy with IL-1α prevents centrocyte 
apoptosis and drives the cells towards a plasmacytoid phenotype 206, induces  
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maturation of precursor T cells in the thymus 207,208 as well as increasing 
proliferation of mature CD4+ T cells in response to mitogens such as PHA 
(phytohemagluttinin) 209 and drives proliferation and maturation of bone 
marrow-derived CD34+ myeloid precursors 210. The significance of these 
observations is underlined by in situ detection of CD23 producing cells in the 
thymus (on a subset of epithelial cells) 207, in bone marrow (on stromal cells) 160 
and in the light zone of germinal centres ( on follicular dendritic cells) 203.  
1.3.1.3  CD23 and EBV 
Growth-promoting effects of the CD23 molecule are closely related with EBV 
transformation. EBV belongs to Herpesvirus family 211 and has been closely 
associated with endemic forms of Burkitt’s lymphoma (BL), while the majority of 
sporadic BL are not EBV related. Although this virus is known to be the causative 
agent in endemic BL its precise role is not fully understood. CD23 is associated 
with the immortalising properties of the virus and as mentioned above the non-
immortalising strains of this virus do not up-regulate CD23 expression. The 
Epstein-Barr virus nuclear antigen (EBNA-2) and latent membrane protein-1(LMP-
1) are two latent genes essential for immortalisation of human B cells and both 
of these genes are involved in CD23 expression 212,213. B cell infection by EBV is 
often considered as a model for B cell activation 167. Following transformation by 
EBV, B cells are activated to release sCD23 that contains autocrine growth-
promoting activity 214,215. In vitro experiments clearly demonstrated that sCD23 
acts as a growth factor for both EBV-immortalised cell lines and antigen receptor 
stimulated normal B lymphocytes 215. 
Apart from the cases of EBV transformed lymphblastoid cell lines (LCLs,) Gordon, 
et. al., have shown that anti-CD23 MAb provided a progression signal to human B 
cells primed by phorbol ester to enter the G1 phase of cell cycle 216. CD23 was 
also shown to enhance growth promoting effects of IL-4 and antibodies to CD40 
214,217. Work by Fournier, et. al., showed that CD23 could play a role in leukemic 
B cell disease, especially chronic lymphocytic leukaemia (CLL); since IFN-α and 
IL-2 selectively upregulated CD23b and stimulated growth of  malignant B cells  
while IL-4 and IL-2 upregulated CD23a and had no growth promoting activities 
but suppressed B-CLL apoptosis 218,219.  
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1.3.1.4 CD23 in disease  
CD23 is involved in a variety of allergic diseases owing to its role in IgE 
regulation. However sCD23 levels are known to be increased in diseases in which 
IgE is not implicated. As mentioned above, a characteristic feature of CLL is high 
serum concentrations of sCD23 which can be 500 times higher than in normal 
individuals and  sCD23 appears to be an independent prognostic variable in this 
disease 220. Interestingly it was also shown that CD23 expression is markedly 
stronger in proliferating CLL cells located in splenic white pulp and proliferating 
centres in lymph nodes in comparison to CLL cells outside these proliferation 
centres 221. Increased CD23 levels have been reported in various chronic 
inflammatory diseases including systemic lupus erythematosus (SLE) 222, 
inflammatory bowel disease 223, Sjogren’s syndrome 222 and rheumatoid arthritis 
(RA)224,225. In the case of RA, successful disease modulation was achieved when 
arthritic mice were treated with either MAb or polyclonal antibodies to mouse 
CD23 in the typeII collagen-induced arthritis (CIA) mouse model 226. This clearly 
establishes the therapeutic importance of CD23 in these disease conditions. 
Although the disease amelioration in the CIA mouse by using anti-CD23 
antibodies is attributed to blocking of cytokine production by macrophages, the 
variety of roles for CD23 in B cell activation and growth indicate a strong role for 
CD23 on B cells in diseases where there is clonal expansion of malignant B cells 
such as CLL or in autoimmune diseases such as SLE.  
The pleiotropic activities of soluble CD23 fragments and particularly the 
activities relating to B cell activation and growth, have not been shown in vitro 
in mouse cell lines or in genetically-engineered mice. Studies in mice have 
confirmed the negative regulatory effects of CD23 in IgE production. Targeted 
deletion of both CD23 alleles (CD23-/-) in mice was shown to produce higher 
levels of IgE than wild-type equivalents on immunisation with thymus-dependent 
antigens 227. Moreover, over-expression of CD23 under certain genetic 
backgrounds showed reduced IgE production in response to antigenic stimulation 
228. Recently, a naturally occurring dominant negative CD23 allele in NZB mice 
was shown to have reduced IgE binding and failed to produce negative feedback 
regulation for IgE responses 229.  However these mice had normal B lymphocyte 
growth and maturation indicating perhaps the differences in the role of human 
and murine CD23 in modulating B cell growth. 
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Several differences in structure and cellular expression may account for the 
differences in function between the human and murine CD23. Murine CD23 has 2 
instead of 1 N-linked glycoslation sites, 4 instead of 3 consensus repeats in the 
leucine zipper motif 173,178 and is also not known to form trimers as it lacks the 
DGR motif by a naturally occurring truncation and the sCD23 fragments bind IgE 
with much lower affinity 230. Murine CD23 is expressed only on B cells, follicular 
dendritic cells and some T-cells. Interestingly the mouse CD21 does not bind EBV  
and mouse and human CD23 could also have evolved with different function in 
relation to EBV infection 231. 
Previous work from our laboratory identified the vitronectin receptor αvβ5 as a 
CD23 receptor on SMS-SB cells. SMS-SB cells do not express CD21 or any other 
CD23 receptors identified and do not produce CD23 mRNA for autocrine CD23 
activity. αVβ5 was shown to bind to an RKC motif (arg-lys-cys) on human CD23 
and this interaction sustained proliferation of the pre-B cell line, SMS-SB 232. The 
growth-promoting effects of sCD23 described so far have been in the mature B 
cells whether it is EBV-transformed LCLs, germinal centre B cells or normal 
mature B cells and these effects have been attributed to CD23-CD21 
interactions. With regard to haematopoiesis, a role for CD23 has been suggested 
either in the myeloid precursors or T cell precursors.  CD40 ligation together 
with IL-3 was indeed shown to induce CD23 expression 169 in human  B cell 
precursors and induce proliferation 169,233. Considering the important role of 
CD23 in mature B cells and other haematopoietic precursors and the expression 
of CD23 by bone marrow stromal cells, it is conceivable that CD23 plays some 
role during B cell development in the bone marrow. However, the precursor B 
cells do not express CD21 and therefore any effects of CD23 on these cells would 
have to be via another receptor.  As shown by the previous work in our 
laboratory on SMS-SB cells, the CD23-αVβ5 integrin interaction could be an 
important mechanism for survival of B cell progenitors in the bone marrow, 
independently or together with other cytokines and adhesion molecules. 
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1.3.2 Integrins 
Integrins are heterodimeric transmembrane adhesion receptors composed of non 
covalently bound α and β subunits 234-237. They mediate cell-to-cell and cell-to-
extracellular matrix (ECM) interactions and are involved in fundamental cellular 
processes such as cell proliferation, migration, differentiation and apoptosis 237. 
The integrin family is composed of 18α and 8β subunits and each α and β 
combination has its own binding characteristics. The integrins are expressed in a 
cell type-specific manner and despite a high degree of redundancy most 
integrins have specific biological functions and differences exist in signalling 
between integrins.  
Ligands for integrin receptors are diverse and ligand binding can induce 
structural changes in the integrin’s interaction with other molecules. For 
example, vitronectin inhibits sCD23 binding to the integrin αVβ3 203. Integrins 
mediate adhesion upon binding to specific adhesion proteins such as vitronectin, 
fibronectin and collagen, often through the recognition of the tripeptide arg-gly-
asp acid (RGD) motif. In addition, they also bind to soluble ligands such as 
fibrinogen or counter receptors on adjacent cells such as intracellular adhesion 
molecules (ICAMs) 234. Although many integrins recognise the RGD sequence in 
their matrix ligands they are also capable of distinguishing different RGD-
containing proteins such that some integrins bind primarily to fibronectin and 
others to vitronectin. 
1.3.2.1 Integrin Signalling  
Integrins not only transduce signals to cells in response to the extracelluar 
environment but they also respond to intracellular cues that alter the integrin 
response to the extracellular environment. Ligand binding leads to integrin 
clustering, assembly of cytoskeletal proteins (such as vinculin, talin, paxilin), 
reorganisation of the actin cytoskeleton, all resulting in the formation of focal 
adhesions 238. In addition to forming a structural link between ECM and the 
cytoskeleton, focal adhesions are also important sites of signal transduction. The 
signalling pathways activated by integrins are similar to the kinase cascades 
activated by growth factor receptors. Depending on the composition of the ECM,  
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integrins activate one or more intracellular pathways. Because integrins, like all 
adhesion receptors, do not have intrinsic kinase activity, activation of signalling 
pathways requires recruitment of non-receptor kinases. These kinases typically 
involve phosphorylation of focal adhesion kinase (FAK) or the related kinase PyK2 
and activate a number of Src-homology domain SH2 and SH3 containing adapter 
proteins 238. FAK is activated by integrin-mediated adhesion and localises to 
focal adhesions, creating a binding site for Src family of tyrosine kinases and 
adaptor proteins such as Grb-2, and subsequent activation of mitogen activated 
protein kinase (MAPK) cascades such as the Ras/ERK pathway 239,240. FAK is also 
known to bind to  PI3K and can activate PI3K-mediated pathways for cell survival 
241.  
Signals from the integrin receptors are also integrated with those originating 
from growth factor and cytokine receptors and association of integrins with 
other membrane proteins has been shown to provide additional coordinate 
signals to cells that are specific for individual integrins 242. Integrin-dependent 
adhesion and signalling is important in regulation of multiple processes such as 
tissue development, inflammation, angiogenesis, tumour cell growth and 
metastasis 237. 
1.3.2.2 Vitronectin receptors 
The vitronectin receptors (VnRs) are members of the integrin family comprising 
the αV chain in non-covalent association with one of five β subunits β1, β3, β5, 
β6 and β8 and bind a broad spectrum of ligands, including fibrinogen, fibronectin 
and vitronectin, typically by recognition of the arg-gly-asp (RGD) motifs 236,237. 
The integrins αVβ5 and αVβ3 are the vitronectin receptors currently defined as 
CD23 receptors. 
The αVβ3 and αVβ5 integrins have been studied for their roles in tumour 
progression, metastasis, angiogenesis and inflammation237. Moreover, mice 
lacking these integrins have been shown to have enhanced tumour growth and 
angiogenesis 243. Studies using antibodies to β3 and β5 domains have shown that 
antibodies to the region of β3 proximal to the ligand binding site failed to 
recognise β5 244. This may relate to the fact that αVβ5 displays a more restricted  
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ligand binding, primarily to vitronectin, while αvβ3 binds to vitronectin, 
fibronectin, fibrinogen and von Willebrand factor 245. These integrins may also 
have different signalling functions as both αVβ3 and αvβ5 localise to focal 
adhesions but only β5 containing complexes undergo endocytosis and are 
capable of sustaining focal adhesion kinase activity at high levels in a Src-
dependent manner 245. These differences in ligand specificity and activation 
patterns indicate that these integrins may have specialised function in different 
cellular processes. 
The integrin αVβ3, consists of 125kDa αV subunit and 105 kDa β3 subunit and has 
been a focus of intensive research because of its major role in several distinct 
processes, such as osteoclast-mediated bone resorption, angiogenesis, 
pathological neovascularisation and tumour metastasis 246. The engagement of 
this integrin is shown to enhance cell invasion in human multiple myeloma 247 and 
it has also been shown to be involved in proliferation and migration of lymphoid 
tumours 248. The crystal structure of αVβ3 binding an RGD ligand has been 
determined, giving more insight into integrin conformation and activation states 
249.   
1.3.2.3 Integrin Structure 
Integrins are large glycoproteins with multiple domains and integrin ligand 
binding is tightly linked to molecular conformation. Each of the α and β subunits 
comprises a large extracellular domain, single transmembrane domain and a 
short cytoplasmic tail. The N-terminal portions of the α and β subunits fold into 
a globular headpiece (containing the ligand binding site) which is connected 
through the α and β tailpiece domain to the membrane (Figure 1.3). Activation 
of the integrin results in  rearrangement in the orientation of these domains 236.  
Structural studies have revealed that the integrins exist in at least three 
different conformational states. A bent conformation, an extended conformation 
with a closed headpiece and an extended conformation with an open 
headpiece250.  It has been suggested that the bent conformation is the low 
affinity state while the open conformation corresponds to the ligand-bound high 
affinity state. Many antibody epitopes that are buried in the bent conformation  
Mridu Acharya,2008   Chapter 1, 41 
 
become exposed in the extended conformation and ligand binding induces the 
high affinity conformation 250. For example, cyclic RGD peptides bind to the low 
affinity bent conformation of αVβ3 and induce conversion to the extended 
conformation with open headpiece 250. The model proposed is that the bent 
conformation represents an inactive physiologically-relevant conformation and 
that activation would be accompanied by a switchblade-like opening of the 
headpiece and tailpiece interface into an extended state 236. The crystal 
structure of αVβ3 revealed a bent conformation where the αV and β3 subunits 
are bent acutely at the knee region (in between the head piece and tail piece). 
The ligands were shown to bind at the major interface between the αV and β3 
subunits making extensive contacts with both 249. 
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Figure  1.3 Representation of bent and extended conformation of extracellular regions of 
integrin αvβ3. 
 
(A) Shows the ribbon diagram of the integrin in the bent conformation with closed headpiece and 
(B) shows the extended conformation with open headpiece. The headpiece and the tailpiece region 
are indicated. The β-propeller region in the headpiece which is found in the ligand binding site and 
the thigh and calf regions are also indicated. This representation is based on the crystal structure of 
αvβ3 and the figure is reproduced from Takagi et.al., (2002)250. 
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In solution or on the cell surface, the integrins are thought not to be fixed in a 
particular conformation but are in equilibrium between them 250. Whether 
equilibrium favours the bent or extended conformation depends on the presence 
of activating intracellular factors and concentration of extracellular ligands.  
Activation by signals within the cell, known as inside-out signalling, induces 
straightening and stabilises the extended form and binding of the extracellular 
ligand also stabilises the extended form enhancing the separation of integrin 
tails, resulting in transmission of signals to the cytoplasm (outside-in-signalling) 
250.  
1.3.2.4 Integrins in hematopoiesis 
Interactions of haematopoietic precursors with the stromal microenvironment 
are critical for controlling their migration, self-renewal and differentiation, and 
many of these interactions are mediated by integrins 251. Aside from retaining 
stem and progenitor cells in the bone marrow, engagement of adhesion 
receptors  on these cells also plays an important role in modulating growth and 
survival signals252. Among the integrins, β1 and the β2 ‘leucocyte integrins’ have 
been identified on haematopoietic progenitor cells. The β1 integrins, 
particularly α4β1 (VLA-4) and α5β1 (VLA-5) and β2 integrin LFA-1 have been 
studied extensively for their roles in cell adhesion and migration in 
haematopoietic cells. Both β1 and β2 integrins are responsible for interactions 
between cells and ECM components such as fibronectin, collagen, laminin and 
thrombospondin or the cell surface expressed adhesion molecules VCAM-1 and 
ICAM-1 158,253-257. A number of studies have assessed the expression of both the 
β1 and β2 integrins in CD34+ HSCs as well as cells from different types of B cell 
leukaemias.  
In vitro experiments demonstrated that adhesion of HSCs and HPCs 
(haematopoietic progenitor cells) to fibronectin is mediated by α4β1 and α5β1 
257,258. α4β1 also mediates binding to VCAM-1 expressed on bone marrow stromal 
cells259. Contact between normal and leukemic hematopoetic progenitors and 
bone marrow adherent layers has also been shown to be maintained in vitro by a 
combination of both β1 and β2 integrins 112,126,255,260.  In vivo experiments have 
shown a dominant role for these integrins in retention of stem cell progenitors in  
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the bone marrow and for trafficking of stem cells and, as mentioned above, 
these functions are modulated by the cytokine SDF-1 113,261. Moreover, α4β1- 
mediated attachement of HPC to fibronectin was also shown to promote 
proliferation 262,263 and prevent apoptosis 264.  
Gene knockout studies have also indicated important roles for both the α4 and 
β1 subunits during hematopoiesis. Studies by Hirsch, et. al., and Potocnick, et. 
al., have demonstrated that β1 integrin is an essential adhesion receptor for 
homing and retention of HSCs in the foetal and adult haematopoietic tissuses 265-
267. Similarly, genetic studies from α4 null chimeric mice revealed that  α4 
integrins are essential for normal development of lymphoid and myeloid lineages 
and homing of lymphocytes to Peyer’s patches 268,269. 
1.3.2.5 αVβ5 integrin in B lymphopoiesis  
The importance of VnRs in general, and αVβ5 in particular, in lymphopoiesis is 
unclear.  The interaction between CD23 and integrin αVβ5 suggests a role for 
this integrin in B cell development. The β5 and β3 knock out mice do not 
indicate any perturbances in B cell development 270; however, the murine and 
human system may have differential requirements for αvβ5 function as murine 
CD23 does not show the cytokine-like activities shown by the human 
counterpart. Moreover, the functioning of the integrins may be different in 
normal systems and in knock out mice.  
Previous results for the staining of αVβ5 integrins on B lymphocytes derived from 
peripheral blood, bone marrow and ALL patients demonstrate that αVβ5 is 
expressed exclusively on normal or leukaemic B cell precursors (Borland, et. al., 
2008 manusript submitted). No αVβ5 expression was seen on CD19+ B 
lymphocytes in peripheral blood from normal individuals while normal human 
bone marrow showed CD19+ cells that were αVβ5+. αVβ5 was shown to be 
expressed universally on ALL-derived samples whereas no αVβ5 expression was 
shown on B–CLL samples. No αVβ3 expression was seen on the precursor cells 
(normal or leukaemic) indicating that αVβ5 is the only CD23 receptor expressed 
on these cells. Expression of the integrin αVβ5 and ubiquity of αVβ5 expression  
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by ALL cells strongly suggests a significant role of αVβ5 expression and function 
during B cell development.   
1.4 Research aims 
The main aim of the research work presented in this thesis was to assess the role 
of αVβ5 integrin during B cell development by testing the hypothesis that the 
integrin αVβ5 delivers a pro-survival signal at all stages of antigen-independent B 
cell development in the bone marrow via the αVβ5-CD23 interaction.  
The specific aims were to: 
(a) Define the expression of αVβ5 integrin (and related αV integrins) during 
specific B cell developmental stages. This was investigated by using cell 
lines representative of different B cell developmental stages and B cells 
from human bone marrow. Cell lines expressing αVβ5 integrin were used 
to address αVβ5 function by assessing proliferation response stimulated 
by the αVβ5-CD23 interaction.  
(b) Explore the role of cytokines chemokines and growth factors important in 
B cell development in regulating αVβ5 function and expression. Cytokines 
(IL-7, IL-3, IL-4, IL-7), the chemokine SDF-1 and platelet-derived growth 
factor (PDGF) were used to assess αVβ5 expression and αVβ5 mediated 
cell proliferation as well as signalling pathway activation in different pre-
B cell lines. 
(c) Determine whether murine B cell precursors could respond to soluble 
stimuli delivered by the αVβ5 integrin. This series of experiments would 
demonstrate whether the data from the human studies could be 
transferred to a murine model that would allow an analysis of the in vivo 
biology of αVβ5 integrin in the haematopoietic system. 
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2 Materials and Methods  
2.1 Antibodies and Reagents 
All routine chemicals used were purchased from Sigma Chemicals Co. Poole, UK 
unless otherwise stated. Recombinant cytokines human (IL-7, IL-3, IL-11, IL-4) 
and mouse (IL-3) were purchased from R&D Systems, Abingdon, UK. Biotinyl-
murine IgG1 and recombinant SDF-1β were purchased from Chemicon, 
Hampshire, UK. PI-3K inhibitor LY294002 and platelet-derived growth factor 
(PDGF-β) were supplied by Cell Signalling Technologies, Beverly, MA, USA. 
Streptavidin-PE, streptavidin-APC and annexinV-FITC were from BD Bioscience, 
Oxford, UK. Anti-actin and horseradish peroxidase (HRP)-conjugated anti-rabbit 
immunoglobulins, AMD3100, propidium iodide (PI), Trypan blue, NHS-LC biotin, 
mouse IgG1 and IgG2a isotype control antibodies, IgG1-PE secondary antibody, 
DMEM (Dulbecco’s Modified Eagle’s Medium), L-Glutamine 200mM and Penicillin-
Streptomycin solution were purchased from Sigma Chemicals Co, Poole, UK. 
Isotype control antibody IgG1-FITC was purchased from DAKO, Cambridgeshire, 
UK. Normal Armenian hamster IgG1-FITC was purchased from Autogen Bioclear, 
Witshire, UK. Foetal Calf serum was supplied by TCS Cellworks, Buckingham, UK 
The MEK inhibitor U0126 and Access RT-PCR System kit were purchased from 
Promega, Southampton, UK. Tritiated thymidine was obtained from Amersham 
International plc, Amersham, Buckinghamshire, UK. Recombinant 25-kDa sCD23, 
encompassing residues Met151-Ser231 with an N-terminal His6 tag, was purchased 
from R&D Systems, Abingdon, UK. A CD23-GST fusion protein preparation 
comprising residues Asp48-Gly248 of CD23 (referred to as sCD2348-248) was obtained 
from Assay designs (Cambridge Bioscience, Cambridge, UK). Der CD23 was a kind 
gift from Dr. Jim McDonnell (University of Oxford, UK). RPMI-1640 medium and 
protein-free hybridoma medium-II (PFHM) were from GIBCO-BRL (Paisley, 
Scotland, UK). 
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The antibodies used and their suppliers were as follows:  
Target Antigen Monoclonal or 
polyclonal 
Clone Isotype Supplier Other 
Human CXCR4 Mouse 
Monoclonal 
12G5 IgG2a R&D Systems, Abingdon, 
Oxford, UK 
Biotinylated 
Human αVβ5 Mouse 
Monoclonal 
P1F6 IgG1 Chemicon, Hampshire, UK  
Human αVβ5 Mouse 
Monoclonal 
15F11 IgG2a Chemicon, Hampshire, UK  
Human αVβ3 Mouse 
Monoclonal 
23C6 IgG1 Chemicon, Hampshire, UK  
Human αVβ3 Mouse 
Monoclonal 
LM609 IgG1 Chemicon, Hampshire, UK  
Human αV Mouse 
Monoclonal 
AMF7 IgG1 Chemicon, Hampshire, UK  
Human αV Mouse 
Monoclonal 
LM142 IgG1 Chemicon, Hampshire, UK  
Human αVβ6 Mouse 
Monoclonal 
10D5 IgG2a Chemicon, Hampshire, UK  
Human β1 Mouse 
Monoclonal 
47BR IgG1 Autogen Bioclear, 
Buckinghamshire, UK 
 
Human αV Rabbit  
polyclonal 
- IgG1 Chemicon, Hampshire, UK  
Human β5 Rabbit  
polyclonal 
- - Chemicon, Hampshire, UK  
Human β3 Goat  
polyclonal 
- - Autogen Bioclear, 
Buckinghamshire, UK 
 
Human Phospho-
p44/42 MAP kinase 
(Thr202/Tyr204) 
Rabbit  
polyclonal 
- - Cell Signalling 
Technologies, Beverly, 
MA, USA 
 
Human p44/42 
MAP kinase 
Rabbit 
 polyclonal 
- - Cell Signalling 
Technologies, Beverly, 
MA, USA 
 
Human IgM (µ-
chain) 
Mouse 
Monoclonal 
SA-DA4 IgG1 Southern Biotech, 
Birmingham, Alabama, 
USA 
 
Human κ-chain Mouse 
Monoclonal 
L1C1 IgG1 Ancell Corporation, 
Bayport, USA 
FITC 
conjugated 
Mouse β3 Armenian 
hamster-
Monoclonal 
2C9.G2 IgG1 Autogen Bioclear, 
Buckinghamshire, UK 
 
Human IgM (µ- 
chain) 
Goat 
 polyclonal 
- - Sigma Chemicals Co, 
Poole, UK 
FITC 
conjugated 
Human CD38 Mouse 
Monoclonal 
HI157 IgG1 Sigma Chemicals Co, 
Poole, UK 
 
Human CD10 Mouse 
Monoclonal 
SS2/36 IgG1 DAKO, Cambridgeshire, 
UK 
FITC 
conjugated 
Human CD9 Mouse 
Monoclonal 
P/33/2 IgG1 DAKO, Cambridgeshire, 
UK 
FITC 
conjugated 
Human CD19 Mouse 
Monoclonal 
HIB19 IgG1 BD Bioscience,  Oxford, 
UK 
PE 
 conjugated 
 
 
 
 
Mridu Acharya,2008   Chapter 2, 48 
 
The following antibodies were used for FACS sorting experiments and were all 
ordered from BD Biosciences, Oxford, UK. All antibodies were mouse monoclonal 
IgG1 isotype. 
Target 
Antigen 
Clone Conjugated 
to  
Human CD19 SJ25C1 PerCP-Cy5.5 
Human CD10 HI10A PE 
Human CD38 HIT2 FITC 
Human CD5 UCHT2 FITC 
Human CD7 M-T701 FITC 
 
2.2   Buffers 
The following buffers were routinely used: 
Buffers  Compostion 
PBS 13mM NaCl, 27mM KCl, 4.3mM Na2HPO4, 
1.4mM KH2PO4  (pH 7.2) 
TBS 50mM Tris HCl (pH 7.4), 150mM NaCl 
TAE 40mM Tris.acetate, 2mM Na2EDTA pH8.5 
Transfer buffer 25mM Tris, 192mM Glycine , 20% (v/v) 
methanol 
Stripping buffer 62.5 mM Tris HCl pH 6.7, 2% (w/v) SDS, 
100mM 2-mercaptoethanol 
Blocking buffer  TBST (1X TBS with 0.1% (v/v) Tween) , 5% 
(w/v) BSA 
    
2.3 Cell lines and cell culture  
The SMS-SB cell line was derived from a female patient at the leukaemic phase 
of lymphoblastic lymphoma 271; SMS-SB cells were cultured in PFHM  with 2 mM 
fresh glutamine, penicillin (100U/ml) and streptomycin (100µg/ml) at 37°C in 5% 
(v/v) CO2 in air in a humidified atmosphere, at 2.5-5 x 10
5 cells/ml ("normal cell 
density"). RS4;11 272, 697, Nalm6, Blin1, Raji, Ramos, Daudi, IB4 and SKW  B cell 
lines were from laboratory liquid nitrogen stocks. Cell lines were maintained in 
RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated foetal calf 
serum, 2 mM fresh glutamine, penicillin (100U/ml) and streptomycin (100µg/ml), 
at 37 °C in a 5% (v/v) CO2 in air in a humidified atmosphere. The BAF03 murine  
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pro-B cell line was also from laboratory stocks  273  and this cell line was cultured 
in RPMI-1640 medium with 50µM 2-ME (mercapto-ethanol) and 1ng/ml murine IL-
3. The stromal cell line hMSC-Tert 274 was maintained in DMEM {10% (v/v) FCS, 2 
mM fresh glutamine, penicillin (100U/ml) and streptomycin (100µg/ml)} and the 
murine stromal cell line OP9 275 ( a kind gift from Dr. Alison Michie, Glasgow, UK) 
was maintained in DMEM {20% (v/v) FCS, 2 mM fresh glutamine, penicillin 
(100U/ml) and streptomycin (100µg/ml) and 50µM 2ME} at 37 °C in  5% (v/v) CO2 
in air in a humidified atmosphere. 
The different B cell lines used and the stages of B cell development represented 
by these cell lines is summarised in table 2.1. The translocations well known for 
each of these cell lines is indicated in the case of the cell lines where these 
translocations and fusion gene products have been well characterised. 
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Table 1 Summary of the different B cell lines used for cell culture experiments. 
Cell 
Line 
Established From Type of Cell 
Line 
Known 
Translocations 
SMS-
SB 
Blood mononuclear 
leuckocytes of 16-year old girl 
in leukaemic phase of 
lymphoblastic lymphoma 
Human Pre-B 
ALL 
None 
RS4;11 
 Bone marrow of a 32-year old 
woman with ALL 
Human Pre-B 
ALL/ Mixed 
lineage 
leukaemia (MLL) 
t(4;11)(q21;q23) 
MLL/AF4 fusion 
gene 
697 Bone marrow of a 12-year old 
boy with ALL (cALL) 
Human Pre-B 
ALL 
t(1;19)(q23,p13) 
E2A-PBX fusion 
gene 
Nalm6 Peripheral blood of a 19-year 
old man with ALL 
Human Pre-B 
ALL 
t(5:12)(q33.2;p 
13.2) 
Blin-1 Bone marrow aspirate of  11-
year old boy with ALL 
Human Pre-B 
ALL 
- 
Raji Left maxilla of 12-year old 
African boy with Burkitt 
lymphoma 
Human Burkitt 
lymphoma 
t(8;14) 
translocation 
associated with 
Burkitt lymphoma 
Ramos Ascitic fluid of a 3-year old boy 
with American type Burkitt 
lymphoma 
Human Burkitt 
lymphoma 
t(8;14) 
translocation 
associated with 
Burkitt lymphoma 
Daudi Left orbital biopsy of a 16-year 
old African boy 
Human Burkitt 
lymphoma 
t(8;14) 
translocation 
associated with 
Burkitt lymphoma 
SKW EBV infection of B cells  EBV transformed 
lymphoblastoid 
cell line (LCL) 
- 
IB4 EBV infection of umbilical cord 
B cells  
EBV transformed 
lymphoblastoid 
cell line (LCL) 
- 
BAF03 IL-3 dependent murine pro B 
cell line from peripheral blood 
derived from BALB/c mouse 
Mouse pro B cells - 
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2.4 Proliferation assays 
SMS-SB cells were harvested and washed in PFHM then plated at a density of 
2500 cells/100-µl culture {low cell density (LCD)}, a seeding density at which the 
cells are prone to apoptose 276, in 96-well microtitre assay plates in PFHM. All 
other cell lines were washed extensively in PFHM prior to culture at 5000 
cells/100-µl cultures. Cultures were propagated in the presence or absence of 
cytokines, monoclonal antibodies (MAbs) or peptides, at 37 °C for 72 h followed 
by addition of 0.3 µCi/well (5.5*10-6 µmol) tritiated thymidine ([3H]-TdR) for 18 h 
prior to harvest; incorporation was determined by liquid scintillation 
spectrometry. Briefly, the cells from 96-well plates were harvested onto glass 
fibre mats (Wallac Oy, Truku, Finland) using a TomTec MachIII Cell Harvestor 
(PerkinElmer, Massachusets, USA). The mats were air-dried, sealed in sample 
bags with Betaplate Scintillin (Wallac Oy, Truku, Finland) and counted using 
Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter (Wallac 
Oy, Truku, Finland). Tritiated thymidine incorporation was measured as count 
per minute (cpm). All determinations were made in triplicates and at least 3 
repeats were performed for each experiment. Cytokines were used at 0.5-32nM 
concentration ranges and sCD23 was employed at 0.4-6nM. In experiments using 
inhibitors, cells were incubated with the inhibitors (5-10µM U0126, 50µM 
LY294002, 50µM AMD3100) for 30 min at 37˚C prior to the introduction of 
stimuli.  
Bone marrow B cell proliferation assays were performed with stromal cell 
support using hMSC-Tert (human telomerised stromal cell line) or OP9 (murine 
stromal cell line) cells. Stromal cells were grown until confluent and irradiated 
in solution (30 Gy [3000rad]) using a cobalt irradiation source and plated at a 
density of 1.5 X104  cells/well at least 3 days before the addition of B cells for 
hMSC-Tert and 2 days before the addition of B cells for OP9 cells in their 
appropriate medium. Pre-B cells, FACS sorted from human mononuclear bone 
marrow cells using anti-CD19 and anti-κ MAbs, were washed and plated on 96-
well plate containing hMSC-Tert stromal cells at a density of 2500-3000 cells/ 
well with appropriate antibody, CD23 or peptide treatment in RPMI-1640 (2% 
(v/v) FCS and 20U/ml DNase I). Stromal cell medium was removed and cells  
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washed extensively with RPMI-1640 immediately before plating the B cells. 
Plates were incubated at 37 °C for 72 h and tritiated thymidine ([3H]-TdR) 
analysis performed as mentioned above.  
Murine bone marrow cells (a kind gift from Dr. Adam Lacy-Hulbert, Boston, USA) 
were harvested from bone marrow of wild type or αV conditional knockout mice 
by flushing the bones in PBS and the cells were then washed with red cell lysis 
buffer (0.83% (w/v) NH4Cl in 50mM Tris HCl pH 7.6). To purify CD19
+ B cells, a 
single cell suspension of bone marrow cells were resuspended in MACS buffer 
(PBS pH 7.2, 0.5% (w/v) BSA and 2mM EDTA) (90µl buffer per 107 cells), with 
mouse CD19 micro beads (10µl/107 cells) (Miltenyi Biotech, Surrey UK) for 15 min 
at 4 °C. After incubation cells were washed and resuspended in MACS buffer. 
The cells were then positively selected using magnetic-activated cell separation 
(MACS) LS columns according to manufacturer’s insctructions (Miltenyi Biotech, 
Surrey UK). Purified CD19+ cells were plated on to OP9 cells containing 
appropriate treatments at 2500-3000 cells/well in RPMI-1640 (10% (v/v) FCS, 
50µM 2ME, 1ng/ml IL-7). Medium was removed and OP9 cells were washed 
extensively with RPMI-1640 immediately before plating the B cells. Plates were 
incubated at 37 °C for 72 h and tritiated thymidine ([3H]-TdR) analysis 
performed as mentioned above.  
2.5 Peptide Biochemistry  
We have previously shown that CD23-derived peptides containing the RKC motif 
recognised by αVβ5 integrin are biologically active. The peptides were used at 
0.5-3.33µM and are numbered according to their position in the original 
screening library 232. The sequences of the specific peptides used in this study 
are #9, KWINFQRKC; #10, SGSGINFQRKCYY; #12, SGSGRKCYYFGKG; #11, 
FQRKCYYFG; LP long peptide, KWINFQRKCYYFGKG; Peptides #8, PEKWINFQR; 
#41, SGSGGEFIWVDGS;  #34, SGSGHTGSWIGLR  #17, SGSGKQWVHARYA; and #58 
SGSGGSGRWNDAF; which lack the RKC motif and do not bind to αVβ5 were used 
as negative control peptides. Peptides were synthesised with a common SGSG 
linker and N-terminal biotin tail or as unlabelled peptides lacking the linker and 
biotin tail (Mimotopes, Clayton, Victoria, Australia). For binding experiments 
Mridu Acharya,2008   Chapter 2, 53 
using FACS, biotinylated peptides were used and for proliferation experiments 
unlabelled peptides were used.  
2.6 Flow cytometry 
Cells were harvested and washed twice with ice-cold PBS and resuspended at 
5×106 cells/ml. 100µl of cell suspension was stained with either biotinylated, 
unlabeled primary MAb or biotinylated CD23-derived peptides (10µg/ml) for 30-
60 min at 4 °C; unlabeled primary antibody was visualized using a secondary PE-
conjugated anti-mouse IgG or, in the case of biotinylated antibody or peptides, 
using streptavidin-PE. Cells were incubated in secondary antibody for 30-60 min 
at 4 °C and washed twice with ice-cold PBS before anlaysis. For assay of 
apoptosis, approximately 1 X 106 cells were washed twice with ice-cold PBS and 
stained with 100µl labelling buffer (10mM HEPES-NaOH pH7.4, 150mM NaCl, 5mM 
CaCl2, 5µg/ml propidium iodide and 5µl annexinV-FITC) and incubated at room 
temperature for 20 min. The labelling buffer was aspirated and the cells were 
resuspended in 400µl binding buffer (10mM HEPES-NaOH pH7.4,150mM NaCl, 
5mM CaCl2). Cells were analyzed on a FACScan flow cytometer, using
 CellQuest 
software.  
For bone marrow analysis and cell sorting frozen human monounclear bone 
marrow cells (Lonza Walkersville, Inc, Walkersville, MD, USA) were thawed in 
RPMI -1640 (10% (v/v) FCS and 20U/ml DNase-I) and washed twice with ice-cold 
PBS and processed as mentioned above. The cells were processed under sterile 
conditions. All antibodies were monoclonal IgG1 isotype except µ-FITC, which 
was a goat polyclonal antibody. Bone marrow mononuclear cells were counted 
and resuspended in PBS and stained with appropriate antibody mixtures and all 
cells were analysed and sorted on BD FACSAria cell sorter (BD Bioscience, 
Oxford, UK). Cells were sorted on the basis of CD19+/κ+or CD19+/κ- and isotype 
control antibodies and control beads (BD Bioscience, Oxford,  UK) were used to 
draw appropriate gates for positive and negative cell populations. 
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2.7 RNA extraction and reverse transcriptase polymerase 
chain reaction (RT-PCR)  
Total RNA was isolated using the Trizol reagent (GIBCO-BRL, Paisley, Scotland) 
according to manufacturer’s instructions. Briefly, 106-107 cells were harvested 
and resuspended in 1ml Trizol/107 cells and RNA solubilised by passing the 
lysates through a pipette a few times. Chloroform was added (0.2ml/1ml Trizol) 
and the sample was shaken vigorously for 15 seconds, left on ice for 5 min 
followed by centrifugation at 12000 x g at 4 ºC for 15 min. The colourless 
aqueous phase containing the RNA was removed from the red phenol-chloroform 
phase and RNA was precipitated by incubating the sample in equal volume of 
ice-cold isopropanol for 10 min followed by centrifugation at 12000 x g at 4 ºC 
for 15 min. RNA was then washed with 70% (v/v) ethanol, air-dried and 
resuspended in 50-100µl of RNAse-free dH20 (Promega, Southampton, UK). 
Sample concentrations and purity were determined by spectrophotometric 
readings of a 1/500 dilution of the sample and using the absorbance at 260nm 
and 280nm wavelengths.  
Total RNA extracted was used for RT-PCR reactions to amplify transcripts using 
the Access RT-PCR system kit (Promega, Southampton, UK) according to the 
manufactuer’s instructions. Briefly 1µg RNA was added to a mixture of AMV Tfl 
reaction buffer, dNTP mix (10mM each dNTP), 1µM each of forward and reverse 
primer, 25mM MgSO4,  AMV reverse transcriptase (5 units), Tfl DNA polymerase 
(5 units) and RNAse-free water to make the volume up to 50µl.   
The primers used were as follows (MWG Biotech, London UK):  
Target 
transcript 
Forward Primer Reverse Primer 
GAPDH 5’-TCCACCACCCTGTTGCTG-3’ 5’-ACCACAGTCCATGCCATCAC-3’ 
Integrin αV 5’-CGGTTGCCGGGCAAGGTGAG-3’ 5’-CAGGCATGGGCGCTGGCTGA-3’ 
Integrin β5 5’-GGCAGTGCCAATGCACGGAG-3’ 5’-GGCCCTGGATCGCTCGCTCT-3’ 
Integrin β3 5’-GACTGCCTGTGTGACTCCGAC-3’ 5’-TGAGCAGGGCGGCAAGGCCA-3’ 
Integrin β6 5’-TGGAGTGCTCTGCAGCGGGC-3’ 5’-GGTTCCCGTTTGCCACTTGGC-3’ 
Integrin β8 5’-TGCACCGATCCCAGGAGCATC-3’ 5’-CTCACGTCGGTAGGTGACTGC-3’ 
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The following programme was used on the thermal cycler  
• For reverse transcription: 
     45 minutes at 45ºC for 1 cycle and  
• For AMV RT inactivation and RNA/cDNA primer denaturation  
     2 minutes at 94ºC for 1 cycle. 
• For PCR amplification: 
      30 seconds at 94ºC, 1 minute at 60 ºC and 2 minutes at 68ºC for 40 cycles 
      7 minutes at 68ºC for 1 cycle 
      Storage at 4ºC  
 
For RT-PCR with the β5 primers in some cell lines, the annealing temperature 
was changed to 62 ºC for 1 minute to obtain a single specific band. PCR products 
were analysed by agarose gel electrophoresis using 2% (w/v) agarose gel in 
1XTAE buffer. 
 
2.8 Western blot analysis 
Approximately 3 X 107 cells in PFHM were stimulated with either SDF-1 
(250ng/ml) sCD23 (160ng/ml), Long peptide (1µg/ml), Peptide #9 (5µg/ml), 
Peptide 8 (5µg/ml), 15F11 MAb (5µg/ml) alone or in combination for specified 
time periods at 37 ºC. Stimulation was stopped by addition of RIPA buffer 
without detergents (50mM Tris-HCl pH7.4, 150mM NaCl, 1mM EGTA, 1mM 
Na3VO4).  Cell pellets were lysed in RIPA buffer with protease inhibitors (RIPA 
buffer as above plus 1% (v/v) NP40, 1mM Na deoxycholate and protease 
inhibitors 1mM PMSF and 2µg/ml Leupeptin) and clarified by centrifugation at 
13,000 x g for 15 min. Protein concentrations were measured using the Bradford 
reagent (BioRad Laboratories Ltd, Hampstead, UK) with BSA as a standard. Equal 
amounts of protein (30-40µg) were loaded per lane and run on a  4-12% NuPAGE 
Novex Bis-Tris gradient gels according to manufacturere’s instruction (based on 
standard SDS-PAGE method as described by Laemmli, 1970) 277 using the MOPS 
buffer supplied (Invitrogen, Paisely, UK). Proteins on the gel were transferred 
onto nitrocellulose (Amersham, Buckinghamshire, UK) using 1X transfer buffer  
Mridu Acharya,2008   Chapter 2, 56 
 
and the membrane was blocked for 1 h in blocking buffer.  Phosphorylated 
protein was detected using specific primary antibodies used at 1/1000 dilution 
with overnight incubation; Blots were washed extensively in TBST and incubated 
for 1 h in secondary antibodies (1/10000 dilution) conjugated to HRP. All 
antibody dilutions were made in TBST with 1% (w/v) BSA. Enhanced 
chemiluminescence (ECL) (Pierce, Rockford, USA) was used according to 
manufacturer’s instruction to develop the blots and blots were exposed to Kodak 
MXB film for appropriate time depending on the siganl to detect antibody 
binding. The same membrane was stripped using stripping buffer and total 
protein was detected using specific primary and secondary antibodies as with 
the phoshphorylated proteins. Bands were quantified by densitometry using the 
ImageJ software. 
2.9 Biotinylation and immunoprecipitation of cell surface 
integrin β5  
108 cells were harvested and washed extensively in PBS. The cells were 
resuspended at 107 cells/ml in 5mM sulfosuccinimidyl-6-(biotinamido) hexanoate 
(NHS-LC-Biotin)/PBS (Sigma Chemicals Co, Poole, UK) and incubated on a roller 
for 30-60 min at room temperature in the dark. The cell pellet was resuspended 
and washed in 50mM Tris HCl pH 7.4/150mM NaCl and then resuspended in 5ml 
RIPA buffer with protease inhibitors (see section 2.7) for 30 min on ice. The cell 
extract was pelleted by centrifugation 12000 x g for 15 min. 1ml of the cell 
lysate was added to 100µl of packed streptavidin beads (in RIPA buffer) and 
incubated at room temperature for 1 h with gentle agitation. The beads were 
pelleted and washed with RIPA buffer and resuspended in 25µl 5X SDS-PAGE 
loading dye (0.225M Tris-HCl pH 6.8, 50% (v/v) Glycerol, 5% (w/v) SDS, 0.05% 
(w/v) Bromophenol blue), boiled for 5 min followed by centrifugation at 12000 x 
g for 1-3 min and the supernatant was loaded on 4-12% NuPAGE Novex Bis-Tris 
gels and transferred onto nitrocellulose membrane. Membranes were probed 
separately using primary anti-αv, β5 and β3 antibodies to detect biotinylated 
integrins. Secondary antibodies conjugated to HRP and enhanced 
chemiluminescence were used to visualise the appropriate bands as mentioned 
in section 2.7. 
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2.10 Staistical Analysis 
Results are shown as mean plus or minus standard deviation (SD) or standard 
error of the mean (SEM) of triplicate results. Statistical comparision was 
performed using the Students paired t test. The minimal level of significance 
was P<0.05. Each result is representative of at least 3 experiments unless 
otherwise stated.  
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3 αV Integrin Expression and Function in Human 
B Lymphocytes 
3.1  Introduction 
The proliferation and differentiation of B lymphocytes is regulated by numerous 
growth factors and adhesive interactions. During development, B cells undergo 
stepwise maturation through different defined stages. Each stage of this 
developmental process is regulated by stage-specific signals that modulate B cell 
growth/survival and differentiation. HSCs in the bone marrow committed to the 
B lineage go through the pro-B, pre-B and immature B cell stages of 
development in the bone marrow. Perturbation of this developmental process in 
the bone marrow leads to malignancies such as ALL. Leukaemias represent a 
heterogenous group of disorders and ALL is a malignant disease of the bone 
marrow in which proliferating early lymphoid progenitors replace the normal 
haematopoietic population. It is a common malignancy in children and  
approximately 80% of childhood ALL constitutes pre-B ALL. In pre-B ALL the 
malignant cells are arrested at an early stage of development 278. 
Previous work in the laboratory demonstrated that the αVβ5 integrin is a 
receptor for the sCD23 molecule and the αVβ5-CD23 interaction sustains 
proliferation of pre-B cell line SMS-SB 232. Furthermore it was also shown that  
αVβ5 is expressed significantly in B cells from patients with ALL (Borland, et. 
al., 2008 manuscript submitted). This led to the hypothesis that the αVβ5 
integrin expression and function has important roles during B cell development 
and malignancies that arise at this stage. Therefore the expression of different 
αV integrins and function of particulary αVβ5 integrin was investigated in 
different pre-B cell lines and some bone marrow B cell precursors. 
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3.2 Results 
3.2.1 Phenotypic characterisation of different pre-B cell lines and 
mature B cell lines  
During development, B cells undergo stepwise maturation through defined 
stages. Various cell surface markers have been identified that allow the precise 
identification of B cells at specific stages in the developmental process. B cell 
lines established from patients with different types of leukaemias are arrested 
at a certain stage in the developmental process and therefore provide a good 
model to study each developmental stage. From a range of cell lines that were 
available in the laboratory, cell lines were chosen as representative of major B 
cell developmental stages. Cell lines were classified as early pre-B, late pre-B, 
immature, transitional or mature B depending on cell surface marker 
expression.  
CD19 expression was used to confirm all the cell lines as B lineage cells and 
surface expression of the µ chain was used to identify the cell lines as B cells in 
Figure 3.2. Surface expression of CD9 was seen in all the pre-B cell lines and the 
pre-B/immature B cell line 1E8 while the transitional and more mature B cell 
lines did not express this molecule (Figure 3.1 and 3.2). The CD38 marker was 
expressed in all the cell lines from pre-B to through to transitional B cell stages 
although the SMS-SB cell line showed lower levels of CD38 expression than other 
pre-B cell lines (Figure 3.1). The mature cell lines SKW and IB4 were CD38 
negative (Figure 3.2).  
SMS-SB and RS4;11 cells were both negative for CD10 (CALLA antigen) (Figure 
3.1) which is a marker for pre-B cells 279,280. SMS-SB cells expressed low levels of 
surface immunoglobulin heavy chain (µ) and RS4;11 cells also were low/negative 
for surface expression of µ chain (Figure 3.1). Therefore, these cell lines were 
designated as early pre-B cells. The 697, Blin1 and Nalm6 cell lines were positive 
for CD10, expressed high levels of surface µ chains and were designated as late 
pre-B cells. The 1E8 cell line was derived originally from Blin1 cells 281 after 
spontaneous re-arrangement of the kappa (κ) light chain genes, leading to 
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differentiation of surface κ-negative pre-B cells into surface kappa positive B 
cells. This is depicted by down-regulation of CD10 expression and the expression 
of immunoglobulin κ light chain by 1E8 cells and these cells were termed as 
immature B cells (Figure 3.1). The cell lines Daudi and Ramos were considered 
to be transitional B cell lines because they were CD10+ and CD38+ but had lost 
CD9 expression, which was characteristic of pre-B cell lines (Figure 3.2).  Both of 
these three cell lines express immunoglobulin light chains κ (Daudi) or λ (Ramos) 
(Figure 3.2). These cell lines were, however, CD21- and IgD-. CD21 and IgD 
expression is a characteristic of transitional and mature B cells. CD21 expression 
was not noted even in the mature B cell lines SKW and IB4. SKW cells were κ 
positive but the IB4 cells were not clearly positive for either a clear kappa or 
lambda light chains (Figure 3.2). This could be because they were more mature 
immunoglobulin-secreting cell types. Both these cell lines were CD38- and lacked 
CD9 or CD10 expression (Figure 3.2) and therefore were designated as mature B 
cells. 
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Figure  3.1 Phenotypic characterisation of different human pre-B cell lines. 
 
Pre-B cell lines were categorised into different stages of B cell development (early pre-B or late 
pre-B) based on expression of surface markers CD19, CD9, µ, CD10 and CD38 using monoclonal 
antibodies (MAbs). FACS staining for the each MAb is shown as grey shaded area and the isotype 
control for the specific antibody is shown as a black line. Data are representative of at least three 
independent staining procedures. 
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Figure  3.2 Phenotypic characterisation of different human immature and mature B cell lines. 
 
B cell lines were categorised into different stages of B cell development (immature, transitional or 
mature B cells) based on expression of surface markers CD9, µ, CD10, CD38 and κ or λ light chain 
expression, using monoclonal antibodies (MAbs). FACS staining for the each MAb is shown as 
grey shaded area and the isotype control for the specific antibody is shown as a black line. Data 
are representative of at least three independent staining procedures. 
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3.2.2  αV integrin expression in pre-B cell lines and mature B cell 
lines  
αV integrin expression was assessed in cell lines representing different stages of 
B cell development. The αV subunit is known to pair with 5 different β subunits 
(β1, β3, β5, β6, β8) and monoclonal antibodies are available for all of these 
heterodimers except for αVβ8. P1F6 and 15F11 are two monoclonal antibodies 
which bind the αVβ5 heterodimer at different epitopes 282, so both antibodies 
were used to assess αVβ5 expression. The 23C6 antibody was used to assess 
surface expression of the αVβ3 heterodimer and the 10D5 antibody detected 
αVβ6 expression. The anti-β1 antibody (4B7R) was used to assess β1 integrin 
expression. However, since the β1 subunit can pair with other α subunits, such 
as α4 and α5, staining with 4B7R could not be considered to demonstrate αVβ1 
expression definitively. 
Figure 3.3 clearly shows that all the pre-B cell lines from RS4;11 through to Blin1 
show high surface expression of αVβ5 as shown by P1F6 antibody staining. 
However, the pattern of staining using 15F11 antibody was very different to the 
P1F6 staining. In general, P1F6 staining was much higher than the 15F11 
staining. Although 15F11 antibody showed staining for αVβ5 in all the pre-B cell 
lines, the cell lines RS4;11, SMS-SBs and 697 cell lines had higher 15F11 staining 
when compared with Nalm6 and Blin1 cell lines. In fact, the cell line 697 had the 
highest expression of the 15F11 epitope.  
αVβ3 integrin expression was more difficult to define accurately as there 
seemed to be very low-level expression in most of the cell lines and this made it 
difficult to conclude whether the cell lines were negative or positive for this 
integrin (Figure 3.3). The three cell lines staining well with 15F11 antibody 
showed very low or negative staining with the 23C6 antibody, while Blin1 and 
Nalm6 cell lines had clearly started to express αVβ3. (Figure 3.3). All the pre-B 
cell lines were clearly negative for αVβ6 integrin and positive for β1 integrin 
expression.  
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Figure 3.3 also depicts an obvious decrease in staining for αVβ5 using P1F6 
antibody in the immature B 1E8 cell line when compared to the pre-B cell line 
Blin1. A similar decrease is seen with the 15F11 antibody although this is less 
pronounced than P1F6 staining. αVβ5 integrin expression is significantly 
decreased in the transitional and more mature B cell lines as shown by P1F6 
staining (Figure 3.4). The transitional cell line Daudi shows low but positive 
staining for αVβ5, as does the mature B cell line SKW, while the cell lines Ramos 
and IB4 are clearly negative for αVβ5. Among the transitional cell lines, Daudi is 
slightly positive and Ramos is either negative or very slightly positive for αVβ3 
expression, while the more mature cell lines SKW and IB4 very clearly show high 
surface expression of αVβ3. Interestingly, the Ramos cell line seemed to express 
low levels of αVβ6 which could not be detected on the other cell lines (Figure 
3.4). Staining for the β1 integrin was significantly reduced in the transitional as 
well as the mature B cell lines (Figure 3.4).  
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Figure  3.3 Expression of different αV integrins on human pre-B cell lines. 
 
Surface expression of αV integrins was assessed by FACS staining using monoclonal antibodies 
P1F6 and 15F11 for αVβ5, 23C6 for αVβ3, 10D5 for αVβ6 and 4B7R for the β1 subunit, in the 
different pre-B or immature B cell lines. Histograms illustrate staining for the integrin antibody as 
grey shaded area and staining for the specific isotype control antibody as a black line. Staining 
data was not available for β1 staining of Nalm6 cells and β6 staining of Blin1 cells. Data are 
representative of at least three independent staining experiments. 
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Figure  3.4 Expression of different αV integrins on human mature B cell lines. 
 
Surface expression of αV integrins was assessed by FACS staining using monoclonal antibodies 
P1F6 for αVβ5, 23C6 for αVβ3, 10D5 for αVβ6 and 4B7R for the β1 subunit, in the different mature 
B cell lines. Histograms illustrate staining for the integrin antibody as grey shaded area and staining 
for the specific isotype control antibody as a black line. Data are representative of at least three 
independent staining experiments. 
 
 
 
 
Mridu Acharya,2008   Chapter 3, 67 
 
3.2.3 RT-PCR analysis of integrin transcripts in different B lineage 
cell lines 
The low levels of αVβ5 and αVβ3 integrin expression found in certain cell lines 
(Figure 3.5) were further investigated using primer pairs specific for integrin 
subunits by RT-PCR. Figure 3.5 shows an RT-PCR product of 460 bp for the β5 
integrin subunit in SMS-SB, 697, RS4;11, Daudi, SKW and IB4 cells and the 
expression was compared to the PCR product from the β5 plasmid. Daudi cells 
showed a very faint band at 460bp but there was a more prominent larger band 
of a higher size. Only the Ramos cell line showed no expression for the β5 
subunit and the IB4 cell line, which showed no cell surface expression of αVβ5 by 
FACS, had transcripts for β5 subunit. The pre-B cell lines SMS-SB, 697 and RS4;11 
showed no transcript for the β3 subunit while the pre-B cell line Blin1 possesed 
transcripts of 504 bp (just above 500bp marker) for β3 subunit (Figure 3.5); 
interestingly, there was no transcript for the β3 subunit detected in the 1E8 cell 
line although we observed staining for αVβ3 by FACS. Nevertheless there is a 
product of higher size in the lane for 1E8. In the transitional cell line category, 
Daudi cells expressed transcript for the β3 subunit but Ramos cells did not; both 
the mature B cell lines SKW and IB4 clearly showed transcripts for the β3 
subunits and this correlated with the results from FACS analysis. The product for 
β6 subunit was not of the correct size so no conclusions could be made from 
them (data not shown). Using the β8 primers a faint band for the correct size of 
transcript was observed in all the cell lines however, very prominent band of 400 
bp was seen in both the mature B cell lines SKW and IB4 (Figure  3.5). 
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Figure  3.5 RT-PCR analysis for αV integrins β subunit expression in the different B cell 
lines. 
 
Total RNA isolated from the different B cell lines was used as template for the RT-PCR reaction 
using primer pairs specific for each β subunit and PCR products were separated by agarose gel 
electrophoresis. For the β5 subunit a PCR product was amplified from β5 plasmid for comparison 
of the size. All the cell lines were previously shown to express the αV integrin subunit (data not 
shown). The size of each subunit was compared with a DNA ladder. * Indicates the position of the 
appropriate sized bands. RT-PCR analysis with GAPDH primers were performed with each cell line 
as a positive control.  Data represent three independent RT-PCR results. 
 
 
 
 
 
* 
* 
* 
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Table 2 Summarises the expression of different cell surface markers (from FACS analysis 
data) for characterisation of different cell lines together with pattern of expression of 
individual αV integrins. 
 
 CD9 CD10 CD38 αvβ5 αvβ3 αvβ6 β1 µ-chain  κ or λ 
SMS-
SBs 
+++ - + +++ - - +++ + - 
RS4;11 +++ - ++ +++ -/+ - +++ - - 
697 ++ + ++ +++ -/+ - +++ + - 
Nalm-6 ++ +++ +++ +++ ++ - NA + - 
Blin-1 ++ +++ +++ +++ ++ NA +++ + - 
1E8 ++ - ++ ++ + + ++ ++ + 
Ramos - ++ +++ - - - +++ ++ ++ 
Daudi - ++ +++ + - - +++  ++ 
SKW - - - + +++ - + ++ ++ 
IB4 - - - -/+ +++ - + ++ ? 
 
**NA- Not available 
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3.2.4 αV Integrin function in human B cell Lines  
Previous data have demonstrated that the integrin αVβ5 is a receptor for sCD23 
on precursor B cells 232. αVβ5 binds an RKC motif on CD23 and this interaction 
was shown to sustain proliferation of the SMS-SB cell line. This effect on 
proliferation was mimicked by CD23-derived peptides containing the RKC motif 
and by specific monoclonal antibodies (MAbs) known to bind to αVβ5. The AMF7 
MAb, which binds the αV subunit, and the 15F11 MAb, which binds the assembled 
αVβ5 heterodimer, sustained proliferation in manner similar to sCD23; however, 
the P1F6 MAb that also binds to the αVβ5 heterodimer had no effect on cell 
proliferation. Therefore, sCD23, CD23-derived peptide (long peptide) and MAbs 
AMF7 and 15F11 were used to assess αVβ5-mediated proliferation across the B 
cell lines representing different stages of B cell development. 
3.2.4.1 Proliferation in response to sCD23 
Figure 3.6 shows that SMS-SB cells proliferate in response to a range of 
recombinant sCD23 types. The optimal concentration for a proliferative response 
varies according to the type of sCD23 used and other constituents in the 
medium. Previous work in the laboratory showed that gel filtration-purified 
recombinant sCD23 induces a bell-shaped dose-response curve with maximum 
growth stimulation seen on addition of approximately 200-500 ng/ml (White, LJ, 
PhD thesis, University of Glasgow, 1995), therefore the concentration range of 
20-250 ng/ml was chosen to assess sCD23 driven SMS-SB cell proliferation. The 
two commercially-available sCD23 (R&D systems) and sCD2348-248 (Assays Designs) 
showed an almost identical dose-dependent increase in tritiated thymidine ([3H]-
TdR) uptake when added to SMS-SB cells (Figure 3.3A). However the derCD23 
(from D. J. McDonnell, University of Oxford) showed optimal increase in cell 
proliferation at 20ng/ml and no effect at 250 or 120ng/ml.  
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Furthermore, as indicated in Materials and Methods, (Chapter 2) protein-free 
medium was always used to assess SMS-SB cell proliferation but some of the pre-
B cell lines used did not survive in protein-free medium alone and therefore, 1% 
FCS was added to the medium. When sCD23-induced cell proliferation was 
assessed in SMS-SB cells with addition of 1% FCS to the medium, an optimal 
increase in cell proliferation was seen at 2ng/ml derCD23. Proliferation induced 
by derCD23 in the presence of 1% FCS was of lesser degree than proliferation 
induced in PFHM (SI of 1.6 vs. SI of 3), (Stimulation index, SI was calculated as 
mean of cpm in presence of treatment/mean cpm untreated cells). Constituents 
of serum such as vitronectin and growth factors such as PDGF will obviously have 
some regulatory effects on this proliferative response therefore the proliferation 
response may differ in the two cases. 
SMS-SB cell proliferation was demonstrated with a commercially available CD23, 
sCD23 48-248. This is a truncated form of the full-length sCD23 and lacks the IgE 
and CD21 binding sites present on the full length CD23. A structural 
representation of the IgE binding site (in red) and CD21 binding site (in blue) is 
depicted in Figure 3.3B. The RKC motif bound by the αVβ5 integrin is 
represented in yellow and is present on the sCD2348-248. The proliferative 
response induced by this sCD23 establishes that the sCD23-induced proliferation 
of human B cell precursors is independent of the presence of the IgE binding site 
or the CD21 binding site. 
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Figure  3.6 SMS-SB cell proliferation in response to a range of recombinant human sCD23. 
 
Low cell density (LCD) cultures of SMS-SB cells were propagated with the indicated concentrations 
of different types of sCD23. Proliferation was assessed after 72 h by 3[H]-TdR incorporation. (A) 
Comparison of proliferation of SMS-SB cells in response to sCD23 from R&D systems, derCD23  
(PFHM) or derCD23 (in PFHM with 1%FCS). (B) Another recombinant sCD23 from Assay Designs 
termed sCD23 48-248 was also used to assess proliferation of SMS-SB cells. The IgE binding site (in 
blue) and CD21 binding site (in red) are illustrated on the structural representation of sCD23. The 
RKC motif is depicted in yellow. Bars represent the standard deviation of triplicate determinations, 
with *p<0.05 or **p<0.005 indicating increase in proliferation in comparison to untreated cells. Data 
are representative of at least three independent experiments. 
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Figure 3.7 shows that the three pre-B cell lines SMS-SB, 697 and RS4;11 showed a 
robust dose-dependent proliferation in response to sCD23 treatment. Both the 
cell lines SMS-SB (SI at 250ng/ml and 120ng/ml of 3.2 and 2.1, respectively) and 
697 (SI at 250ng/ml and 120ng/ml of 3.5 and  3.5, respectively) show an almost 
identical response while the concentration range for the optimal response is 
slightly different for RS4;11 cells (SI at 20ng/ml and 2ng/ml of 2.5 and 3.2, 
respectively) which show a strong response at 2ng-20ng/ml and no response at 
250ng/ml. However, the sCD23 used in the case of RS4;11 was derCD23 and that 
could be the reason for the difference in the effective concentration range. This 
is verified by the different concentration range at which the 697 cells show 
optimal effect in cell proliferation in response to derCD23 (Figure 3.7).  
The Blin1 cell line showed a slight proliferative response to sCD23 treatment at 
2ng/ml and 20 ng/ml  (SI of 1.5 and 1.4, respectively). Interestingly, the cell 
line 1E8 which is more mature than Blin1 also showed a slight increase in cell 
proliferation at 2ng/ml (SI of 1.9) (Figure 3.7). None of the transitional B cell 
lines (Daudi, Raji, Ramos) or the mature B cell lines (SKW and IB4) show a robust 
increase in cell proliferation with derCD23 when compared to early pre-B cell 
lines (Figure 3.8). However, with the Daudi and SKW cell lines there is a slight 
but significant increase in cell proliferation observed at 2-20ng/ml (SI of 1.9 for 
Daudi and SI of 1.6 for SKW). Both of these cell lines express small amounts of 
αVβ5 integrin (Figure 3.4) and the effect on cell proliferation could be mediated 
via this integrin. The cell lines Raji, Ramos and IB4 clearly do not show any 
response in cell proliferation with any of the concentrations of derCD23 used and 
these were the cell lines that did not express αVβ5 on cell surface (αVβ5 
expression data not shown for Raji cells which were αVβ5-negative and 
expression of  other cell surface were identical to Daudi and Ramos; therefore 
this cell line was also considered to be a transitional B cell line).  
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Figure  3.7 Proliferation of different pre-B cell lines in response to human sCD23. 
 
LCD cultures of SMS-SB cells in PFHM or other cell lines in PFHM with 1%(v/v) FCS were 
propagated with indicated concentration of sCD23 (R&D sCD23 for SMS-SB cells, derCD23 for 
RS4;11, Blin1 and 1E8 cells and either RND or derCD23 for 697 cells). Proliferation was assessed 
after 72 h by 3[H]-TdR incorporation. Bars represent the standard deviation of triplicate 
determinations, with *p<0.05 or **p<0.005 indicating increase in proliferation in comparison to 
untreated cells. Data represent at least three independent experiments. 
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Figure  3.8 Proliferation of different mature B cell lines in response to human sCD23. 
 
LCD cultures (5000 cells/well) of the indicated cell lines in PFHM were propagated with the 
indicated concentration of sCD23 (derCD23). Proliferation was assessed after 72 h by 3[H]-TdR 
incorporation. Two sets of results are displayed for SKW cell line as in one experiment there was 
slight proliferative response with sCD23 at 2ng/ml whereas there was no significant response at the 
same concentration in another experiment. Bars represent the standard deviation of triplicate 
determinations, with *p<0.05 indicating increase in proliferation with sCD23 treatment, in 
comparison to untreated cells. Data represent at least three independent experiments. 
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3.2.4.2 Proliferation in response to Long peptide 
The change in proliferative response to sCD23 in the different cell lines was 
verified by using the sCD23-derived long peptide (LP). This peptide contains the 
RKC motif bound by the integrin αVβ5 and previous surface plasmon resonance 
(SPR) analysis has confirmed the binding of this peptide to αVβ5. Consistent with 
the data for sCD23, the pre-B cell lines SMS-SB, RS4;11 and 697 showed a robust 
dose-dependent proliferative response to LP treatment with stimulation indices 
(at 10ng/ml) of 7.6, 8 and 17.5 for SMS-SB, RS4;11 and 697 cells, respectively 
(Figure 3.9).  In each case, the negative control peptides that do not contain the 
RKC motif (peptide 8, 13 or 58) showed no effect on cell proliferation.  
Proliferation induced by LP is of higher magnitude (when comparing SI) than 
sCD23, however since the peptides are smaller in structure compared to sCD23 
they might bind better to the integrin; the peptides are also used at a higher 
concentration than sCD23. 
The late pre-B cell line Nalm6 did not show any significant increase in cell 
proliferation with LP but Blin1 cells showed a slight increase in cell proliferation 
at 5µg/ml. The proliferative response of the 1E8 cell line was more difficult to 
define because in one assay there was a slight response to LP at 10 and 5µg/ml 
(SI 2.3 and 2.6; however this proliferative response was not statistically 
significant in comparison to negative control peptide #8-induced proliferation) 
but in another assay there was no response at all to LP (Figure 3.9). Again 
consistent with the data observed for sCD23, the transitional B cell lines and the 
mature B cell lines did not show a significant increase in cell proliferation with 
LP treatment apart from a slight increase in proliferation in Daudi and SKW cell 
lines at 5-10ng/ml LP treatment (Figure 3.10). 
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Figure  3.9 Proliferation of different pre-B cell lines in response to the CD23-derived long 
peptide. 
 
LCD cultures of SMS-SB and Nalm6 cells in PFHM or other cell lines in PFHM with 1%FCS were 
propagated with indicated concentration of LP (KWINFQRKCYYFGKG ) or negative control peptide 
#8 (PEKWINFQR). Proliferation was assessed after 72 h by 3[H]-TdR incorporation. Two sets of 
results are displayed for 1E8 cell line because different responses were observed in two different 
experiments. Bars represent the standard deviation of triplicate determinations, with *p<0.05 or 
**p<0.005 indicating increase in proliferation in response to LP treatment in comparison to peptide 
#8 treatment at the same concentration. Data represent at least three independent experiments. 
 
 
 
Untreated LP Peptide #8 
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Figure  3.10 Proliferation of different mature B cell lines in response to CD23-derived long 
peptide. 
LCD cultures (5000 cells/well) of the indicated cell lines in PFHM were propagated with indicated 
concentrations of LP (KWINFQRKCYYFGKG ) or negative control peptide #8 (PEKWINFQR). 
Proliferation was assessed after 72 h by 3[H]-TdR incorporation. Bars represent the standard 
deviation of triplicate determinations, with *p<0.05 indicating increase in proliferation with LP 
treatment in comparison to peptide #8 treatment at the same concentration. Data represent at least 
three independent experiments. 
 
 
 
3.2.4.3 Proliferation in response to anti-αVβ5 monoclonal antibodies (MAbs) 
Figure 3.11 shows that the pre-B cells lines (SMS-SB, RS4;11 and 697) proliferate 
in response to αVβ5 ligation by 15F11 or AMF7 antibody. SMS-SB cells showed a 
Untreated LP Peptide #8 
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significant proliferative response when stimulated with either the 15F11 
antibody or the AMF7 antibody at 5µg/ml when compared with the respective 
isotype controls (Figure 3.11). RS4;11 cells showed significant proliferation with 
15F11 antibody when compared to the isotype control IgG2a antibody (Figure 
3.11), but these cells showed no response with AMF7 antibody (data not shown). 
The 697 cell line was similar to SMS-SB cell line and showed a significant 
response in cell proliferation with both the AMF7 and the 15F11 antibody. The 
P1F6 MAb failed to provoke a significant proliferative response in any of the cell 
lines (Figure 3.11).  
None of the other cell lines tested showed any response to any anti-αVβ5 MAbs 
(AMF7, 15F11 or P1F6) (Figure 3.12 and 3.13). The mature B cell lines SKW and 
IB4 that expressed high levels of αVβ3 but little or no αVβ5 were used to 
investigate if αVβ3 could regulate cell proliferation in a manner similar to αVβ5; 
both the cell lines showed minimal proliferation in response to the 23C6 
antibody challenge compared to the isotype control IgG1 antibody (Figure 3.13). 
No proliferative response was observed with a second αVβ3 antibody LM609 or 
the αV antibody LM142 (Figure 3.13). However, the case with the transitional 
cell lines was slightly more complicated. The cell lines Raji and Daudi both 
demonstrated significant cell proliferation when stimulated with 23C6 although 
αVβ3 expression was very low in these cell lines (Figure 3.12). In contrast, the 
Ramos cell line showed an inhibition of cell proliferation when treated with the 
23C6 antibody (Figure 3.12). No proliferative effect was noted when with the 
MAbs LM609 or LM142 were used to stimulate these cell lines (Figure 3.12). No 
proliferative response was seen in the Ramos cell line with the 10D5 antibody 
(Figure 3.12) although these cells showed some αVβ6 expression by FACS analysis 
(Figure 3.4) 
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Figure  3.11 Proliferation of  pre-B cell lines in response to αVβ5 monoclonal antibodies. 
 
LCD cultures of SMS-SB cells in PFHM or 697 and RS4;11 cell lines in PFHM with 1% FCS were 
propagated with indicated MAbs. All MAbs and their specific isotype controls were used at 5µg/ml. 
The AMF7 antibody was dissolved in a buffer containing BSA therefore BSA was used with the IgG 
isotype control antibody. Proliferation was assessed after 72 h by 3[H]-TdR incorporation.  The 
inset on the results for SMS-SB cells displays proliferation in response to AMF7 and antibody and 
its isotype control. For SMS-SB cells, results are displayed for both the αVβ5 antibodies (P1F6 and 
15F11) while for 697 and RS4;11 results are shown only for the antibodies where we observed a 
proliferative response. Bars represent the standard deviation of triplicate determinations, with 
*p<0.05 or **p<0.005 indicating increase in proliferation in response to each MAb treatment in 
comparison with specific isotype control antibody. Data are representative of three independent 
experiments. 
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Figure  3.12 Proliferation of mature B cell lines in response to different αV integrin 
monoclonal antibodies. 
 
LCD cultures (5000cells/well) were propagated in PFM of cell lines Raji, Ramos and Daudi with the 
indicated MAbs and proliferation was assessed after 72 h by 3[H]-TdR incorporation. All the MAbs 
and there isotype controls were used at 5µg/ml. Bars represent the standard deviation of triplicate 
determinations, with **p<0.05 indicating increase in proliferation with antiboody treatment in 
comparison to the isotype control.  Data are representative of three independent experiments. 
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Figure  3.13 Proliferation of mature B cell lines in response to different αV integrin 
monoclonal antibodies. 
 
LCD cultures (5000cells/well) were propagated in PFM of cell lines SKW and IB4 with the indicated 
MAbs and proliferation was assessed after 72 h by 3[H]-TdR incorporation. All the MAbs and there 
isotype controls were used at 5µg/ml. Bars represent the standard deviation of triplicate 
determinations, with **p<0.05 indicating increase in proliferation with antiboody treatment in 
comparison to the isotype control.  Data are representative of three independent experiments. 
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3.2.5 αV integrin expression on human  bone marrow B cell 
precursors 
Frozen human bone marrow mononuclear cells were thawed and used for FACS 
analysis using a panel of MAbs  for CD19, CD10, CD9, µ, κ, αVβ5 and αVβ3 
expression. The cell surface markers were chosen to delineate the different 
stages in B cell development in the bone marrow and to allow for correlation 
with the cell line data. In all cases lymphocyte populations were first gated from 
the forward scatter/side scatter dot plots and B cells were identified from the 
total population by using the anti-CD19 antibody conjugated to PerCP-Cy5.5 and 
further analysis was only done on the CD19+ B cells. 
Figure 3.14 illustrates that bone marrow B cell precursors express both the 
integrin αVβ5 and αVβ3 as shown by staining with the P1F6 MAb for αVβ5 and 
23C6 MAb for αVβ3 expression. However, αVβ5 expression was higher than αVβ3 
expression (25.9% of CD19+/αVβ5+ cells vs. 15.3% of CD19+/ αVβ3+ cells on the 
upper right quadrants of the dot plots). Some of the αVβ5-positive cells were 
CD10 positive (Figure 3.15) and majority of the αVβ5-positive cells were also 
positive for CD9 as shown in Figure 3.15. In both cases, positive staining for CD9 
or CD10 is represented by the blue histogram. This is in agreement with the cell 
line data and shows the bone marrow B cell precursors positive for CD9 or CD10 
are αVβ5 positive.  More importantly, Figure 3.16 depicts that CD10-negative B 
cells are αVβ5-negative but CD10-positive B cells are αVβ5-positive. αVβ5 
staining in CD10-negative population is represented as a red histogram and was 
derived from  the upper left population on the dot plot and  αVβ5 staining in 
CD10-positive cells is shown as a red histogram and these cells represent the 
population at upper right quadrant. CD10-positive B cells represent the 
precursor B cells in bone marrow while CD10-negative B cells represent the re-
circulating B cells. Therefore these data supports the hypothesis that αVβ5 is 
expressed on B cell precursors but not on more mature cells.  
Figure 3.17 shows the expression of αVβ5 or αVβ3 integrin in three different cell 
populations based on staining for the µ-chain. B cell populations were gated as  
either, CD19- or CD19+/ µ-chain-negative or CD19+/µ-chain-positive and αVβ5 or  
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αVβ3 staining in each of these population is shown as a histogram overlay. Figure 
3.17A illustrates that αVβ5 expression is highest in the CD19+/µ-chain-negative B 
cell population and is lower in the CD19+/µ-chain-positive B cell population. The 
µ-chain-negative B cell precursors probably represent pro-B cells, and therefore 
these data support the hypothesis that αVβ5 expression is highest in the earlier B 
cell precursors and decreases as the cells mature. However, no staining was 
observed with the CD34 MAb and, due to the lack of data on CD34-positive pro-B 
cells, αVβ5 expression on pro-B cell precursors cannot be confirmed. Moreover, 
αVβ3 integrin showed a very similar expression pattern to αVβ5 (Figure 3.17B). 
From the cell line data it would be expected that perhaps αVβ3 expression 
increases as the B cells mature, since more mature cell lines showed more αVβ3 
expression. However, the pre-B cell lines also expressed αVβ3 integrin and 
therefore it is possible that the bone marrow B cell precursors express both 
these integrins. Analysis of αVβ3 integrins in more mature B cells would be 
required to further confirm the expression pattern. 
Data shown in Figures 3.18A and 3.18B indicate that both µ-chain-positive and κ-
chain-positive B cells are also αVβ5+. Since κ-chain-positive B cells represent 
BCR-positive cells it was surprising to see αVβ5 expression in these cells. 
However, the kappa-positive immature B cell line 1E8 also expressed αVβ5 and 
the kappa-positive population encompasses the immature and mature B cells and 
so the αVβ5 expression could be because of an immature B cell population. 
Comparing the histograms for αVβ5 expression in µ- chain-positive and κ-chain-
positive B cells it is evident that there are more µ-chain-positive cells expressing 
αVβ5 than the kappa-positive B cells. The kappa antibody showed some non 
specific binding so it was difficult to analyse different B cell populations with 
varying κ-chain expression. 
Finally, Figures 3.19 A and 3.19 B indicate that both αVβ5 and αVβ3 are 
expressed on some CD5+ B cells. CD19+/αVβ5+ cells were analysed for CD5 
staining. CD19+ but αVβ5-negative B cells are also CD5+ (red histogram) however 
there are a proportion of αVβ5+ B cells are CD5+ (blue histogram). A similar 
result was seen with αVβ3 staining (Figure 3.19B). 
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Figure  3.14 Expression of integrins αVβ5 and αVβ3 in bone marrow B cell precursors. 
 
Frozen samples of BM mononuclear cells were thawed and prepared for FACS analysis as 
described in materials and methods. B cell precursors were identified from the mononuclear cell 
population by using anti-CD19-PerCpCy5.5 MAb. Compensation gates were based on isotype 
control mouse IgG1-κ conjugated beads (BD Bioscience, Oxford, UK). Biotinylated P1F6 MAb with 
secondary streptavidin APC was used to detect αVβ5 integrin and biotinylated 23C6 MAb with 
secondary streptavidin APC was used to detect αVβ3 integrin.  
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Figure  3.15 Expression of CD9 and CD10 markers on αVβ5 positive bone marrow B cell 
precursors. 
 
BM mononuclear cells were simultaneously stained with P1F6-biotin (and streptavidin APC), CD9-
FITC, CD10-PE and CD19-PerCPCy5.5. The CD19+/αVβ5+ population was further analysed for 
CD10 and CD9 expression as histograms. The twodot plots show the αVβ5+ and CD19+ 
populations on the upper right quadrant and histgrams for CD10 (top) CD9 (bottom) were drawn 
based on this population. The histogram in red represents background staining for FITC or PE from 
unstained samples and the histogram in blue represents staining for CD10-PE or CD9-FITC. 
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Figure  3.16 Analysis of αVβ5 expression on CD10-negative and CD10-positive bone marrow 
B cell precursor populations. 
 
BM mononuclear cells were simultaneously stained with P1F6-biotin (and streptavidin APC), CD10-
PE and CD19-PerCPCy5.5. The dot plots show CD19+ and CD10+ population in the upper right 
quadrant and CD19+ and CD10- population in the upper left quadrant. These two populations were 
analysed for αVβ5 expression. The histogram shows staining for αVβ5 on CD19+ /CD10- population 
in red and αVβ5 staining for CD19+  and CD10+ population in blue.  
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Figure  3.17 Analysis of αVβ5 and αVβ3 integrin in bone marrow B cells at different stages. 
 
BM mononuclear cells were simultaneously stained with either P1F6-biotin or 23C6-biotin (and 
streptavidin APC), µ-FITC and CD19-PerCPCy5.5. The dot plots show different populations gated 
on CD19 and µ chain expression. In both dot plots the circular gate on the far left represents the µ-
low or negative/CD19+ population, the circular gate in the middle represents the CD19-negative 
population and the elliptical gate on the right represents µ-positive /CD19+ B cell precursors. αVβ5 
or αVβ3  expression in  each of these populations is represented as histograms. The plots on the 
top (A) represent staining for αVβ5 and plots on the bottom (B) represent staining for αVβ3. 
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Figure  3.18 Expression of αVβ5 integrin on µ-positive and κ-positive bone marrow B cell 
precursors. 
 
BM mononuclear cells were simultaneously stained with P1F6-biotin (and streptavidin APC), µ-
FITC or κ-FITC and CD19-PerCPCy5.5. The dot plots show the CD19+ and αVβ5+ B cell population 
on the upper right quadrants. αVβ5+ and µ-chain-positive cells are shown as histograms in (A) and 
αVβ5+ and κ-chain postive cells are shown as histogram in  (B) 
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Figure  3.19 Analysis of αVβ5 or αVβ3 integrin expression on CD5+ B cells from the bone 
marrow. 
 
BM mononuclear cells were simultaneously stained with MAbs P1F6-biotin or 23C6-biotin (and 
streptavidin APC), CD5-FITC and CD19-PerCPCy5.5. The dot plots identify CD19+ and αVβ5+ B 
cell population (A) or CD19+ αVβ3+ B cell population (B) on the upper right quadrants. These cell 
populations were analysed for expression of CD5 as shown by the histograms. The histogram in 
blue indicates CD5+ αVβ5+ cells (A) or CD5+ αVβ3+ cells (B) and the histogram in red shows CD5+/ 
CD19+ cells that are negative for either integrins; these are derived from the upper left quadrants as 
shown in the dot plots.  
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3.2.6 Proliferation response of B cell precursors in the bone 
marrow 
B cell precursors in the human bone marrow mononuclear cells were FACS sorted 
by using the CD19 and kappa MAbs. The CD19+ population was sorted into kappa 
positive and kappa-negative populations. The kappa negative population 
represents precursor B (pro-B to pre-B) cells that have not started to express the 
kappa light chain while the kappa positive population encompasses immature, 
transitional and mature B cells all expressing the kappa light chain. Both 
populations were separately used in proliferation assays to determine their 
proliferation response to αVβ5 ligands. The number of cells sorted were not 
enough to confirm αVβ5 expression in the sorted population. However an aliquot 
of the bone marrow mononuclear cells was stained for CD19, αVβ5 and kappa 
light chain expression to make sure there were significant numbers of αVβ5-
positive cells in the sorted populations. 
B cell precursors were cultured on irradiated stromal cells (hMSC-Tert) in RPMI 
with 2% (v/v) FCS with different treatments and proliferation measured as 
mentioned in materials and methods (Chapter 2). The CD19+/κ+ cells did not 
show a significant proliferation response with any treatment and did not survive 
for too many days in the culture. The CD19+/κ- B cell precursors survived in 
culture for a few days and as shown in Figure 3.20 they showed a significant 
proliferative response with sCD23 (250ng/ml) and with the CD23-derived LP 
(5µg/ml). The negative control peptide #8 did not cause any effect in cell 
proliferation. Proliferation with the LP was more robust than proliferation with 
sCD23 and this was seen in proliferation assays with the B cell lines as well.  
However, we did not see a significant effect in cell proliferation with the 15F11 
MAb which binds αVβ5 integrin and induces a proliferative response in pre-B cell 
lines SMS-SB, RS4;11 and 697. Perhaps, a higher concentration of this antibody 
could be required to see a response in the bone marrow B cell precursors.  The 
other αVβ5 antibody, P1F6, or the αVβ3 antibody 23C6 also failed to induce a 
proliferative response. Moreover, these data are representative only of one 
experiment so this experiment would have to repeated to obtain conclusive 
data. 
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Figure  3.20 Proliferation of human CD19+/ κ- B cells in response to LP and CD23. 
 
CD19+/κ- B cells were FACS sorted from a BM mononuclear cell population and used for 
proliferation experiments. 4000 sorted B cells/well were plated on γ-irradiated stromal cells in 96-
well plates and proliferation was assessed 72 h by 3[H]-TdR incorporation. Bars represent the 
standard deviation of triplicate determinations, with *p<0.05 indicating increase in proliferation with 
CD23 or LP treatment in comparison to the negative control peptide #8 treatment. Data represent 
one experiment (n=1). 
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3.3 Discussion 
The data presented in this chapter indicate that αVβ5 expression and its 
influence on B cell proliferation is regulated in a developmental stage-specific 
manner.  
Different B cell lines were chosen to represent a broad range of developmental 
stages, but it was not always possible to categorise each cell line into a specific 
stage definitively. RS4;11 is a well-characterised MLL (mixed lineage leukaemia)  
bearing an MLL/AF4 rearrangement 283, and known to be at the pro-B stage; in 
agreement with this, it was surface µ- , CD10-. However, RS4;11 cells were not 
CD34+ which is a common marker for pro-B cells.  SMS-SB cells were also CD10-
negative but expressed low levels of surface µ. Bertrand, et. al., have described 
another MLL-rearranged Blin-3 cell line with the t(4;11) translocation that was  
µ- and became  µ+ in vitro 284. Furthermore, the overall phenotype of the MLL-
rearranged pro-B and pre-B ALL is known to be largely identical. Therefore, 
although we did not know the t(4;11) translocation status of SMS-SB cells, 
because of the similarities in surface marker expression, SMS-SB cells and RS4;11 
cells were categorised together as early pre-B cells.   
The CD10+ pre-B cell lines were designated as late pre-B cell lines. However, 
CD10 expression was lower in the 697 cell line in comparison with Blin1 or Nalm6 
cell lines and therefore the 697 cell line could be at a slightly different stage 
than the Blin1 or Nalm6 cells. CD20 expression at the small pre-B stage is known 
to coincide with cessation of cell division, exit from the bone marrow and 
maturation towards a mature B-cell phenotype 285, and this is followed by a 
concomitant decrease in expression of CD10 and CD24 286.  Therefore, other pre-
B cell markers such as CD20 and CD24 could have been employed to more 
directly delineate the cell stages. The κ+ and CD10 negativity showed that 1E8 
cells, although derived from the Blin1 cells, were at a more mature stage of 
development. 
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CD38, CD10 and CD24 antigens have previously been identified as immature B 
cell markers in human bone marrow and CD10 expression is characteristic of 
human transitional (T1) B cells 48 . As the cell lines Daudi, Raji and Ramos were 
all positive for immunoglobulin light chain expression, they were considered to 
be more mature than immature B cells and because of their CD10 expression 
they matched the transitional B cell phenotype. However, human transitional B 
cells are also known to be IgD positive but none of these cell lines showed IgD 
expression. These cell lines were also negative for CD21 expression, which is a 
marker for mature B cells. The mature B cell lines also lacked CD21 expression, 
therefore it is not clear whether the antibody was not able to detect CD21 
expression or the cells were all indeed CD21 negative. The fact that the cell 
lines SKW and IB4 were CD10-negative indicated that they were a stage further 
from the transitional B cell lines and therefore were designated as mature B 
cells.  
It is clear from the P1F6 and 15F11 staining data that the pre-B cells express 
high levels of αVβ5 and the integrin expression decreases as the cell mature. 
P1F6 staining showed similar levels of αVβ5 expression in the early and late pre-
B cells but with the 15F11 MAb early pre-B cell lines and 697 cells showed higher 
levels of staining for αVβ5 than the late pre-B cells Blin1 or Nalm6. In fact, the 
three pre-B cell lines (SMS-SB, RS4;11 and 697) showing significant 15F11 staining 
were the cells lines that showed a robust proliferative response to αVβ5 ligation. 
More importantly, there was a down-regulation of αVβ5 expression in the 1E8 
cell line that had started to express immunoglobulin light chains when compared 
to the original cell line Blin1 from which they were derived, indicating that B 
cell maturation may be accompanied by αVβ5 down-regulation. 
There was also a clear down-regulation in αVβ5 expression in the transitional 
and mature B cell lines as shown by FACS analysis. However, this difference was 
not clear when assessing transcripts for β5 in the different cell lines. The β5 
transcript was present in all the cell lines tested except for the Ramos cell line. 
It is possible that in the cell lines such as IB4 although they have the β5 
transcripts they do not express the β5 protein on the cell surface. A western blot  
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analysis of β5 would be needed to confirm the presence of β5 protein in the 
cells. Nevertheless, the fact that cell lines such as Daudi and SKW still showed 
slight surface expression of αVβ5 indicates that the cell lines such as IB4 may 
also express small amounts of αVβ5 that was not detected by FACS analysis.  
In the case of αVβ3, it was difficult to conclude exactly at what stage αVβ3 
expression began and one can only conclusively say that the mature B cell lines 
like SKW and IB4 expressed high levels of αVβ3 in comparison with any of the 
other cell lines. A further complication in the analysis was the fact that the 
precise stage of development of the mature B cell lines SKW and IB4 could not 
be defined. Although they both expressed most of the surface markers tested, 
IB4 cell lines were not positive for surface light chain expression. These cell lines 
are both CD23 positive and both are EBV transformed cell lines. Therefore the 
high αVβ3 expression could also be because of EBV transformation as previous 
studies have shown that EBV transformation induces expression of αVβ3 integrins 
287.  
From the analysis of B cell precursors in the bone marrow, it was noted that the 
CD19+/CD9+ and CD19+/CD10+ cells expressed αVβ5 as well as αVβ3, but αVβ5 
expression was higher in comparison to αVβ3 expression. αVβ3 expression in the 
bone marrow B cell precursors indicate that low levels of αVβ3 might be 
expressed in pre-B cells, consistent  with data for αVβ3 expression in Blin1 and 
Nalm6 cells. The bone marrow data also indicates that CD10+ B cell precursors 
are αVβ5+ but CD10- re-circulating B cells are αVβ5-negative. We also observed 
in the bone marrow that the κ+ B cells still expressed αVβ5 although the 
expression was lower than the µ+ B cell precursors (Figure 3.18). A more rigorous 
study of bone marrow B cell precursors is required to obtain conclusive data. In 
our study we were also unable to detect CD34+ pro-B cells in the bone marrow 
and this could be because we were using frozen bone marrow samples. Analysis 
of pro-B cells and pre-B cells is particularly important, since it is in these early 
stages that αVβ5 expression seems to be highest and most functionally important 
from the cell line data and we could see a similar pattern from the bone marrow 
expression data (Figure 3.17).  
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Therefore, it cannot be conclusively said that αVβ5 expression is exclusive to the 
pre-B cells but it can be concluded that αVβ5 expression decreases as the B cells 
mature. This is also in agreement with previous data from the laboratory 
showing that αVβ5 expression is significantly increased in cells from patients 
with ALL (Borland, et. al., 2008 manuscript submitted). With regard to the 
comparison of αVβ5 and αVβ3 expression, analysis of the mature B cells in the 
peripheral blood will also be necessary in order to identify and compare the 
pattern of expression of these two integrins. Since a similar expression pattern 
was seen between αVβ5 and αVβ3 integrins in the bone marrow B cell precursors 
it would be important to analyse the more mature B cells in order to identify if 
there is a difference in expression pattern of these two integrins. Another 
interesting finding from the bone marrow expression study is that the CD5+ B 
cells are positive for αVβ5 and αVβ3 integrins (Figure 3.19). CD5+ B cells in 
humans are considered to be equivalent to the murine B-1a cells. These cells 
represent a minor B cell population but have been implicated in malignanices 
such as CLL and in autoimmune diseases. The fact that these cells express αV 
integrins implies that these integrins could have a role in 
proliferation/differentiation of these cells which could have an important 
impact on the development of CD5+ cells associated B cell disorders. 
SMS-SB cells proliferate in a similar manner in response to recombinant sCD23 
from different sources. The three different sCD23 proteins were slightly 
different in the amino acids they encompassed and this allowed the comparison 
of different motifs in inducing a proliferative response. The amino acid 
sequences of the three different sCD23 are presented in an aligned format in 
Figure 3.21. R&D sCD23 and sCD23 48-248 encompassed nearly the same length of 
amino acids 48-321 and 48-248, respectively, and this could be the reason they 
both gave nearly identical proliferative responses. The derCD23 contained amino 
acids 156-298. We also did not assay the specific activities of these sCD23 
proteins so they could be inducing proliferative responses at different 
concentrations because of the difference in their specific activities. The sCD2348-
248 lacks IgE and CD21 binding motif but contains the RKC motif bound by αVβ5.  
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The proliferative response induced by this sCD23 clearly indicates that 
proliferation mediated by sCD23 is independent of the need for CD21 and IgE 
binding. 
The three pre-B cell lines SMS-SB, RS4;11 and 697 showed a significant 
proliferative response when αVβ5 was ligated using sCD23 or the CD23-derived 
long peptide; a similar response was seen with the αVβ5 antibody, 15F11. The 
AMF7 MAb which binds to the αV subunit shows a significant response in 
proliferation in SMS-SB cells and 697 cells but not in RS4;11 cells.  The 
transitional and mature B cell lines that do not express αVβ5 did not show any 
response in cell proliferation with sCD23, LP or the MAbs. Moreover, the cell 
lines Daudi and SKW that do express small amounts of αVβ5 showed a slight 
response in cell proliferation with sCD23 and with LP. The αVβ5 staining in these 
cell lines was done using P1F6 antibody and it is possible that these cell lines 
have low expression of the epitope that is recognised by 15F11 antibody and 
therefore do not show any proliferative response with this antibody.  Moreover, 
both of these cell lines are EBV-transformed cell lines and previous studies have 
demonstrated that sCD23 induces proliferation of EBV-transformed cell lines 215. 
This response is thought to be mediated by the CD23-CD21 interaction. Although 
we did not see any CD21 expression in these cell lines we cannot be sure they do 
not express this antigen because we did not see positive CD21 expression in any 
cell line. Furthermore, the fact that only sCD23 and LP induced a proliferative 
response in these cell lines, but not the αVβ5 MAbs (AMF7 or 15F11), indicates 
that perhaps the proliferative response we observed could be delivered via the 
CD23-CD21 interaction. 
Other αV integrin levels might also affect the proliferative response as the levels 
of different αV integrins change in the cells at different stages of development. 
The αVβ3 integrin was not associated with a proliferative response in the mature 
B cell lines that expressed high levels of this integrin and were low or negative 
for αVβ5. By contrast, in the transitional B cell lines Raji and Daudi, a significant 
increase in proliferation with the 23C6 MAb that is known to bind to αVβ3 
heterodimer was noted; no response with any other anti-αV MAbs was observed.  
From the expression data it is clear that these cells expressed very low, if any,  
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αVβ3 integrin and therefore it was surprising to see a proliferative response with 
this antibody on these cells; we did not see such an effect with 23C6 in the early 
pre-B cell lines. However, it should also be noted that the cell lines that were 
used for the functional studies had been in culture longer than the cell lines that 
were used for expression studies and the integrin expression did vary in the cells 
as they were in culture for an extended period (data not shown).  
It is possible that as the cells had been in prolonged culture, the αV integrin 
levels had changed in these cells and therefore their proliferative response to 
23C6 was different. It is also equally possible that pattern of expression of  
different αV integrin varies in the transitional and mature B cell lines and so the 
proliferative response is different depending on the αV integrins expressed. For 
example, it is clear from the RT-PCR data that both the SKW and IB4 cell lines 
express high amounts of transcripts for the β8 subunit when compared to any of 
the other cell lines. It is not known whether αVβ8 expression has a role in 
regulating proliferative responses when compared to the ligation of other αV 
integrins. Similarly, β1 integrin levels were characteristically different in cell 
lines at each of the developmental stages so αVβ1 integrin expression could also 
be affecting the function of other αV integrins.  
The Ramos cell line that was categorised to be of the same stage as Raji and 
Daudi cell lines, showed an inhibition in cell proliferation with the 23C6 
antibody. Among all the cell lines tested this cell line was the only cell line 
showing some staining for the αVβ6 heterodimer. Therefore, it is possible that 
the presence of αVβ6 negatively regulates the response through αVβ3. The αVβ6 
antibody (10D5) however did not have any effect on this cell line. Indeed a 
previous study has shown that β1 integrin regulates αVβ3 and αVβ5 integrin 
expression 288 and therefore cross talk between the different αV integrins could 
potentially have important roles in determining the function of each αV integrin.   
Extensive functional studies on bone marrow B cell precursors are required to 
confirm the effects of αVβ5 ligation on cell proliferation of normal B cell 
precursors. A more detailed study of the expression of all the different αV 
heterodimers together with the functional studies would also be required to 
identify exactly the stage(s) of development at which αVβ5-mediated cell 
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proliferation is critical and the role of different αV heterodimers in mediating 
this proliferative effect. Preliminary results for proliferation of normal human 
bone marrow B cells precursors, FACS sorted, on the basis of κ light chain 
expression, showed that the CD19+/κ- precursors proliferated well in response to 
both sCD23 and long peptide. But we did not observe a proliferative response 
with the αVβ5 MAbs. However, the CD 19+/κ- cells encompass a heterogeneous 
population of both pre-B, pro-B cells and this could be the reason for not seeing 
any response with the 15F11 antibody. Therefore this needs to be repeated, and 
a separate comparison of pro and pre-B cells would be required in order to 
compare the proliferation data for normal bone marrow B cell precursors with 
the cell line data. The CD19+/κ+ cells expressing αVβ5 showed no proliferative 
response with αVβ5 ligation.  
These findings indicate that the αV integrins, αVβ5 and αVβ3 are expressed in 
bone marrow B cell precursors and in B cell lines representing the precursor 
stages of development in the bone marrow. While the differential pattern of 
expression of these two integrins could not be identified, the proliferation data 
indicated that αVβ5 integrin regulates proliferation of B cell precursors in a 
stage-specific manner. It remains to be investigated what is the exact difference 
in the function of αVβ5 and αVβ3 integrin and how their expression pattern is 
regulated. αV integrin expression and function could have important implications 
for growth and differentiation of normal and neoplastic B cell precursors and  
therefore it is important to identify mechanisms regulating the expression and 
function of these integrins in B cell precursors. 
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Figure  3.21 Alignment of amino acid sequences for the three different types of sCD23. 
 
The three different types of sCD23 used in the experiments are represented as RnDCD23 (R & D 
CD23), Assay design CD23 (Ad CD23) and Der CD23. The sequence highlighted in red represents 
the sequence for the CD23-derived long peptide (LP). 
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4 Modulation of αVβ5 Integrin Function by 
Chemokines, Cytokines and Growth Factors. 
4.1 Introduction  
Signals mediating growth and survival of B cells at any stage of development 
need to be highly regulated for normal progression through each stage of 
development. The bone marrow microenvironment comprises a huge variety of 
cytokines, chemokines, growth factors and adhesion molecules all providing 
coordinated signals that allow maturation of B cells along the developmental 
pathway. Therefore, any growth/proliferation signal relating to B cell precursors 
in the bone marrow will be regulated by a number of positive and negative 
mechanisms.  
The integrin αVβ5 was shown to bind to an RKC motif on CD23 232 and this 
interaction sustained proliferation of precursor B cell lines expressing αVβ5 
(Chapter 3). Therefore we used sCD23, CD23-derived peptides and MAbs AMF7 
and 15F11 to assess the role of chemokines, cytokines and growth factors in 
modulating αVβ5 function and expression. The chemokine SDF-1 and a 
combination of cytokines as well as PDGF were used in combination with the 
αVβ5 ligands to assess SMS-SB cell proliferation. 
PDGFs are a family of closely related proteins which exist as disulphide-bonded 
dimers of approximately 30 kDa and three isoforms of PDGF, αα, αβ, ββ are 
encoded by two genes termed PDGFA and PDGFB 289. The PDGF receptor also 
comprises two isoforms, PDGFR-α and PDGFR-β. The α-receptor binds all three 
isoforms with high and equal affinity whereas the β receptor preferentially binds 
ββ homodimers and interacts with αβ heterodimers with reduced affinity. PDGF 
is a major growth factor in serum and is a potent mitogen for cells of 
mesenchymal origin. Exaggerated and inappropriate signalling by the PDGF 
receptor tyrosine kinase has been implicated in a variety of diseases 290. 
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A role for PDGF in the haematopoietic system has been shown by a number of 
studies.  It was shown that PDGF can alter the phenotype of stromal cells 291 and 
PDGF has been implicated in myeloid leukaemias 292 and in expansion of CD34+ 
cord blood cells 293. As SMS-SB cells were previously shown to express PDGFRβ 294 
and since PDGF has been extensively studied in the adherenet cell systems for 
integrin-growth factor cross-talk we assessed the role of PDGF in modulating 
αVβ5 function together with other cytokines and chemokines.  
4.2 Results 
4.2.1 SDF-1 Enhances Proliferation Induced by Ligation of αVβ5 
Integrin 
When treated with sCD23, SMS-SB cells show an increase in cell proliferation in a 
dose-dependent manner (Chapter 3). Other pre-B cell lines cell lines such as 
RS4;11 and 697 show a similar effect in cell proliferation (Chapter 3). SMS-SB 
cell proliferation induced by a sub-optimal concentration of sCD23 (158ng/ml) 
was enhanced by SDF-1 treatment as shown in figure 4.1A. Optimal 
enhancement of cell proliferation was seen with 250ng/ml SDF-1 and 158ng/ml 
sCD23. At 250ng/ml sCD23 treatment no enhancement of proliferation was 
observed with SDF-1 treatment and in fact there was a slight reduction in sCD23-
induced cell proliferation of SMS-SB cells (data not shown)  SDF-1 alone did not 
show any effect on proliferation of SMS-SB cells at any concentration used. The 
proliferative effect driven by the antibody 15F11 alone was also enhanced when 
SDF-1 was used together with 15F11 as shown in figure 4.1B. Peptide #9 (a CD23- 
derived peptide containing the RKC motif) showed a similar effect in cell 
proliferation while peptide #34, a negative control peptide (lacking the RKC 
motif) showed no effect in cell proliferation (Figure 4.1C). Similarly, SDF-1 
enhanced proliferation of SMS-SB cells, stimulated with the RKC containing long 
peptide (LP) (Figure 4.1D). As with sCD23, optimal enhancement of cell 
proliferation was seen at 250ng/ml SDF-1. Both the peptides and sCD23 showed 
an enhancement in cell proliferation with SDF-1 at a concentration slightly lower 
than the optimal concentration at which they themselves induced cell 
proliferation (Chapter 3).  
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FACS analysis for surface expression of the receptors showed that in addition to 
expressing the CXCR4 receptor, SMS-SB cells also expressed CXCR7, another 
receptor known to bind SDF-1 (data not shown). In order to show that the 
enhancement of αVβ5-mediated cell proliferation was indeed mediated via 
CXCR4 and SDF-1, we used the SDF-1 antagonist AMD3100 that is known to block 
binding of SDF-1 to CXCR4. Figure 4.2A shows that when SMS-SB cells were 
treated with AMD3100 (50µM) there was no difference in proliferation induced by 
long peptide with or without SDF-1 treatment. In the AMD3100-treated cells, 
basal cell proliferation is slightly increased but LP-induced cell proliferation is 
still very evident but there is no enhancement of this LP-induced cell 
proliferation in combination with SDF-1. 
A similar result was observed with the antibody 12G5 which is known to bind to 
CXCR4. There was no difference in proliferation induced by LP with or without 
SDF-1 in presence of the 12G5 antibody (Figure 4.2B). However, in the MAb 
12G5-treated SMS-SB cells, the basal proliferative response was lower than 
untreated cells or cells treated with IgG2a isotype control antibody. Although 
the 12G5 treated cells showed a proliferative response with LP treatment the 
cell count was much lower than in the untreated cells or IgG2a-treated cells. 
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Figure  4.1 SDF-1 enhances proliferation mediated via the αVβ5 integrin in SMS-SB cells. 
 
(A) The proliferation of LCD cultures of SMS-SB cells in response to a sub-optimal concentration of 
sCD23 (158ng/ml) together with indicated concentrations of SDF-1 (black bars) and SDF-1 alone 
(hatched bars). Panels B-D illustrate the proliferative response of SMS-SB cells to stimulation with 
5µg/ml 15F11 MAb (B), 5µg/ml peptide #9 (C), and 1µg/ml long peptide (LP) (D), respectively, in 
combination with SDF-1. In each panel the treatment with SDF-1 alone is shown as a hatched bar, 
the combination of SDF-1 and stimulus as a black bar, and the combination of SDF-1 with either 
isotype control IgG2a (B) or irrelevant peptide #34 (C) is shown as a white bar. Bars represent the 
standard deviation of triplicate determinations, with *p<0.05 or **p<0.005 indicating increase in 
proliferation in cells treated with different concentrations of SDF-1 and αVβ5 stimulants (sCD23, 
15F11MAb, peptide #9 or LP) in comparison to SDF-1 treatment alone, and #p<0.05 and 
##p<0.005 indicating enhancement in proliferation with 250ng/ml SDF-1 and αVβ5 stimulants when 
compared with αVβ5 stimulants alone. Data are representative of three independent experiments. 
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Figure  4.2 SDF-1 enhances proliferation mediated via the αVβ5 integrin in SMS-SB cells via 
the CXCR4 receptor. 
 
Proliferation response of LCD cultures of SMS-SB cells in presence of LP and CXCR4 antagonist 
AMD3100 or anti-CXCR4 antibody 12G5. (A) represents proliferation with sub-optimal 
concentration of LP (1µg/ml) and SDF-1 (250ng/ml) in untreated cells and cells treated with 50µM 
AMD3100 for 30 min prior to initiation of the assay. In both cases no stimulus is represented as 
grey bars, LP treatment is represented as black bars, the LP and SDF-1 combination as white bars 
and SDF-1 alone as hatched bars. (B) The proliferation response of SMS-SB cells to LP (1µg/ml) 
alone or with SDF-1(250ng/ml) in untreated cells, cells treated with 12G5 antibody or cells treated 
with IgG2a isotype control antibody. In all cases no stimulus is represented as grey bars, LP 
treatment is represented as black bars, the LP and SDF-1 combination as white bars and SDF-1 
alone as hatched bars Bars represent the standard deviation of triplicate determinations, with 
*p<0.05 or **p<0.005 indicating increase in proliferation in cells treated with different concentrations 
of SDF-1 and αVβ5 stimulants (sCD23, 15F11MAb, peptide #9 or LP) in comparison to SDF-1 
treatment alone, and #p<0.05 and ##p<0.005 indicating enhancement in proliferation with 250ng/ml 
SDF-1 and αVβ5 stimulants when compared with αVβ5 stimulants alone. Data are representative 
of three independent experiments. 
A 
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4.2.2 SDF-1 treatement does not change αVβ5 expression and 
αVβ5 ligation does not change CXCR4 expression 
In order to verify whether SDF-1 was affecting αVβ5 function by modulating  
expression levels of the latter, we monitored changes in αVβ5 expression after 
SDF-1 treatment. SMS-SB cells were treated with 250ng/ml of SDF-1 and αVβ5 
surface expression was assessed after 24 and 48 hours. The two antibodies 15F11 
and P1F6 are known to recognise different epitopes on αVβ5 282, therefore we 
used both the antibodies to assess changes in αVβ5 expression. However, there 
was no change in αVβ5 expression in cells treated with SDF-1 when compared to 
untreated cells (Figure 4.3A). SDF-1 is known to modulate the affinity of 
integrins for their ligands, therefore we also assessed binding of the CD23-
derived peptides to SMS-SB cells with and without SDF-1 treatment. A 
representative result (Figure 4.3B) shows that there was no change in binding of 
one of the sCD23-derived peptides (peptide #9) to SMS-SB cells regardless of 
SDF-1 treatment. On the other hand, ligation of αVβ5 did not have an effect on 
CXCR4 expression either. Figure 4.3C shows that treatment of SMS-SB cells with 
either the LP (1µg/ml) or sCD23 (160ng/ml) does not cause a change in CXCR4 
expression after 24 hours of treatment of SMS-SB cells.  
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Figure  4.3 Effects of SDF-1 on αVβ5 expression and αVβ5 ligation on CXCR4 expression. 
 
SMS-SB cells cultured in the presence or absence of 250ng/ml SDF-1 (24 h) were stained for αVβ5 
expression using the anti-αVβ5 MAbs, P1F6 and 15F11 (Figure 4.3A). Fluorescence intensity 
histograms for the relevant αVβ5 MAb are represented as grey shaded area and isotype control 
antibody staining is represented by the black line. Figure 4.3B illustrates the fluorescence intensity 
plots for binding of 1µg/ml peptide #9 or #11 (grey shaded area), the negative control peptide #41 
(black line) to SMS-SB cells following 24 h treatment with 250ng/ml SDF-1 or no treatment. Figure 
4.3C represents CXCR4 staining in untreated SMS-SB cells or cells treated for 24 h with sCD23 
(160ng/ml), LP (1µg/ml) or the negative control peptide #8 (1µg/ml). CXCR4 was stained using 
biotinylated-12G5 antibody and detected using streptavidin-PE (grey shaded area); the isotype 
control IgG2a–biotin is shown as a black line.  
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4.2.3 The effect of SDF-1 on αVβ5-driven proliferation is specific 
to early B cell precursors 
We assessed CXCR4 expression in different precursor B cell lines and observed 
that CXCR4 expression varied in the precursor cell lines at different stages of B 
cell development. The cell lines representing earlier stages of B cell 
development had lower levels of CXCR4; CXCR4 expression increased in pre-B 
cell lines such as Blin1 and mature B cell lines like Daudi, and declined again in 
the more mature B cell lines such as IB4. CXCR4 expression in comparision to 
αVβ5 expression in the different cell lines is represented in Figure 4.4A and 
4.4B. In particular, the pre-B cell lines (SMS-SB, RS4;11) which proliferated well  
in response to αVβ5 ligation had lower levels of CXCR4 and the expression of 
CXCR4 increased  in  the cell lines that were less responsive to αVβ5. Moreover, 
the enhancement of αVβ5-mediated cell proliferation by SDF-1 was only seen in 
pre-B cell lines, such as SMS-SB and RS4;11, with low CXCR4 expression (Figure 
4.4C).  Proliferation was not assessed with SDF-1 for the 697 cell line, but CXCR4 
staining in this cell line was also low, similar to SMS-SB or RS4;11, and we would 
predict that their proliferative response would be similar to SMS-SB or RS4;11 
cells. A representative result from the cell line RS4;11 is shown in figure 4.4C. 
SDF-1 enhances the proliferation induced by LP in a manner similar to that noted 
in SMS-SB cells. By comparison, SDF-1 had no effect on the cell line Daudi which 
shows little or no proliferative response to αVβ5 ligation and had higher 
expression of CXCR4 (Figure 4.4A and C). Furthermore, SDF-1 had no effect on 
the very modest response to αVβ5 ligation noted in the Blin1 cell line (Figure 
4.4C).  
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Figure  4.4 CXCR4 expression and cell proliferation in different precursor and mature B cell 
lines. 
 
Panels (A) and (B) show the fluorescence intensity histograms for staining of CXCR4 (12G5) and 
αVβ5 (P1F6) respectively, in five cell lines. In both cases antibody staining is shown in the grey 
shaded area and the isotype control staining by the black line. The cell lines are represented as 
early or late pre-B and transitional or mature B, cell stage depending on surface marker expression 
as described in chapter 3. (C) In the different cell lines shown, proliferation driven by αVβ5 ligation 
(either with 2ng/ml sCD23 or with 1µg/ml LP) and SDF-1 is shown by black bars and proliferation 
induced with SDF-1 alone is shown as hatched bars. Bars represent the standard deviation of 
triplicate determinations, with *p<0.05 indicating increase in proliferation in cells treated with 
different concentration of SDF-1  and αVβ5 stimulants (sCD23, 15F11MAb, peptide #9 or LP) in 
comparison to SDF-1 treatment alone,  and #p<0.05 indicating enhancement in proliferation with 
250ng/ml SDF-1 and αVβ5 stimulants when compared with αVβ5 stimulants alone. Data are 
representative of three independent experiments. 
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4.2.4 Other cytokines do not mimic SDF-1 but PDGF may have a 
similar role to  SDF-1 in modulating αVβ5 function  
Many other cytokines are known to be important during B-cell development, and 
we therefore examined the effects of the cytokines IL-7, IL-11, IL-3 and IL-4 to 
determine if they mimicked the effects of SDF-1 on αVβ5-induced cell 
proliferation. None of the above-mentioned cytokines showed similar effects to 
SDF-1. IL-7 showed varied effects on cell proliferation induced via αVβ5 but 
there were no consistent data to show that it enhanced αVβ5-induced cell 
proliferation (Figure 4.5A). IL-11 itself induced an increase in cell proliferation 
(Figure 4.5B) but had no effect on αVβ5-induced cell proliferation and neither 
IL-3 nor IL-4 enhanced αVβ5-induced proliferation (Figure 4.5C and 4.5D).  
αVβ5 expression was also analysed in presence of the above-mentioned 
cytokines. The cytokines were used at the same concentrations as SDF-1 (5nM) 
and αVβ5 expression was again analysed using P1F6 and 15F11 antibody. IL-7 did 
not influence the levels of αVβ5 expression as depicted in Figure 4.6A nor did IL-
11 (Figure 4.6B). With IL-3 treatment although the biotinylated isotype control 
staining was lower than the untreated cell, P1F6 staining was of the same 
intensity as the untreated cells. There was no change in αVβ5 staining in 
untreated cells and IL-3-treated cells with 15F11 antibody, whereas IL-4 
treatment resulted in decreased αVβ5 expression as shown by P1F6 staining 
(Figure 4.6B). But, when these experiments were repeated IL-4 seemed to 
increase αVβ5 expression on one instance and no change was seen in another 
instance, therefore no conclusion could be made from these data. It could be 
that IL-4 influences αVβ5 expression depending upon the stage the cells are in 
culture, and therefore we observed different results in different experiments. 
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However, we noted that the platelet-derived growth factor (PDGFβ) was, like 
SDF-1, able to enhance SMS-SB cell proliferation driven by αVβ5. PDGF has been 
studied in connection with the SMS-SB cells previously and this cell line is known 
to express the PDGF receptor β (PDGFRβ) 294.  Figure 4.7A and 4.7B show that 
PDGFβ significantly enhanced both LP and sCD23-induced proliferation in SMS-SB 
to a very similar extent as SDF-1. Similar to SDF-1, PDGF treatment did not 
result in any changes in αVβ5 expression (Figure 4.7C). 
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Figure  4.5 αVβ5-mediated cell proliferation in the presence of other cytokines. 
 
Figures 4.4 (A), (B), (C) and (D) represent proliferation of LCD cultures of SMS-SB cells in 
response to 1µg/ml LP or 5µg/ml peptide #9, together with the indicated concentrations of IL-7, IL-
11, IL-3 and IL-4, respectively. In each case, proliferation induced by the peptides and the cytokine 
is shown in black bars, cytokine alone is shown as hatched bars and cytokine with negative control 
peptide # 41or #8 is shown as white bars. The concentrations of each cytokine are equivalent 
molar concentrations. Data are representative of three independent experiments. 
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Figure  4.6 αVβ5 expression in presence of the cytokines IL-7, IL-3, IL-11 and IL-4. 
 
SMS-SB cells were treated with 5nM of the indicated cytokines or left untreated and αVβ5 
expression was analysed by FACS using P1F6 or 15F11 antibody. (A) Represents histograms for 
staining of αVβ5 in untreated cells or cells treated with IL-7 and IL-3. (B) Represents αVβ5 
expression in cells treated with IL-11 and IL-4 or untreated cells. In all cases the staining with 
relevant αVβ5 MAbs is represented as grey shaded area and staining with isotype control antibody 
is represented as a black line. 
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Figure  4.7 αVβ5-mediated cell proliferation in the presence of PDGFβ. 
 
LCD SMS-SB cultures were stimulated with the indicated concentrations of PDGFβ and 1µg/ml LP 
(Figure 4.7A) or 160ng/ml sCD23 (Figure 4.7B) for 72 h prior to addition of [3H]-TdR and 
determination of proliferation. Proliferation induced by PDGF and LP or sCD23 in combination with 
PDGF is shown as black bars and proliferation driven by PDGF alone is shown as hatched bars. 
Bars represent the standard deviation of triplicate determinations, with *p<0.05 or **p<0.005 
indicating increase in proliferation in cells treated different concentrations of PDGF and αVβ5 
stimulants (sCD23, LP) in comparison to PDGF treatment alone, and #p<0.05 and ##p<0.005 
indicating enhancement in proliferation with 250ng/ml PDGF and αVβ5 stimulants when compared 
with αVβ5 stimulants alone. (C) SMS-SB cells, untreated or treated with 250ng/ml PDGF (24 h), 
were stained for αVβ5 expression using the anti-αVβ5 MAbs P1F6 and 15F11. Fluorescence 
intensity histograms for the relevant αVβ5 MAbs represented by the grey shaded area and isotype 
control antibody staining is represented by the black line. Data are representative of three 
independent experiments. 
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4.2.5 SDF-1 enhances ERK phosphorylation induced via sCD23 
and other αVβ5 ligands and PDGF shows a similar effect. 
We next examined the signalling pathways that might be involved in synergistic 
activation of cell proliferation by αVβ5 ligation and SDF-1 treatment, paying 
particular attention to ERK phosphorylation since SDF-1 is known to target this 
pathway 121.  
Treatment of SMS-SB cells with sCD23 promoted an early (0-2 min) and transient 
rise in phospho-ERK levels that was followed by a later (30-60 min) more 
sustained and robust level of ERK phosphorylation (Figure 4.8A). SDF-1 alone 
provoked an early, modest increase in phospho-ERK levels with no evidence of a 
later, stronger increase in phosphorylation of ERK (Figure 4.7A). By contrast, 
combined treatment of SMS-SB cells with SDF-1 and sCD23 stimulated a very 
robust initial phase of ERK phosphorylation that was sustained until 10 minutes 
post-stimulation, yielding phospho-ERK levels that were some 15-fold greater 
than either stimulus alone (Figure 4.8B). The 15F11 MAb induced a modest initial 
level of phospho-ERK, followed by a more pronounced second phase and in this 
case co-stimulation with SDF-1 promoted a more sustained wave of ERK 
phosphorylation over the first 30 minutes of the experiment (Figure 4.8C).   
The RKC-containing CD23-derived peptide #9 behaved similarly, inducing a 
biphasic response by itself and a more robust and sustained response when 
added together with SDF-1; peptide #8, which lacks the RKC motif, failed to 
induce robust phosphorylation either alone or in association with SDF-1 (Figure 
4.8D). Finally, the RKC-containing pentadecameric LP induced sustained and 
robust ERK phosphorylation that was enhanced in magnitude and persistence by 
SDF-1 co-stimulation (Figure 4.8E). LP has an affinity for αVβ5 that is an order of 
magnitude greater than that of CD23 itself (~ 10-7 M vs 6 x 10-6 M) and this 
greater affinity may explain the higher and more sustained levels of ERK 
phosphorylation noted with LP.   
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The data are consistent with the interpretation that ligation of αVβ5 by a soluble 
ligand alone promotes a biphasic pattern of ERK phosphorylation, with a modest 
initial peak of phosphorylation followed by a later phase of higher and more 
sustained phosphorylation. The data also indicate that SDF-1 enhances the initial 
αVβ5-driven early activation of ERK phosphorylation and maintains this at a 
robust level for a sustained period, the length of which may reflect the affinity 
of the ligand used to challenge the αVβ5 integrin. A similar pattern of 
enhancement of ERK phosphorylation was observed with PDGF treatment. 
Treatment of SMS-SB cells with 250ng/ml of PDGF resulted in significant ERK 
phosphorylation (2-10 min) (Figure 4.9A). However this phosphorylation was 
significantly enhanced when PDGF was used together with 160ng/ml sCD23 
(Figure 4.9B) with a sustained increase in ERK phosphorylation from 0-30 min. 
This enhancement in ERK phosphorylation correlates well with the enhancement 
in cell proliferation observed with PDGF and sCD23 treatment of SMS-SB cells. 
The MEK inhibitor U0126 was used to confirm the role of ERK phosphorylation in 
SMS-SB cell proliferation. Treatment of SMS-SB cells with U0126 (5µM or 10µM) 
prior to the initiation of the proliferation assay completely abolished any effect 
of sCD23 or its peptides on cell proliferation (Figure 4.10A). Moreover, U0126 
abolished the basal survival of SMS-SB cells in low-density cultures after few 
hours of initiation of the culture. U0126 treatment abrogated the ERK 
phosphorylation driven by SDF-1 or sCD23 individually and also completely 
prevented the enhancement of ERK phosphorylation seen with SDF-1 and sCD23 
(Figure 4.10C).  
The PI3K inhibitor LY294002 was employed to confirm that the inhibition of 
proliferation and survival was specific to U0126. LY294002 also inhibited the 
proliferation of SMS-SB cells in response to αVβ5 ligation, but the inhibition was 
less complete than that observed with U0126 (Figure 4.10B). Indeed, after 48 
hours of treatment a small increase in cell proliferation was still evident in 
response to LP treatment in cells pre-treated with LY294002 (Figure 4.10B), 
whereas proliferation was absent by 12 h following U0126 treatment. Also, 
unlike U0126, LY294002 treatment does not inhibit the basal survival of SMS-SB 
cells. We confirmed this difference by measuring survival of SMS-SB cells after  
Mridu Acharya,2008   Chapter 4, 117 
 
U0126 and LY294002 treatment. Analysis of SMS-SB cell survival using annexinV/ 
propidium iodide (AV/PI) staining demonstrated that U0126 treatment results in 
a higher proportion of AV/PI double-positive cells than LY294002 after a 12 h 
treatment (Figure 4.10D), illustrating that U0126 leads to increased apoptosis in 
comparison to LY294002 treatment. This indicates that the ERK phosphorylation 
pathway is important for SMS-SB survival and cell proliferation. 
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Figure  4.8 ERK phosphorylation in SMS-SB cells treated with SDF-1 alone or in combination with αVβ5 ligands. 
Lysates from treated SMS-SB cells were separated by SDS-PAGE and transferred to nitrocellulose. Membranes were probed with antibodies to phosphorylated ERK and 
subsequently stripped and reprobed with antibodies to total protein (either ERK or actin). (A) Western blots of phosphorylated and total ERK in untreated SMS-SB cells and 
cells treated with sCD23 (160ng/ml), SDF-1 (250ng/ml) or a combination of sCD23 and SDF-1, at the time points shown. The increase in phosphorylation was quantitated by 
densitometric analysis of the bands (B). Figure (C) represents western blots for phosphorylation of ERK and of total actin in SMS-SB cells treated with 15F11 MAb alone or in 
combination with SDF-1. (D) and (E) Western blots for phosphorylated and total ERK in SMS-SB cells treated with peptide #9 (5µg/ml), negative control peptide #8 (5µg/ml) or 
LP (1µg/ml) alone or in combination with SDF-1 (250ng/ml).  Data are representative of three independent experiments. 
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Figure  4.9 ERK phosphorylation in SMS-SB cells treated with PDGF alone or in combination 
with αVβ5 ligands. 
 
Lysates from treated SMS-SB cells were separated by SDS-PAGE and transferred to nitrocellulose. 
Membranes were probed with antibodies to phosphorylated ERK and subsequently stripped and reprobed with 
antibodies to total protein (either ERK or actin). (A) Western blots for phosphorylated ERK or actin in SMS-SB 
cells treated  with PDGF (250ng/ml). (B) Western blots for phosphorylated ERK and actin in SMS-SB cells 
PDGF (250ng/ml) with sCD23 (160ng/ml). Data represent three  independent experiments. 
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Figure  4.10 Effect of inhibition of ERK and PI-3K signalling on αVβ5-mediated proliferation 
of SMS-SB cells. 
 
SMS-SB cells were treated with 10µM U0126 or 50µM LY294002 or left untreated for 30 min prior 
to plating at LCD; proliferation was assessed by 3[H]-TdR incorporation after 72 h of culture. Panel 
A shows cell proliferation with LP (1µg/ml) and/or SDF-1 (250ng/ml) in untreated cells and cells 
treated with U0126. Panel B shows cell proliferation with long peptide and/or SDF-1 in untreated or 
cells treated with LY294002. In both cases, unstimulated cells are represented as grey bars, LP-
treated as black bars, the LP and SDF-1 combination as white bars and SDF-1 alone as hatched 
bars. Bars represent the standard deviation of triplicate determinations, with *p<0.05 or **p<0.005 
indicating increase in proliferation in cells treated with different concentrations of SDF-1 and αVβ5 
stimulant (LP) in comparison to SDF-1 treatment alone, and #p<0.05 and ##p<0.005 indicating 
enhancement in proliferation with 250ng/ml SDF-1 and αVβ5 stimulants when compared with αVβ5 
stimulants alone. Data are representative of three independent experiments. Panel C Western blot 
analysis of phosphorylated ERK and total actin in SMS-SB cells pre-treated with U0126 (10µM) 30 
min before stimulation with SDF-1 (250ng/ml) or sCD23 (160ng/ml) or a combination of SDF-1 and 
sCD23. Panel D shows contour plots for PI/annexinV staining of cells exposed to U0126 (10µM), 
LY294002 (50µM), DMSO (vehicle) or no treatment for 12 h. Quadrant gates in the insets are  
based on unstained, annexinV or PI stains alone. Data are representative of 3 independent 
experiments. 
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4.3 Discussion 
It is well established that chemokines dynamically regulate the positioning of 
cells of the immune system by influencing the structure of integrin molecules to 
ensure cells attracted to a specific niche are retained there via adhesion 
reactions with tissue matrix proteins.  Chemokines can also positively influence 
signalling via integrins in such adhesion-dependent interactions, as exemplified 
by the action of SDF-1 on haematopoietic precursors at the level of the VLA-4- 
ICAM-1 interaction 114,295. The results presented in this chapter demonstrate that 
SDF-1 positively influences signalling events delivered to integrins in a soluble, 
adhesion-independent manner. Thus, ligation of αVβ5 using specific MAbs, sCD23 
or RKC-containing peptides derived from sCD23 all provoke ERK phosphorylation 
and proliferation responses in B cell precursors that are enhanced by SDF-1. 
Remarkably, PDGF also enhances signalling delivered via soluble ligation of 
αVβ5, suggesting that both tyrosine kinase and G protein-coupled receptor-
linked pathways may modulate adhesion-independent signalling by αVβ5. 
Soluble CD23-mediated proliferation of SMS-SB cells was enhanced by addition of 
SDF-1 and identical effects were seen with sCD23-derived peptides (containing 
the RKC motif bound by αVβ5) and the anti-αVβ5 MAb 15F11, all of which 
promote proliferation of these cells. Blocking the binding of SDF-1 to CXCR4 
using the previously described SDF-1 antagonist AMD3100 296,297 abolished this 
enhancement. However SDF-1 did not influence proliferation induced by the MAb 
AMF7 which binds to αV subunit and sustains proliferation of SMS-SB cells. In 
relation to this as mentioned in chapter 3 we did not observe any proliferative 
response with this antibody in RS4;11 cell line which showed similar proliferation 
to SMS-SB cells in response to αVβ5 ligation. Moreover, the response to AMF7 
might also be dependent on other αV integrins expressed.   
Interestingly, SDF-1-mediated enhancement of cell proliferation was seen only in 
the cell lines SMS-SB and RS4;11, both of which represent the early precursor 
stage of B-cell development (CD19+, CD10- and surface µ low or negative). It is in  
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these early precursors that the most robust proliferative response to ligation of 
αVβ5 with sCD23, or CD23-derived peptides, was observed (Chapter 3). Blin1 
cells, which showed a slight but comparatively modest proliferative response 
following sCD23 treatment, did not show any enhancement of proliferation with 
SDF-1. Higher CXCR4 expression did not influence the lack of response to αVβ5 
ligation noted in the more mature cell lines. SDF-1-mediated modulation of αVβ5 
function seems to be important in early B-cell precursors, which express lower 
levels of CXCR4. This is consistent with data showing that although B-cell 
precursors express higher levels of CXCR4 with increasing maturation, the cells 
chemotactic response to SDF-1 itself is apparently blunted 298.  
CXCR4 is continuously expressed on the surface of B-cells. It has been shown 
that when B lymphocytes mature and start to express IgM at the cell surface 
they lose their chemotactic response to SDF-1 despite sustained expression of 
CXCR4 298-300.  Glodek et. al., showed that SDF-1 triggers a sustained adhesion 
response specifically in progenitor (pro and pre-B) cells that diminishes during 
maturation in the bone marrow; circulating mature B cells exhibit only transient 
SDF-1-induced adhesion 301. Furthermore, recent studies have linked the 
expression of CXCR4 with the potentiation of plasma cell long-term survival in 
the bone marrow 302-304. This developmental stage-specific function of SDF-1 is 
interesting in relation to the data showing that αVβ5 function and expression is 
important in early B cell precursors and decreases as the cell mature (Borland, 
et. al., 2008 manuscript submitted) This supports a developmental stage-
specific role for adhesion molecules and growth factors in B lymphopoiesis.  
SDF-1 modulation of αVβ5 integrin function does not involve changes in receptor 
expression. SDF-1 treatment did not change αVβ5 expression (Figure 4.3A) and 
αVβ5 ligation does not change CXCR4 expression (Figure 4.3C). Although the 
15F11 and P1F6 MAbs recognise different epitopes on αVβ5 282, it is not known 
what conformational states of the integrin are recognised and so no conclusions 
can be drawn concerning the effects of SDF-1 on the conformational state of 
αVβ5. Furthermore, treatment of SMS-SB cells did not influence the CD23-
derived peptides binding to SMS-SB cells (Figure 4.3B) indicating that SDF-1 does 
not alter binding of these peptides to αVβ5. 
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SMS-SB cells undergo apoptosis in LCD culture conditions 276, therefore we used 
these culture conditions to study their survival and subsequent proliferation. The 
inhibition of cell proliferation by U0126 demonstrated that basal ERK 
phosphorylation is necessary for the survival of SMS-SB cells; in the presence of 
U0126 the cells rapidly undergo apoptosis. The ERK phosphorylation observed 
following sCD23, RKC-containing peptides and 15F11 treatment demonstrated 
that the proliferation induced by ligation of αVβ5 with sCD23 is induced via the 
ERK signalling pathway. The enhancement in proliferation noted with SDF-1 and 
sCD23 correlated well with the sustained increase in ERK phosphorylation with 
SDF-1 and sCD23. This was verified by similar enhancement seen with the CD23-
derived peptides and 15F11 antibody. Moreover, PDGF showed the same effect 
as SDF-1 in enhancement of sCD23-driven ERK phosphorylation. As in the case of 
SDF-1, this enhancement of ERK phosphorylation correlated well with the 
potentiation of cell proliferation seen with PDGF and sCD23 co-stimulation 
(Figure 4.7A and B). Other signalling molecules could also be involved in 
regulating SMS-SB cell proliferation and the observation that LY294002 inhibited 
the enhancement of αVβ5-mediated proliferation by SDF-1 indicates that AKT 
could be involved in regulation of adhesion-independent signalling by integrins. 
This would be consistent with other studies that have reported that SDF-1 
activates both ERK and AKT 123,124,305,306.  
Many other cytokines are known to modulate integrin function and B-cell 
precursor survival. We noted no similar enhancement in αVβ5-mediated 
proliferation by the cytokines IL-7, IL-3, IL-4 and IL-11. Therefore, we did not 
assess ERK signalling pathway activation following treatment with these 
cytokines.  However, it is possible that some combination of these cytokines, 
with or without SDF-1, might influence αVβ5-mediated proliferation. For 
example, recent work by Juarez, et al., shows that interaction of SDF-1, IL-3 
and IL-7 induce proliferation of ALL cells co-cultured with stromal cells. This 
study shows that IL-7 alone does not induce ERK activation but there is 
synergistic ERK activation following IL-7 and SDF-1 co-stimulation 306. However, 
the ALL cells were propagated on stromal cells and the effects on ERK and other 
signalling pathways would have been affected by multiple adhesion contacts 
between the ALL cells and stromal cells. Therefore, the Juarez data illustrate  
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convincingly that ERK phosphorylation can occur in an adhesion-dependent 
manner, while our data demonstrate the synergistic activation of ERK signalling 
can also occur when αVβ5 is stimulated using soluble ligands in an adhesion-
independent assay.  
With regard to the influence of other cytokines it was particularly interesting to 
observe that IL-3 and IL-4 potentially could influence αVβ5 expression although 
these cytokines did not influence αVβ5-mediated proliferation. IL-4 has 
previously been shown to inhibit pre-B cell proliferation 307 and to induce 
differentiation of murine precursor B cells 308 and therefore it would be 
interesting to assess further the role of IL-4 on  αVβ5 expression. Although these 
cytokines tested differ from SDF-1 which is a chemokine, because of the well 
established role of these cytokines in precursor B cell growth and development 
we assessed their role in the same manner as SDF-1 instead of investigating 
other chemokines.  
Finally, PDGF enhanced the proliferation induced via αVβ5 in a manner similar to 
that observed with SDF-1. Interestingly, a previous study showed that early pre-B 
cells, but not mature B cells, express the PDGFRβ 309. PDGF was shown to 
promote proliferation of these cells and not of more mature or even immature 
pre-B cells 309. PDGF has previously been shown to interact with the integrin 
αVβ3 and to stimulate proliferation of oligodendrocytes by activation of this 
integrin in adhesion-dependent manner 310. Therefore it is plausible that PDGF 
and αVβ5 also interact and are involved in mediating adhesion-independent 
proliferation. Further studies would be needed to investigate interaction of 
PDGF and αVβ5 integrin. Moreover, further experiments are also required to 
assess αVβ5-mediated proliferation after blocking the PDGF receptor in order to 
confirm the role of PDGF in enhancing αVβ5-mediated proliferation. 
The data indicate that αVβ5 synergises with two distinct signalling pathways, via 
a tyrosine kinase receptor (PDGFR-β) and G protein-coupled receptor (CXCR4), 
to promote ERK phosphorylation and pre-B cell growth. It will be important to 
determine the common molecules downstream of both these pathways leading 
to ERK phosphorylation to understand further the mechanisms involved in αVβ5-
mediated cell proliferation. Both PDGFR-β and CXCR4, as well as the ERK 
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signalling pathway are targets for drug therapies, and the interaction of these 
receptors with the αVβ5 integrin need to be explored in order to evaluate 
whether they have potential as a new therapeutic strategy for ALL since αVβ5 
was shown to be highly expressed in ALL cells (Borland, et. al., 2008 manuscript 
submitted). 
B cell development in different compartments of the haematopoietic 
microenvironment is accompanied by various stage-specific changes that are 
critical for proliferation, differentiation and maturation of the cells into later 
developmental stages.  A range of adhesion and signalling molecules controlling 
each stage are not only key to understanding the progression into the 
developmental pathway but also in developing therapies for neoplasias that arise 
in different stages of B-cell development.  
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5 CD23-αVβ5 Interactions in Murine B Cells 
5.1 Introduction 
Cytokine-like activity is known to be unique to human CD23 231. The RKC motif 
on human CD23 that is bound by the integrin αVβ5 is QKC (gln-lys-cys) in the 
murine CD23 sequence. This suggested the hypothesis that the arginine 172 
(R172) on the RKC motif is critical for the cytokine-like activity of human CD23. 
We investigated the importance of the RKC motif for CD23 and integrin 
interaction by assessing the activity of human sCD23 and CD23-derived peptides 
on murine B-cell precursors. 
5.2 Results 
5.2.1 Human sCD23-derived peptides bind to murine B cells  
Figure 5.1 shows that the human CD23-derived, biotinylated peptides (#9-12), all 
containing the RKC motif, bind significantly to murine bone marrow B cells when 
compared with the negative control peptide #17 that lacks the RKC motif. The B 
cell population in the bone marrow was identified using the B220 antibody and 
similar binding to peptide #9 is seen in B220+ B cells from murine spleen. In both 
the bone marrow and spleen there are B220- populations that also bind the 
peptides (Figure 5.1), indicating other cell types apart from  B cells also bind the 
peptides. In the B220+ compartment from the bone marrow, the majority of the 
cells bind to the peptides, but there is a small percentage of cells in the bone 
marrow that are B220+ but do not bind the peptides (especially in the cases of 
peptide #10 and #11). As the bone marrow cells comprise a heterogenous 
population of cells at different stages in development, this could indicate a 
difference in αVβ5 expression in cells of different stages. Binding of the CD23-
derived peptides was also shown in a murine pro-B cell line, BAF03. As shown in 
figure 5.2A the CD23-derived peptides (#9-#12) bind significantly to BAF03 cells 
(shown in grey) in comparison the negative control peptide #58 (shown as a 
black line). BAF03 cells displayed a characteristic feature of two populations, 
one with strong peptide staining and the other negative for peptide binding. This  
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feature has also been observed in some human cell lines previously and could 
reflect the cell cycle status of the cells. We also assessed the binding of 
biotinylated sCD23 to the BAF03 cells. Figure 5.2B illustrates the binding of 
sCD23  to BAF03 cells in comparison to binding of the peptides. At 1µg/ml sCD23 
showed significant binding to the BAF03 cells, although the binding was less than 
that observed for the peptides. Furthermore, no binding of sCD23 was observed 
at 250ng/ml, which was the concentration of sCD23 used for functional 
experiments in human cell lines. Therefore, the higher concentration  of sCD23 
was used for functional studies in the BAF03 cell line.  
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Figure  5.1 Binding of CD23-derived peptides to murine bone marrow and splenic B cells. 
 
Primary murine bone marrow cells and spleen cells were stained simultaneously with B220-PE 
antibody and biotinylated peptides {visualised with Streptavidin-QR (SA-QR)}. Peptide #17 lacking 
the RKC motif was used as a negative control peptide and quadrant gates on the insets are based 
on the unstained sample and staining for the negative control peptide.The upper right quadrant 
represents B220+ cells that bind the peptides. Data represent three independent staining 
procedures. 
 
 
 
 
 
 
Bone Marrow
Spleen
Mridu Acharya,2008   Chapter 5, 129 
 
 
 
 
 
A 
Peptide 9 Peptide 11 sCD23
 
B 
 
Figure  5.2 Binding of CD23-derived peptides and sCD23 to BAF03 murine pro-B cell line. 
 
 (A) Fluorescence intensity histograms for binding of biotinylated peptides #9-#12 to BAF03 cells 
was detected using SA-QR.  The top row in panel A represents antibody staining for BAF03 cells 
with CD19 and B220 antibodies as B cell specific markers and Thy 1.2 as T- cell marker. Binding of 
peptides with the RKC motif is shown as grey shaded area and binding of the negative control 
peptide #58 is shown as black line. (B) Binding of sCD23 (1µg/ml) in comparison to binding of 
peptide #9 and #11 (1µg/ml) to BAF03 cells. Peptide binding was detected using streptavidin-PE. 
In each case binding of the peptides or sCD23 in grey shaded area is compared with binding to the 
negative control peptide shown as black line. 
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5.2.2  Arginine 172 (R172) influences, but is not mandatory for, 
peptide binding 
In order to assess further the importance of the RKC motif on human CD23, the 
effect upon binding of various substitutions in the RKC motif of peptide #9, #11 
or #12 was assessed. As shown by the mean fluorescence index (MFI) for binding, 
peptides with scrambled sequences (9SCR, 11SCR) and peptides without the 
arginine in the RKC motif (peptides with 9R-Q, 11R-Q and 11R-K mutations) all 
bind to BAF03 cells, indicating that the arginine 172 itself is not critical for 
binding (Figure 5.3A). However, binding of these peptides is significantly 
reduced when compared to the MFI for binding of wild type peptides #9-#12. 
Peptides #9 and #12 with replacements (R-A, RK-AA, K-A and C-S) were also 
assessed for binding to BAF03 cells. The peptides with R-A, RK-AA and K-A 
mutations bind to the cells but peptides with RK-AA and C-S mutations showed 
significantly reduced binding (Figure 5.3B).   
Peptide 9R-Q, representing the sequence at the αVβ5 binding motif in murine 
CD23 also binds to the cells, but the binding is lower compared to peptide #9 
(Figure 5.3A). Peptide 11R-Q representing the same substitution shows a greater 
reduction in binding when compared to wild type peptide #11. These peptides 
have different affinities of binding to the integrin αVβ5 (A. Edkins, personal 
communication) and 232 and therefore the replacements might affect the binding 
of each peptide in a different manner. Furthermore, the peptide 9C-S 
substitution almost completely inhibits the binding ability of both  peptide #9 or 
#12 (Figure 5.3B) suggesting that perhaps the peptides work best as disulphide-
bonded dimers. Previous SPR analysis have also demonstrated that peptide 9C-S 
does not bind to the to αVβ5 integrin (A. Edkins, personal communication) 
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Figure  5.3 Importance of the RKC motif in CD23-derived peptides for binding to BAF03 cells. 
 
Mean fluorescence Index (MFI) data derived from FACS analysis for  binding of the peptides #9-
#12 to BAF03 cells was compared with the MFI for binding of peptides with different substitutions in 
the RKC motif. Peptide #58 was used as a negative control peptide to assess binding. (A) A 
comparison of binding of wild type peptides #9-#12 and peptides with the original sequences 
scrambled as well as peptides with R-Q and R-K substitution. (B) Depicts comparison of peptide #9 
or #12 wild-type with peptides with indicated substitutions in the RKC motif. Data are representative 
of 3 independent experiments. 
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5.2.3 BAF03 cells express the integrin αVβ5 but not αVβ3 
Well-characterised antibodies for the murine αVβ5 heterodimer are not 
commercially available, therefore we used a rabbit anti-human β5 antibody to 
confirm the expression of this subunit on BAF03 cells. Surface expression of the 
β5 subunit was confirmed by cell surface biotinylation of BAF03 membrane 
proteins followed by western blot using the anti-human β5 antibody (Figure 
5.4B). The murine β5 subunit is known to be of approximately 95 kDa and 
western blot with the human anti-β5 resulted in a product of slightly less than 97 
kDa. Since the β5 subunit cannot reach cell surface membrane without pairing 
with the αV subunit 311 expression of the β5 subunit was used as an indication of 
expression of the αVβ5 heterodimer. Expression of the β3 subunit was 
determined by FACS analysis using a commercially available anti-mouse β3 
antibody. As shown in figure 5.4A there was no staining for the β3 antibody when 
compared to the isotype control antibody in BAF03 cells. 
 
 
β3
β5
97 kDa
Marker
Subunit 
 
Figure  5.4 Expression of the β3 and β5 integrin subunits in murine pro-B cell line BAF03. 
 
 (A) FACS staining for the murine anti-β3 antibody is shown as grey shaded area and the isotype 
control antibody staining is shown as black line. (B) Lysates from surface biotinylated BAF03 cells 
were incubated with streptavidin-agarose beads and separated by SDS-PAGE, transferred to 
nitrocellulose membrane and probed with either anti- β5 or β3 antibodies. A band of less than 97 
kDa was detected in western blot using anti- β5 antibody and no band was detected with the anti-
β3 antibody (data not shown). 
 
 
  
A B 
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5.2.4 BAF03 cells proliferate in response to human sCD23-derived 
peptides or sCD23 
 Data from the human cell line work (Chapters 3 & 4) indicated that the αVβ5-
CD23 interaction sustains proliferation of some of the cell lines expressing the 
αVβ5 integrin. We also assessed proliferation of the murine BAF03 cell line in 
response to sCD23 or peptide treatment 
BAF03 cells are IL-3-dependent for survival 273 and the cells did not survive in 
culture without IL-3 in the presence of the CD23-derived peptides alone. In the  
presence of IL-3 alone, the BAF03 cells proliferated effectively in a dose-
dependent manner without any addition of serum (Figure 5.5A). However, when 
the peptides were used with a sub-optimal concentration of IL-3 (1ng/ml), cell 
proliferation was greatly enhanced in the presence of 10 or 5µg/ml peptides 
(Figure 5.5A and 5.5 B). Figure 5.5B depicts the proliferative response of BAF03 
cells in response to the human sCD23-derived peptides #9, #12 and long peptide 
(LP). In the human cell line system, peptide #9 and LP induced the best 
proliferative response, and the proliferation response of the BAF03 cell line is 
similar to this. The negative control peptide #8 showed no effect in cell 
proliferation either alone or in combination with sub-optimal IL-3. At 1ng/ml IL-
3 there is a very slight proliferative response in comparison to untreated cells 
and this response is significantly enhanced in the presence of the peptides. 
Stimulation of BAF03 cells with 1ng/ml IL-3 supplemented with 5µg/ml or 
10µg/ml peptide #9 induced a sustained increase in proliferation compared to 
cells exposed to 1ng/ml IL-3 only (SI of 4 and 2 respectively for peptide #9 
induced cell proliferation).  
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Figure 5.6A illustrates that proliferation of BAF03 cells induced by peptide #9 is 
reduced when the RKC motif is replaced by QKC in the 9R-Q peptide. This is 
important because the 9R-Q peptide represents the QKC motif present in murine 
CD23.  The decrease in proliferation is obvious at 10µg/ml but less so at 5µg/ml 
of peptide. At 5µg/ml peptide #9R-Q also has some significant effect on cell 
proliferation but nevertheless it is slightly less than peptide #9 (P<0.05).  Figure 
5.3B demonstrated that the C-S substitution in the RKC completely inhibited 
binding of peptide #9 or #12 to BAF03 cells. This inhibition of binding correlates 
well with the inability of the peptide 9C-S to induce proliferation compared to 
peptide 9 as illustrated in figure 5.6B. This indicates that the cysteine residue in 
the RKC motif influences the binding and activity of these peptides. The 
peptides would be expected to form intermolecular disulphide bonds and the 
fact that the substitution of cysteine with serine inhibits the proliferative 
capapcity of peptide #9 is consistent with the interpretation that the formation 
of disulphide bonded peptide dimers is necessary for biological activity. The 
existence of the peptide as disulphide bonded dimers was also tested by   
Ellman’s test for free sulphydryl groups, (A . Edkins, personal communication). 
This notion was further tested by using 2-Mercaptoethanol (2-ME) to reduce the 
inter-peptide disulphide bonds as BAF03 cells grow in culture with 2-ME and it 
does not interfere with their growth capacity. Reduction with 12mM 2-ME greatly 
reduced peptide #9 bioactivity but 6mM 2-ME did not. The data strengthen the 
idea that the disulphide bonded peptide dimers may be the optimally active 
form.  
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Figure  5.5 Proliferation of BAF03 cells in response to CD23-derived peptides. 
 
(A) Cultures of BAF03 cells (5000 cells/well) were propagated with the indicated concentration of 
peptides #9 and IL-3 alone or in combination with 1ng/ml IL-3. Proliferation with peptide #9 alone is 
shown as grey bars, peptide #9 with 1ng/ml IL3 as black bars, peptide #33 with 1ng/ml IL3 as 
hatched bars and proliferation with different concentrations of IL3 alone is shown as white bars. 
Proliferation was assessed after 72 h by 3[H]-TdR incorporation (B) Proliferation of BAF03 cells in 
response to indicated concentrations of  peptide #9 #12, LP or peptide #8 with sub-optimal 
concentrations of IL-3 (1ng/ml). 1ng/ml IL3 was used together with the different peptides and 
proliferation with peptide  #9  is shown as black bars, peptide #12 as grey bars, LP as hatched bars 
and peptide #8 as white bars. Bars represent the standard deviation of triplicate determinations, 
with  **p<0.005 indicating increase in proliferation in comparison to the negative control peptide at 
the same concentration or in comparison to untreated cells (in case of IL-3 treatment alone). Data 
are representative of at least three independent experiments. 
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Figure  5.6 Importance of the RKC motif on peptide #9 in mediating proliferation of BAF03 
cell line. 
 
Peptide #9 and 9R-Q and 9C-S were used to assess the difference in proliferation resulting from 
these replacements. (A) BAF03 cell proliferation in response to the indicated concentrations of 
peptide #9, 9R-Q and negative control peptide #33 in presence of 1ng/ml IL-3. Proliferation with 
peptide #9 alone is shown as grey bars, peptide #9 with 1ng/ml IL3 as black bars, peptide #33 with 
1ng/ml IL3 as hatched bars and peptide 9R-Q with 1ng/ml IL3 as white bars (B) BAF03 cell 
proliferation in response to 5µg/ml  peptide #9, 9C-S or 9A and B (peptide #9 dissolved in buffer 
supplement with 12mM (A) or 6mM (B) 2-ME); all in presence of IL-3 1ng/ml. Bars represent the 
standard deviation of triplicate determinations, with *p<0.05 or **p<0.005 indicating increase in 
proliferation in comparison to the negative control peptide at the same concentration and #p<0.05 
indicating a significant difference between proliferation induced by peptide #9 and peptide 9R-Q at 
5µg/ml. Data are representative of at least 3 independent experiments. 
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The effect on proliferation of BAF03 cells, mediated by the CD23-derived 
peptides was verified by assessing proliferation induced by recombinant human 
sCD23. As shown in Figure 5.7, human sCD23 induces a robust increase in cell 
proliferation at 5µg/ml. We observed no significant effect on cell proliferation 
at lower concentrations of 1µg/ml or 0.5µg/ml. The proliferation data clearly 
indicate that human sCD23-derived peptides containing the RKC motif and sCD23 
itself are able to sustain proliferation of murine B cell line BAF03.  
 
 
Figure  5.7 Proliferation of BAF03 cells in response to human sCD23. 
 
Cultures of BAF03 cells (5000cells/well) were propagated in PFHM with the indicated concentration 
of recombinant sCD23 (R&D Systems). Proliferation was assessed after 72 h by 3[H]-TdR 
incorporation. Bars represent the standard deviation of triplicate determinations, with *p<0.05 or 
**p<0.005 indicating increase in proliferation in comparision to the untreated cells. Data are 
representative of 3 independent experiments. 
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Proliferation assays with murine bone marrow B cells isolated from mice bearing 
a B cell-specific knockout of the αV gene (CD19-cre) were used to investigate 
the role of sCD23 in proliferation of murine bone marrow B cell precursors.  
CD19+ B cells from bone marrow of control or αV knockout mice were harvested 
and grown on OP9 stromal cells with 10% FCS and 1ng/ml IL-7 and used to assess 
proliferation in the presence of human sCD23. As shown in figure 5.8 there was a 
significant increase in cell proliferation following sCD23 treatment (5µg/ml) in B 
cells from control mice but there was no change in proliferation of B cells from 
αV knockout mice with or without sCD23 treatment. Surprisingly, the untreated 
B cells from αV knockout mice had a slight increase in proliferation when 
compared to the untreated B cells from control mice but sCD23 induced no 
change in their survival.  
 
 
Figure  5.8 Proliferation of control and αV knockout murine bone marrow B cells in presence 
of human sCD23. 
 
Bone marrow B cells purified from either the control or the knockout mice bone marrow  were 
propagated in the proliferation assay culture on γ-irradiated stromal cell line OP9 and stimulated 
with 5µg/ml sCD23 or left untreated. Proliferation was assessed after 72 h by 3[H]-TdR 
incorporation. Bars represent the standard deviation of triplicate determinations, with *p<0.05 or 
**p<0.005 indicating increase in proliferation in comparision to untreated cells. Data represent one 
experiment (n=1). 
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5.2.5 ERK phosphorylation in response to sCD23-derived 
peptides in BAF03 cells 
In the human cell line SMS-SB, sCD23-mediated cell proliferation was shown to 
be associated with the activation of ERK phosphorylation pathway (Chapter 4). 
We therefore investigated whether there was a similar role for ERK 
phosphorylation in BAF03 cells.  
Figure 5.9A shows that peptide #9 alone induces a very slight ERK 
phosphorylation. However, IL-3 alone induces a significant increase in ERK 
phosphorylation from 5-30 min. When peptide #9 is used together with IL-3 there 
is a significant increase in ERK phosphorylation from 2-30 min, but this pattern 
of phosphorylation is not very different from ERK phosphorylation stimulated by 
IL-3 alone. Although an earlier onset of ERK phosphorylation is noted (at 2 min) 
with peptide #9 and IL-3, when compared to IL-3 alone, this difference in ERK 
phosphorylation does not clearly explain the enhancement in cell proliferation 
seen with peptide #9 and IL-3 together. 
In the proliferation assays, an obvious difference in survival of BAF03 cells 
treated with peptide and IL-3 compared to cells exposed to IL-3 treatment 
alone, was observed only after approximately 12 h of initiation of the assay. 
Therefore, we investigated if there was a difference in ERK phosphorylation in a 
longer time course experiment (24 h). Figure 5.9B illustrates that with IL-3 alone 
or with IL-3 plus peptide #9 there is a significant increase in ERK phosphorylation 
from 30-60 min. However, in the cells treated with IL-3 and peptide #9, ERK 
phosphorylation was observed at 4 h and 12 hr that was absent in cells treated 
with IL-3 alone. This could be the reason we observe an enhancement in 
proliferation with addition of IL-3 and peptide #9 in comparison to proliferation 
with IL-3 alone.  
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Figure  5.9 ERK phosphorylation in BAF03 cells in response to treatment with CD23-derived 
peptide #9 or IL-3 alone or in combination. 
 
Lysates from treated BAF03 cells were separated by SDS-PAGE and transferred to nitrocellulose. 
Membranes were probed with antibodies to phosphorylated ERK and subsequently stripped and 
reprobed with antibodies to ERK. (A) Western blots for phosphorylated and total ERK in BAF03 
cells treated with peptide # 9 (5µg/ml) alone, IL-3 (1µg/ml) alone or combination of both, at the time 
points shown. Figure 5.8 (B) illustrates western blots for phosphorylated and total ERK in BAF03 
cells unstimulated, stimulated with peptide #9 (5µg/ml) and IL-3 (1ng/ml) or IL-3  (1µg/ml) alone, for 
a longer time course up to 24 hr. Blots represent three independent experiments. 
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We also assessed cell proliferation in the presence of the MEK inhibitor U0126 in 
order to elucidate further the role of the ERK phosphorylation pathway in 
mediating proliferation and/or survival of BAF03 cells. As shown in figure 5.10, 
LP induced a significant increase in cell proliferation in comparison to untreated 
cells (cultured with 1ng/ml IL-3 alone) or cells exposed peptide #8 treatment. 
This proliferative effect was abrogated by treatment with the MEK inhibitor 
U0126. DMSO was used as a vehicle control as it was the solvent for the 
inhibitors and was without any effect. Although the MEK inhibitor abolished 
proliferation we also observed total inhibition of proliferation of BAF03 cells 
with the PI3K inhibitor LY294002. Therefore, the enhancement in cell 
proliferation observed via IL-3 and the CD23-derived peptides or CD23 could also 
be potentially mediated via the PI3K signalling pathway. 
 
Figure  5.10 10 Effect of inhibition of ERK and PI-3K signalling on LP-induced proliferation of 
BAF03 cells. 
 
BAF03 cells were treated with (10µM) U0126, 50µM LY294002, equivalent volume of DMSO or  left 
untreated for 30 min prior to plating at 5000 cells/well; proliferation was assessed by 3[H]-TdR 
incorporation after 72 h of culture. Proliferation induced by the long peptide in presence of 1ng/ml 
IL-3 was compared with the cells treated with the two different inhibitors or vehicle control DMSO. 
Peptide #8 was used as a negative control peptide. 
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5.2.6 Discussion 
Human sCD23 displays pleiotropic cytokine-like activities and in pre-B cell lines 
the sCD23-αVβ5 interaction was shown to sustain proliferation (Chapter 3). 
However, the cytokine-like activities of sCD23 in vitro have not been shown in 
murine cells. Murine CD23 is a 49 kDa sialoglycoprotein and shares only 57% 
amino acid homology with the human CD23 molecule. CD23-/- mice display 
normal lymphocyte development, normal B cell proliferation and germinal 
centre formation but have impaired IgE-dependent functions 312. 
Murine CD23 lacks the inverse RGD motif present on human sCD23, as a natural 
truncation and there are other known structural differences between human and 
murine CD23; these differences could provide more understanding into why 
human CD23 and not murine CD23, possesses cytokine-like activity. In relation to 
human sCD23-αVβ5 interaction it was interesting to observe that the RKC motif 
bound by αVβ5 is present as QKC on murine CD23. We investigated whether 
murine B cell precursors could bind and respond to human CD23-derived 
peptides and how important arginine 172 on the RKC motif of the peptides was 
in regulating their activity. 
We first compared the binding of various CD23-derived peptides and sCD23 to 
murine B cells and then assessed proliferation mediated by the peptides and 
sCD23 itself. Binding of the CD23-derived peptides and sCD23 to αVβ5 has 
already been studied in human cell lines and also the interactions of the 
peptides and sCD23 to αVβ5 has been extensively characterised using SPR 
analysis (A. Edkins, personal communication) and 232. Therefore, we used the 
different peptides available to assess their binding to murine B cells.   
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CD23-derived peptides #9-#12 containing the RKC motif bound to murine bone 
marrow B cells, splenic B cells and to BAF03 cells, a murine pro-B cell line.  In 
all the cell populations, peptides with the RKC motif showed strong binding and 
peptides with substitutions in the RKC motif showed reduced binding. As the 
substitutions (R-Q and R-K) and scrambled sequences did not abolish binding, 
peptides with further replacements in the RKC sequence were also assessed for 
binding. In figure 5.3B peptides with 9RK-AA mutation show greatly reduced 
binding compared to peptides with 9K-A mutations. In comparison to binding of 
peptide #9, binding of peptide #9R-K is reduced by about 20-30% while binding of 
peptide 9RK-AA is further reduced by about 50%.  Peptides with K-A substitution 
retain slightly more basic characteristic compared to peptides with RK-AA 
substitutions where both the basic amino acids (arginine and lysine) are 
converted to alanine. This indicates that the integrins require the basic domains 
on the peptides for binding. This could also explain the binding seen in peptides 
with R-Q and R-K mutations as these peptides still retain some basic residues and 
peptides with the scrambled RKC sequences also retain the basic characteristics 
of the RKC motif. Similar results have also previously shown the importance of 
the basic residues for binding in human B cell line 232.  
CD23-derived peptides #9, #12 and the LP all induced a strong proliferative 
response in the BAF03 cells when used in combination with sub-optimal 
concentrations of IL-3. The data indicate that the peptides synergise with IL-3 to 
induce a proliferative response. A strong effect in cell proliferation was also 
confirmed with the commercially-available recombinant human sCD23.  These 
cells express the αVβ5 integrin as shown in figure 5.4B and the proliferation 
results indicate that the αVβ5-CD23 interaction is important for proliferation of 
murine B cells. Peptide #9R-Q, representing the sequence in murine sCD23 
showed reduced binding to the cells in comparison to peptide #9 and in 
functional experiments proliferation induced by peptide #9 is significantly 
reduced by substitution of the glutamine for arginine in the RKC motif; although 
the proliferative effect is not completely inhibited with peptide 9R-Q. This 
implies that the arginine on the RKC motif is important for the binding and 
inducing cell proliferation but not critical since replacement of the arginine still 
resulted in some binding and a modest effect on cell proliferation. Furthermore  
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the lack of ability to induce proliferation by peptide 9C-S and peptide #9 treated 
with 2-ME indicated dimers of these peptides may be necessary for their 
activity.  
Interestingly, a higher concentration of human sCD23 was required to produce a 
response in the BAF03 cells in comparison to human cells (5µg/ml vs. 250ng/ml). 
The binding affinity of human sCD23 to the murine integrin could be much lower 
than the equivalent affinity for human integrin and therefore a higher 
concentration of ligand might be required. These results establish the 
importance of human sCD23 and the CD23-derived peptides with the RKC motif 
in mediating cell proliferation; however we did not have access to any murine 
sCD23 protein and proliferation data with murine sCD23 would be important to 
verify the unique role for human sCD23. 
In order to confirm that the CD23-mediated proliferation was via αVβ5 integrin 
we performed preliminary experiments with B cell precursors from the B cell–
specific αV conditional knockout mice. The data showed that sCD23-mediated 
proliferation was not seen in B cell precursors from bone marrow of αV knockout 
mice, but B cell precursors from the control mice showed an enhancement in 
cell proliferation after sCD23 treatment. These experiments will have to be 
repeated to confirm the effect of the αVβ5-sCD23 interaction. Due to the lack of 
an effective RNAi system in human pre-B cell lines, the B cells from the αV 
knockout mice provide an important model to confirm αVβ5-CD23 interactions. 
The ERK phosphorylation data indicated that perhaps ERK phosphorylation at  
later time points (4 h and 12 h) could be responsible for the enhancement in 
proliferation noted with peptide #9 and IL3 together. However, inhibition of 
peptide #9 mediated cell proliferation by both U0126 and LY294002 indicated 
that both the ERK and the PI3K/AKT pathway could be responsible for 
enhancement of cell proliferation. Therefore, it will also be important to 
investigate AKT phosphorylation in the same way as ERK phosphorylation. 
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CD23 is reported to interact with the β2 integrins on murine monocytes204 and 
αvβ3 expression in murine B-cell precursors has been reported 313 but there are 
no data to suggest that murine CD23 interacts with the αv family of integrins. 
Previous studies have shown that CD23 or its soluble fragments have potential 
regulatory effects on hematopoiesis. It was shown to promote differentiation of  
T cell precursors in synergy with IL-1α 207 and also to induce proliferation of 
myeloid stem cells and down-regulate proliferation of  myeloid leukemic cells 
210. It is important to understand the differences in the role of human and 
murine sCD23 not only because sCD23-αVβ5 interactions can have profound 
implications in the growth of human B cells but also because human sCD23 and 
the sCD23-derived peptides can be used in a mouse model system, to study the 
effects of αvβ5 on B-cell precursors. 
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6 Discussion 
The data presented in this thesis demonstrate that the αVβ5 integrin is 
expressed on pre-B cell lines and B cell precursors in the bone marrow and that 
the αVβ5-CD23 interaction sustains proliferation of some pre-B cell lines. 
Previous work in the laboratory demonstrated that αVβ5 is a receptor for sCD23 
and that this interaction sustains proliferation of the pre-B cell line SMS-SB.  The 
main aim of this project was to identify exactly at what stage of B cell 
development αVβ5 is expressed and is functional.  
Results in Chapter 3 demonstrated that αVβ5 is expressed on and sustains 
proliferation of early pre-B cell lines. Transitional and more mature B cell lines 
down-regulated αVβ5 expression and did not proliferate in response to αVβ5 
ligation. Data in Chapter 4 indicated that this proliferative function of αVβ5 was 
modulated by the chemokine SDF-1 and PDGF, both important molecules in early 
B cell development. This regulation of αVβ5-mediated proliferation was shown 
to be via modulation of the signalling pathways activated downstream of integrin 
and the growth factor or chemokine receptors.  SDF-1 and PDGF treatment both 
enhanced ERK phosphorylation induced via αVβ5 ligation. The role of αVβ5-CD23 
interaction in mediating proliferation of B cell precursors was further confirmed 
in a murine pro-B cell line BAF03 as shown by the results in Chapter 5.  
6.1 αVβ5 Expression  
Different pre-B cell lines were characterised into distinct stages of B cell 
development based on cell surface marker expression, and αVβ5 expression was 
assessed at each stage of development (Chapter 3). All pre-B cell lines showed 
significant levels of αVβ5 expression and transitional B cell lines such as Raji, 
Daudi and Ramos showed low levels or no αVβ5 expression (Figure 3.3 and 3.4). 
Mature B cell lines like SKW and IB4 also showed low or no αVβ5 expression 
(Figure 3.4). These data indicate that αVβ5 expression is down-regulated as the 
pre-B cells differentiate into transitional B cells and more mature B cells. This 
was supported by the finding that αVβ5 expression decreases in the immature B 
cell line 1E8 in comparison to the pre-B cell line Blin1, which was the original  
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cell line from which 1E8 was derived (Figure 3.3). The expression of integrin 
αVβ3, which is closely related to αVβ5 and is also known to bind sCD23, was 
more difficult to define. Although it was obvious that the levels of this integrin 
were higher in the mature B cell lines SKW and IB4, in comparison to other cell 
lines, most of the cell lines seemed to express low levels of this integrin.  
In order to correlate the data from the cell lines to bone marrow B cell 
precursors, αVβ5/αVβ3 expression was analysed in bone marrow B cell 
precursors, using a similar panel of cell surface markers used to characterise the 
pre-B cell lines. The data indicated that αVβ5 was expressed in a percentage of 
pre-B cells in the bone marrow (CD19+/CD9+ and CD19+/CD10+) (Figure 3.15). 
Furthermore the data also indicated that αVβ3 integrin was expressed in similar 
pattern to αVβ5 (Figure 3.14, 3.17). Although αVβ5 expression was higher than 
αVβ3 expression, the general pattern of expression was similar with relation to 
most of the markers. A clear down-regulation of αVβ5 expression could not be 
detected in the bone marrow B cell precursor population as αVβ5 expression was 
noted in CD19+/κ+ cells (Figure 3.18), which are more mature than the pre-B 
cells owing to the expression of the kappa light chains. Therefore we could not 
conclude that αVβ5 expression is exclusive to pre-B cells. We could not stain any 
CD34+ pro-B cells or any mature B cells from the blood, and so a more extensive 
staining of B cell precursors from the bone marrow and B cell populations from 
peripheral blood is required to confirm αVβ5 expression and down-regulation of 
this expression in mature B cells.  
6.2 αVβ5 Function  
The sCD23-αVβ5 interaction was previously shown to sustain proliferation of the 
SMS-SB cell line. Therefore, the proliferative response to sCD23 treatment was 
used to assess αVβ5 function in the different cell lines (Chapter 3). The pre-B 
cell lines SMS-SB, RS4;11 and 697 proliferated robustly in response to sCD23 and 
sCD23-derived LP treatment (Figure 3.6, 3.7 and 3.9), and this response was 
mimicked by the 15F11 MAb which binds to αVβ5 integrin (Figure 3.11), 
indicating that the sCD23-dependent proliferation is mediated via this integrin. 
The MAb P1F6 which is also known to bind αVβ5 did not induce a proliferative  
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response and the MAb AMF7 which binds the αV subunit induced proliferation in 
SMS-SB cells but failed to induce a proliferative response in the RS4;11 cell line. 
A slight proliferative response to sCD23 treatment was observed in the pre-B cell 
line Blin1 and in the cell lines Daudi and SKW (Figure 3.7 and 3.8). However, all 
of these responses were much lower in comparison to the response of SMS-SB, 
RS4;11 and 697 cells.  
The SMS-SB and RS4;11 cell lines had very low levels or lacked surface µ 
expression (Figure 3.1), suggesting that perhaps very early B cell precursors 
(either pro-B cells or  pre-BI) respond well to αVβ5 stimulation. The CD10- status 
of both these cell lines (Figure 3.1) also indicated that the αVβ5-mediated 
growth response was restricted to cells at a specific stage of development. 
However, B cell precursors in the normal bone marrow, including the pro-B cells 
are CD10+ and the cell line 697 which was CD10+ also responded well to αVβ5 
stimulation, indicating that it is not only the CD10- cells that respond to αVβ5 
stimulation. However, a common feature of these three cell lines was that they 
all stained well with the 15F11 antibody that recognises the αVβ5 heterodimer 
(Figure 3.3). While the αVβ5 MAb P1F6  indicated similar levels of staining in all 
the pre-B cell lines tested, 15F11 staining for αVβ5 was higher in SMS-SB, 697 
and RS4;11 and lower in all other pre-B cell lines (Figure 3.3).  
Another common characteristic of these three responding cell lines was that 
they all expressed very low levels or none of the integrin αVβ3 in comparison to 
the other pre-B cell lines (Figure 3.3). These data indicate that αVβ5-mediated 
proliferation is important in early B cell precursors at a specific stage in B cell 
development. However, a confirmation of this proliferative response from bone 
marrow B cell precursors would be needed to define the exact window of B cell 
development where αVβ5-mediated proliferation is important. The proliferation 
data presented for bone marrow B cell precursors was on CD19+/κ- B cells (Figure 
3.20). These data indicated that B cell precursors in the bone marrow that have 
not begun to express the κ light chain but express αVβ5 integrin, can proliferate 
in response to sCD23 stimulation but the κ-positive B cell precursors do not. This 
is in agreement with the hypothesis that αVβ5-mediated proliferation is 
important for early B cell precursors and not for the more mature ones. A more  
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detailed analysis of the proliferation of bone marrow B cell precursors in the 
pro-B and pre-B stage would be required to make specific conclusions relating to 
the stage of B cell development where αVβ5-mediated proliferation could have 
important implications. Together with this, a study of proliferation of B cells 
from patients with ALL would also be needed to establish the importance of 
αVβ5-mediated cell proliferation in neoplastic cells. Previous results from the 
lab demonstrated that αVβ5 is highly expressed in B cells from patients with 
ALL. As ALL is malignancy of early B cell precursors in the bone marrow, αVβ5 
could be delivering an important proliferative signal to these cells depending on 
their maturation stage. 
The cell line data clearly indicate that some pre-B cells proliferate in response 
to αVβ5 stimulation and this could have important implications for growth and 
proliferation not only of bone marrow B cell precursors expressing αVβ5 but 
more importantly, of leukemic B cell precursors. Moreover, the cell line RS4;11 
is a well-known MLL-rearranged leukemic cell line and the SMS-SB cells have a 
similar phenotype to RS4;11. The fact that both of these cell lines show a 
significant proliferative response to αVβ5 indicates that this stage-specific 
proliferative response to αVβ5 could be very important in survival of some 
specific types of leukemic cells. Human ALL frequently represents clonal 
expansion of a CD19+ B-lineage cells at one of several stages of B-cell 
development and the t(4;11)(q21;q23) cytogenetic abnormality, characterized by 
expression of the MLL/AF4 fusion protein is a frequent subtype of infant acute 
leukaemia and some adult leukaemia. Leukemic blasts expressing MLL/AF4 are 
arrested at an early progenitor stage with lymphoid or monocytoid 
characteristics. MLL-rearranged B cell precursor ALL represents a more 
aggressive leukaemia, particularly in infants, and is associated with a poor 
prognosis 272,314. Therefore, the fact that αVβ5 stimulates proliferation of these 
cell types indicates that this integrin may have a very important therapeutic 
potential in the treatment of these leukaemias. 
The proliferative function mediated via αVβ5 was confirmed in the mouse cell 
line BAF03 which expressed the integrin αVβ5 but not αVβ3 (Chapter 5). BAF03 
cells which represent a murine pro-B stage cell line are dependent on IL-3 for  
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survival 273 and offer a good model to test the proliferative function of αVβ5. 
Due to the lack of murine αVβ5 antibody, αVβ5 expression was confirmed via 
surface biotinylation and αVβ3 expression was confirmed by flow cytometry for 
the expression of the β3 subunit (Figure 5.4). In the presence of sub-optimal IL-3 
concentrations, BAF03 cells showed significant proliferation in response to 
human sCD23 treatment (Figure 5.7)  or stimulation with sCD23-derived peptides 
(Figure 5.5), thus indicating that the proliferative function of human sCD23 can 
be detected in murine B cell studies. In support of this, murine bone marrow  B 
cell precursors also proliferated well in response to sCD23 treatment and murine 
B cells from αV knockout mice did not show similar enhancement in proliferation 
with sCD23 treatment when compared to the B cells from the bone marrow of 
wild-type mice (Figure 5.8). These results indicate the importance of the αV 
integrin and sCD23 in mediating this proliferative response. 
6.3 Modulation of αVβ5-mediated proliferative effects by 
molecules important in early B cell development.  
A variety of soluble factors as well as contact interactions between the 
precursor cells and the stromal microenvironment dictate the fate of B cell 
progenitors. A number of growth factors, chemokines, cytokines and adhesion 
molecules have been described that regulate the survival, differentiation and 
migration of B cell progenitors. In order to assess the importance of the αVβ5-
mediated proliferation during B cell development, the role of cytokines, 
chemokines and growth factors in modulating αVβ5 function was investigated.  
SDF-1, a chemokine with established roles during B lymphopoiesis, enhanced the 
proliferative effect mediated via αVβ5 (Figure 4.1). Furthermore, PDGF had a 
similar effect to SDF-1 in enhancing αVβ5-mediated cell proliferation in SMS-SB 
cells (Figure 4.7). As both PDGF and SDF-1 have been implicated in early B cell 
development these data further support a role for αVβ5-mediated cell 
proliferation in early B cell developmental stages. However, surprisingly, the 
cytokine most implicated in early B-cell proliferation, IL-7, did not show a 
similar effect to SDF-1 (Figure 4.5). Although the requirement for IL-7 in human 
B lymphopoiesis is not as absolute as in murine B lymphopoiesis, many studies  
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have shown that IL-7 induces proliferation of early human B cell precursors 1,12. 
It could be that the requirement for IL-7 and requirement for αVβ5 are at 
slightly different stages of development and they do not overlap, or it could also 
be that concentrations of IL-7 used in the experiments here were different from 
the concentrations of IL-7 required for enhancing the proliferative effect. The 
cytokines were all used in the same concentration range as SDF-1 and it is 
possible that these cytokines produce a response at different concentration 
ranges. Similarly, IL-3 and IL-4 have both been implicated in having different 
roles in B cell development but neither affected the function of αVβ5 in the 
experimental context used (Figure 4.5). Expression data indicate that perhaps 
IL-4 could modulate αVβ5 expression, which might have important implications, 
and none of the other treatments used affected αVβ5 expression (Figure 4.6).   
A number of other molecules, such as Flt3 ligand 90, are known to be important 
in early B cell development and are also known to influence integrin function 
and therefore could be regulating αVβ5 function. Similarly, the role of αVβ5 
integrins cannot be studied in isolation from other integrins. Not only could 
other αV integrins be modulating αVβ5 function but also other integrins such as 
the β1 and β2 families have been implicated in hematopoiesis in an adhesion-
dependent manner. Therefore, these integrins could be having an important role 
in modulating αVβ5 function in an adhesion-dependent or independent manner. 
So, it would also be important to assess whether ligation of the β1 and β2 
integrins influences αVβ5-mediated cell proliferation. Moreover, the role of the 
αVβ5 integrin function also cannot be assessed without considering the matrix 
proteins and in particular, vitronectin since αVβ5 is known to bind primarily to 
vitronectin.  
Previous work regarding the αVβ5-CD23 interaction indicated that αVβ5 binds to 
the RKC motif on sCD23 and that RGD peptides do not influence the αVβ5-
mediated proliferation of SMS-SB cells. Furthermore, the αVβ5 MAb P1F6 that 
blocks binding to vitronectin did not elicit a proliferative response and did not 
influence sCD23-mediated proliferation either (data not shown). Vitronectin 
coated on to 96-well plates and soluble vitronectin were both used to assess 
their influence on αVβ5-mediated cell proliferation; however, there were no  
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conclusive data to suggest either increase or decrease in αVβ5-mediated cell 
proliferation in the presence of vitronectin, and vitronectin itself did not 
influence the proliferation of SMS-SB cell (data not shown) 232. Fibronectin alone 
also did not influence SMS-SB cell proliferation or αVβ5-mediated cell 
proliferation (data not shown).  
A key molecule guiding B cell development is the pre-BCR on precursor B cells 
and BCR on mature B cells. Pre-BCR signalling has not only been implicated in B 
cell differentiation but cross-linking the pre-BCR in the presence of other soluble 
factors such as IL-7 is known to induce B cell proliferation 315,316. Therefore, it 
will be important to determine whether pre-BCR ligation influences αVβ5-
mediated cell proliferation.  
Proliferation and differentiation are interlinked and interdependent events in 
many ways. Therefore, it was hypothesised that αVβ5 expression was linked to B 
cell differentiation. This seemed particularly plausible as αVβ5 function seemed 
to be important in early B cell precursors. The influence of pre-BCR on αVβ5 
expression was assessed in the pre-B cell lines SMS-SB and Blin1. However, pre-
BCR cross-linking by anti-µ MAb did not influence αVβ5 expression and αVβ5 
stimulation did not influence surface µ expression (data not shown). A signalling 
complex, termed pro-BCR, competent in transducing signals has been recently 
reported and it was demonstrated that cross-linking of pro-BCR on pro-B cells 
isolated from bone marrow induced phosphorylation of various signalling 
molecules including Syk, PI3K and ERK and that the pro-B cells could be induced 
to differentiate to the pre-B stage of development 15. Since αVβ5 seems to 
regulate proliferation of early B cell precursors it is possible that it regulates 
differentiation of the pro-B cells and therefore it would be interesting to 
investigate if ligation of the pro-BCR and the subsequent differentiation induced, 
influences αVβ5 function or expression. 
Some preliminary results indicated that expression of κ light chains on Blin1 cells 
resulted in down-regulation of αVβ5 expression (data not shown) but cultures of 
Blin1 cells expressing κ light chains could not be established on a long-term basis 
to assess this down-regulation conclusively.  Evidence for the role of αV integrins 
in differentiation is provided by studies showing a switch between the αV- 
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associated β integrin subunit during development in different cell systems. It has 
previously been shown that oligodendrocyte progenitors sequentially express 
αVβ1, αVβ3 and αVβ5 integrins during differentiation in vitro with up-regulation 
of αVβ5 and down-regulation of αVβ3 317. Furthermore it was also demonstrated 
that, in these cell types, αVβ3 may regulate cell proliferation and that both 
down-regulation of αVβ3 expression and subsequent signalling through αVβ5 may 
be critical for continued differentiation in vitro 318. A similar developmental 
switch, with up-regulation of αVβ3 and down-regulation of αVβ5 expression, has 
also been established during osteoclast differentiation 319. Therefore, it would 
be very interesting to characterise the role of both αVβ5 and αVβ3 and the other 
αV integrins during B cell development with regard to proliferation and 
differentiation.  This information would be valuable in understanding B cell 
malignancies that can arise at specific stages of development due to disruption 
in proliferation and differentiation mechanisms.  
6.4 Signalling via the αVβ5 integrin 
Although integrins and growth factor receptors can independently propagate 
intracellular signals, many of the signalling pathways and effectors which are 
activated by integrin ligation are also activated by growth factor stimulation. 
There are two major families of growth factor receptors that signal via distinct 
pathways and cooperate to regulate cell growth: the G-protein-coupled 
receptors (GPCRs) and the receptor tyrosine kinases (RTKs). The GPCRs signal by 
inducing dissociation of heterotrimeric G-proteins into Gα and Gβγ subunits, 
each of which initiate a specific response 320,321, while RTKs are activated 
following binding of polypeptide growth factors which induces RTK dimerization 
239,322. A number of studies, particularly in the adherent cell system, have 
demonstrated that the function of growth factors can be positively modulated by 
integrin-mediated cell adhesion.  Both integrins and growth factors are known to 
activate Rho family GTPases, the Ras-Raf-MAPK pathway, PI3K, ribosomal S6 
(RSK) and Jun amino-terminal kinase (JNK) 323,324. Synergy between growth 
factors and cell adhesion has been observed in the activation of the MAPK 
pathway 325,326 and PI3K/AKT pathway 327. Coimmunoprecipitation of growth 
factor receptors with integrins has also been shown in various studies; for 
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example, αVβ3 has been found to associate with PDGFR or VEGFR (vascular 
endothelial growth factor receptor) 328-331. Studies on cross-talk between the 
integrins and growth factor signalling has also given important insights into 
specific functions of the integrins. For example, cell adhesion and migration 
studies have identified a critical role for cross-talk between growth factor 
receptors with the integrin αVβ5 but not with αVβ3 during adhesion and 
migration on vitronectin 332. Similarly, it was demonstrated in both chick and 
mouse models that αVβ5-bearing melanoma cells depend on ex-vivo pre-
stimulation with IGF (insulin-like growth factor) for metastasis, whereas αVβ3 
bearing melanoma cells metastasize in the absence of growth factor treatment 
333. In the haematopoietic cell system, a number of studies have shown that SDF-
1 modulates signals for adhesion and migration via the β1 integrins VLA-4 and 
VLA-5 and the β2 integrin LFA-1 295. Signalling data from the studies investigating 
modulation of αVβ5-mediated proliferation by SDF-1 and PDGF (Chapter 4) 
indicated a role for growth factor-integrin cross talk in an adhesion-independent 
manner leading to enhanced proliferation of SMS-SB cells. 
Stimulation of αVβ5 integrin using sCD23, LP or 15F11 MAb induced  significant 
ERK phosphorylation in SMS-SB cells showing that the αVβ5-mediated 
proliferative response was probably regulated by the ERK, MAPK pathway (Figure 
4.8). A transient ERK phosphorylation induced by SDF-1 treatment in these cells 
was markedly enhanced when SDF-1 was added together with sCD23, LP or 15F11 
MAb. These results indicated that the synergy between SDF-1 signalling and αVβ5 
signalling could be via the ERK signalling pathway. Furthermore, the synergy 
between PDGF and sCD23 in mediating proliferation and ERK phosphorylation in 
a manner similar to SDF-1 indicated that αVβ5-mediated signalling mechanisms 
synergise with both GPCR-mediated and RTK-mediated signalling to produce 
proliferative responses. Further support for synergy of αVβ5-mediated signalling 
with growth factor signalling came from the mouse cell line data. The IL-3-
dependent cell line BAF03 proliferates in a dose-dependent manner in response 
to IL-3 treatment. When sCD23 or CD23-derived peptides were added together 
with a sub-optimal concentration of IL-3 there was a robust enhancement in cell 
proliferation indicating a synergy between IL-3-mediated and αVβ5-mediated 
proliferative responses.  
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However, in the BAF03 cells it was not clear whether this proliferation was 
mediated via the ERK signalling pathway. Although there was an enhancement in 
ERK signalling with IL-3 and sCD23-derived peptides on a longer time course 
experiment there was no difference in ERK phosphorylation induced by CD23-
derived peptide alone or in combination with IL-3 on a shorter time course 
(Figure 5.9). These data indicated that there could also be other signalling 
pathways involved in regulating the synergistic effect on cell proliferation.  The 
PI3K/AKT-mediated pathway could potentially be involved in mediating this 
synergy and it needs to be investigated. In the SMS-SB cell line, the PI3K 
inhibitor LY294002 inhibited the proliferation induced by stimulation of αVβ5 
alone or in combination with SDF-1 (Figure 4.10). Although this inhibition was 
not as absolute as the inhibition seen with the MEK inhibitor, these results 
indicate that PI3K/AKT pathway could also be mediating this enhancement of 
αVβ5-mediated signalling by growth factor receptors.  
With regards to signalling mechanisms, it would be very useful to characterise 
the signalling pathways or patterns induced by αVβ5 ligation versus αVβ3 
ligation. Particularly in some transitional cell lines where a proliferative 
response was seen with 23C6 (anti-αVβ3 MAb) ligation, it would be interesting to 
investigate whether there is a similar ERK phosphorylation pattern to that seen 
with αVβ5-mediated proliferation. A characteristic biphasic pattern of ERK 
phosphorylation was seen in SMS-SB cells with ligation of αVβ5 and this pattern 
of phosphorylation, when compared with ERK phosphorylation due to αVβ3 
ligation, could give important information regarding why αVβ5 but not the αVβ3 
integrin induces proliferation in some pre-B cell lines.  
Similarly, a comparison of ERK phosphorylation due to αVβ5 ligation in the 
different pre-B cell lines would further establish why a proliferative response is 
observed in some cell lines and not in others. αVβ5 and αVβ3 integrins may also 
regulate different signalling pathways leading to different outcomes in cell 
proliferation, therefore comparison of other signalling pathways, particularly 
PI3K/AKT pathway, could provide important information regarding the distinct 
function of these two integrins in B cells. Furthermore, signalling mechanisms 
could also give more information on the role of vitronectin in influencing αVβ5  
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function. A comparison of ERK phosphorylation induced by soluble vitronectin, 
vitronectin coated on plates and sCD23 could give important information in 
distinguishing the role of stimulation of αVβ5 by sCD23 and vitronectin.  
These data support a model in which signals from αV integrins together with 
signals from other soluble molecules regulate important proliferation and 
differentiation decisions during B cell development and can impact on B cell 
disorders that arise due to disruption of normal proliferation and differentiation 
pathways (Figure 6.1). As indicated by the proliferation data, the model in 
Figure 6.1 suggests that the αVβ5-CD23 interaction probably regulates 
proliferation of B cell precursors at early pre-B stage. The exact stage, whether 
it is at the pro-B stage or just after this stage still needs to be verified. The 
expression of αVβ5 integrin in ALL cells and the role of the αVβ5-CD23 
interaction in regulating pre-B cell proliferation indicates that the αVβ5-CD23 
interaction might be important in the growth of ALL B cells. Although there are 
no data indicating a role for αVβ5 in B cell differentiation, the fact that αVβ5 
integrin regulates proliferation and is expressed in stage-specific manner 
indicates that αVβ5 could be directly or indirectly linked with B cell 
differentiation. Coordinated signals from the different αV integrins probably 
regulate the B cell proliferation/differentiation balance. The role of αVβ5 in 
proliferation and differentiation could also implicate this integrin in the mature 
B cell malignancy CLL. As the CD5+ B cell population is expanded in B-CLL, and 
since the data suggested the presence of αVβ5 and αVβ3 integrins on CD5+ B 
cells from bone marrow, there could potentially be a link between αV integrin 
expression and CLL (Figure 6.1).   
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Figure  6.1 Model for the role of αVβ5 integrin during B cell development and implications for 
B cell leukaemias. 
 
This model represents the potential role of αVβ5 integrin in B cell proliferation and differentiation 
based on the data available. Different stages in B cell development in the bone marrow and blood 
are depicted in yellow. Changes in αVβ5 integrin expression levels are presented in blue. B cell 
development is regulated by a balance between cell proliferation and differentiation which 
determines the number and maturation stages of the cells in each compartment. ALL is a B cell 
malignancy that arises during early B cell stages in the bone marrow due to disruption in this 
balance and results in clonal proliferation of cells arrested at a certain stage. While CLL is a B cell 
malignancy that arises at a more mature stage of B cell development. The αVβ5-CD23 interaction 
regulates proliferation of B cell precursors at early stages of B cell development. The * indicates 
that the CD23 could either be found in the bone marrow stromal cells or could be soluble CD23 in 
blood. This stage specific role of αVβ5-mediated proliferation could be influenced by a variety of 
other molecules important in B cell development. Deregulation of αVβ5 or αV integrin  expression 
and function might also be implicated in pathogenesis of CLL. 
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The data from this thesis illustrate that stimulation of αVβ5 integrin via sCD23 or 
antibodies such as 15F11 activates signalling pathways leading to cell 
proliferation. Furthermore, this activation is probably developmental stage-
specific and is regulated by cross talk with signals from other soluble molecules 
important during B cell development. Further work on αVβ5-mediated cell 
proliferation could establish αVβ5 integrin as an important molecule in 
proliferation of normal B cell precursors and in proliferation of leukemic B cells 
in ALL. Data from αV conditional knockout mice which have αV integrin deleted 
in the B cells (CD19-cre) indicate that αV integrin could regulate differentiation 
into the CD5+ (B1) B cell development, as these subsets are increased in the 
knockout mice (Dr. Adam Lacy-Hulbert personal communication). Therefore, αV 
integrins could not only have important roles in ALL but could be involved in 
autoimmune disease and malignancies such as chronic lymphocytic leukaemia, 
both of which involve a clonal proliferation of CD5+ B1 B cells. Although the role 
of αV integrins could probably be slightly different in the mouse models and in 
humans, as indicated by the difference in activities of human and mouse CD23, a 
detailed study of αV integrins in mouse models relating them to human disease 
context is required. These studies can provide important information not only 
for B cell disorders but will place αV integrins as important receptors in 
regulating B cell development. 
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